Amedeo Smart

Free Medical Literature Service

 

Amedeo

Diabetes
  Free Subscription

Articles published in
Diabetes Obes Metab
    March 2026
  1. ZHANG Y, Ji JL, Yao DD, Zhou Y, et al
    Oxaloacetate Restores HIF-1alpha-Mediated Mitochondrial Homeostasis to Counter Tubulointerstitial Injury in Diabetic Kidney Disease.
    Diabetes Obes Metab. 2026 Mar 3. doi: 10.1111/dom.70612.
    >> Share

  2. BONIFACIO E, Scholz M, Weiss A, Ziegler AG, et al
    Comparison of IA-2 Bridge ELISA and Radiobinding Assays for Progression Risk Assessment in Early-Stage Type 1 Diabetes.
    Diabetes Obes Metab. 2026 Mar 3. doi: 10.1111/dom.70630.
    >> Share

  3. ENG PC, Tag WY, Sivaramasubramaniam S, Aung AT, et al
    Pre-Existing Diabetes and Prediabetes in Pregnancy: Evaluation on Glycaemic Control, Pregnancy Outcomes and Clinical Gaps.
    Diabetes Obes Metab. 2026 Mar 2. doi: 10.1111/dom.70619.
    >> Share

  4. TOKGOZ S, Boss M, Meijer RI, Jansen TJP, et al
    Sex Differences in [(68)Ga]Ga-NODAGA-Exendin-4 Uptake in the Pituitary of Individuals With Type 2 Diabetes.
    Diabetes Obes Metab. 2026 Mar 2. doi: 10.1111/dom.70600.
    >> Share

  5. MECANI R, Basta S, Baumann PM, Cigler M, et al
    Performance of continuous glucose monitoring systems (CGMs) during commercial flights in T1DM: A within-subject comparative pilot study.
    Diabetes Obes Metab. 2026;28:2245-2254.
    >> Share

  6. VAN BAAL L, Raess L, Mathew A, Lahner H, et al
    Accuracy and reliability of a continuous glucose monitoring system with a focus on hypoglycaemia.
    Diabetes Obes Metab. 2026;28:2166-2174.
    >> Share

  7. MECANI R, Basta S, Baumann PM, Cigler M, et al
    In-flight glycaemic control using automated insulin delivery systems: A within-subject comparative pilot study.
    Diabetes Obes Metab. 2026;28:2159-2165.
    >> Share

  8. JOUBERT M, Dreves B, Arnould T, Soussi A, et al
    Comparative accuracy of smartphone apps and a generative AI tool for carbohydrate counting: An independent bicentric study.
    Diabetes Obes Metab. 2026;28:2105-2112.
    >> Share

  9. ZHANG Q, Zhou Y, Fu L, Xing Z, et al
    Relationship between cardiometabolic index and worsening renal function in T2DM: Insights from machine learning, growth mixture modelling, and development of a web-based risk prediction tool.
    Diabetes Obes Metab. 2026;28:1899-1914.
    >> Share

  10. SUNG KH, Yu J, Kim S, Kim MK, et al
    Glucose tolerance and mortality across 24 cancer types and stages: A K-CURE Nationwide registry study.
    Diabetes Obes Metab. 2026;28:2051-2060.
    >> Share

  11. JIMENEZ-TEN HOEVEL C, Besora-Moreno M, Queral J, Llaurado E, et al
    Ultrasound and MRI abdominal fat distribution and its associations with metabolic conditions in adults with abdominal obesity.
    Diabetes Obes Metab. 2026;28:2061-2074.
    >> Share

  12. STONE J, Tripyla A, Scalise MC, Balmer ML, et al
    Taxonomic and functional shifts in the microbiome of severely obese, prediabetic patients: Ketogenic diet versus energy-matched standard diet.
    Diabetes Obes Metab. 2026;28:1826-1835.
    >> Share

  13. TAJ S, Zuber M, Rashid M, Chhabra M, et al
    Injection-site and dermatologic reactions associated with glucagon-like peptide-1 receptor agonists: Insights from meta-analysis of randomised controlled trials and real-world evidence.
    Diabetes Obes Metab. 2026;28:1956-1971.
    >> Share

  14. NOVODVORSKY P, Thieme L, Lankova I, Frankova S, et al
    Insulin therapy DE-intensificAtion with iGlarLixi: A phase 4, open-label, parallel-group randomised controlled trial.
    Diabetes Obes Metab. 2026;28:1817-1825.
    >> Share

    February 2026
  15. LU X, Yuan Z, Lin X, Huang Z, et al
    Association of Elevated Lipoprotein(a) and Diabetes Mellitus With Survival Outcomes in Patients With Coronary Artery Disease: Findings From the CIN-II and RED-CARPET Cohorts.
    Diabetes Obes Metab. 2026 Feb 27. doi: 10.1111/dom.70603.
    >> Share

  16. NAUCK MA, Punov V, Kang YM, Lim S, et al
    Dose-Escalation Regimens for Incretin Mimetics in Type 2 Diabetes Are Associated With Tolerance for Nausea and Vomiting.
    Diabetes Obes Metab. 2026 Feb 27. doi: 10.1111/dom.70613.
    >> Share

  17. MOUNT J, Boye K, Lebrec J, Wilkes E, et al
    Impact of early and tight HbA1c control on the risk of long-term complications and cardiovascular death in patients with type 2 diabetes from the Swedish National Diabetes Register.
    Diabetes Obes Metab. 2026 Feb 27. doi: 10.1111/dom.70584.
    >> Share

  18. HONG JH, Yu SH, Baek KH, Yu J, et al
    Effectiveness and Safety of Evogliptin in Patients With Type 2 Diabetes Mellitus: A Multicenter, Prospective, Observational Study.
    Diabetes Obes Metab. 2026 Feb 26. doi: 10.1111/dom.70601.
    >> Share

  19. IPAYE T, Goldney J, Yates T, Zaccardi F, et al
    Sodium-glucose co-transporter 2 inhibitors and obesity-associated cancers in people with type 2 diabetes: A real-world observational study.
    Diabetes Obes Metab. 2026 Feb 26. doi: 10.1111/dom.70562.
    >> Share

  20. LI Y, Liu W, Wang Y, Wang B, et al
    Rapid improvement of renal microcirculatory homeostasis by liraglutide following diabetes induction.
    Diabetes Obes Metab. 2026 Feb 26. doi: 10.1111/dom.70594.
    >> Share

  21. LIM MY, Lian W, Phua HP, Htun HL, et al
    Visit-to-visit HbA1c variability, risk of all-cause mortality and diabetes-related vascular complications among adult individuals with type 2 diabetes mellitus.
    Diabetes Obes Metab. 2026 Feb 26. doi: 10.1111/dom.70576.
    >> Share

  22. SORENSEN KK, Yazdanfard PDW, Zareini B, Wood-Kurland HK, et al
    Sustained glucagon-like peptide-1 receptor agonist treatment improves glycemic control and reduces all-cause mortality compared to dipeptidyl peptidase-4 inhibitors: A real-world target trial emulation in type 2 diabetes.
    Diabetes Obes Metab. 2026 Feb 25. doi: 10.1111/dom.70581.
    >> Share

  23. ULRICH FS, Frost Nielsen M, Napoli N, Burden AM, et al
    Real-world treatment trajectories preceding GLP-1 receptor agonist initiation in type 2 diabetes: A descriptive UK population-based cohort study on adherence to national clinical guidelines.
    Diabetes Obes Metab. 2026 Feb 25. doi: 10.1111/dom.70548.
    >> Share

  24. SCHMIDT S, Petersen TS, Karstoft K
    Counting days: Cardiovascular and kidney event postponement with glucagon-like peptide 1 receptor agonists in individuals with type 2 diabetes.
    Diabetes Obes Metab. 2026 Feb 24. doi: 10.1111/dom.70589.
    >> Share

  25. ZHANG Z, Gan L, Camille C, He X, et al
    Mo-Rubbing abdominal improves metabolic homeostasis in type 2 diabetes mellitus mice via a jejunum-specific GLP1-dependent mechanism.
    Diabetes Obes Metab. 2026 Feb 23. doi: 10.1111/dom.70563.
    >> Share

  26. ZHANG Y, Cai Y, Li X, Zhang Q, et al
    Gut microbiota-mediated branched-chain amino acid metabolism: A novel mechanism by which Bacteroides uniformis improves type 2 diabetes mellitus.
    Diabetes Obes Metab. 2026 Feb 23. doi: 10.1111/dom.70559.
    >> Share

  27. DUNN T, Doshi R, Divino V, Chen J, et al
    Real-world predictors of progression to type 2 diabetes among adults with prediabetes.
    Diabetes Obes Metab. 2026 Feb 23. doi: 10.1111/dom.70583.
    >> Share

  28. LADO-ABEAL J, Gude F, Ginzo-Villamayor MJ, Al-Zubaidi K, et al
    Impact of specialised endocrinology care on metabolic control and healthcare utilisation outcomes after kidney transplantation in patients with diabetes: A 12-month observational cohort study.
    Diabetes Obes Metab. 2026 Feb 23. doi: 10.1111/dom.70596.
    >> Share

  29. LEOHR J, Klein O, Heise T, Zijlstra E, et al
    Characterisation of steady-state pharmacokinetics and glucodynamics of once-weekly insulin efsitora alfa in individuals with type 2 diabetes.
    Diabetes Obes Metab. 2026 Feb 23. doi: 10.1111/dom.70585.
    >> Share

  30. MAIER GA, Hennig B, Rathmann W, Kuss O, et al
    Comparative effectiveness of combination therapy with SGLT-2 inhibitors and GLP-1 RAs compared with SGLT-2 inhibitors in individuals with type 2 diabetes: A prevalent new-user cohort study.
    Diabetes Obes Metab. 2026 Feb 22. doi: 10.1111/dom.70523.
    >> Share

  31. TEOH H, Verma S, Mancini GBJ, Quan A, et al
    Evaluation of evolocumab on saphenous vein graft patency following coronary artery bypass graft surgery in people living with and without diabetes in the NEWTON-CABG CardioLink-5 trial.
    Diabetes Obes Metab. 2026 Feb 19. doi: 10.1111/dom.70590.
    >> Share


  32. Correction to "Efficacy and safety in tirzepatide-treated Korean adults with type 2 diabetes-A post hoc analysis of SURPASS-AP-combo and SURPASS-3".
    Diabetes Obes Metab. 2026 Feb 19. doi: 10.1111/dom.70591.
    >> Share

  33. TAN RJL, Ahuja A, Shrestha A, Gallen G, et al
    A retrospective observational study evaluating the safety and effectiveness of commercially available automated insulin delivery systems in people with type 1 diabetes and gastroparesis.
    Diabetes Obes Metab. 2026 Feb 19. doi: 10.1111/dom.70575.
    >> Share

  34. YANG Z, Jiao Y, Sun Y, Wu Y, et al
    Associations of metformin and sulfonylurea on vascular complications in early- and late-onset type 2 diabetes: A cohort study.
    Diabetes Obes Metab. 2026 Feb 18. doi: 10.1111/dom.70564.
    >> Share

  35. ZHOU X, Lu J, Wang Z, Cheng KK, et al
    Causal role of genetically predicted impairment of branched-chain amino acid catabolism on insulin secretion and insulin resistance in type 2 diabetes.
    Diabetes Obes Metab. 2026 Feb 18. doi: 10.1111/dom.70565.
    >> Share

  36. HU J, Ge T, Zhu Q, Yao Y, et al
    Association between the oxidative balance score and risk of microvascular complications in type 2 diabetes: A prospective UK biobank cohort study.
    Diabetes Obes Metab. 2026 Feb 18. doi: 10.1111/dom.70566.
    >> Share

  37. WU Y, Feng K, Fu Y, Zhuo Q, et al
    Unveiling glycaemic variability patterns linked to the triglyceride-glucose index in type 2 diabetes: Insights from continuous glucose monitoring.
    Diabetes Obes Metab. 2026 Feb 18. doi: 10.1111/dom.70558.
    >> Share

  38. TONG X, Xing C, Zhang L, Zhang L, et al
    Cost-utility of once-weekly insulin icodec versus once-daily basal insulins for type 2 diabetes in China.
    Diabetes Obes Metab. 2026 Feb 18. doi: 10.1111/dom.70567.
    >> Share

  39. TRAN RH, Raghupathy P, Hazim M, Thompson E, et al
    Hepatic and abdominal adiposity in type 2 diabetes as assessed with machine learning on computed tomography scans.
    Diabetes Obes Metab. 2026 Feb 18. doi: 10.1111/dom.70557.
    >> Share

  40. FOUNTOULAKIS N, Pavlou P, Stathi D, Goubar A, et al
    Effect of lixisenatide on arterial stiffness in people with type 2 diabetes and kidney disease: Results of a randomised controlled trial.
    Diabetes Obes Metab. 2026 Feb 18. doi: 10.1111/dom.70481.
    >> Share

  41. ULRICH FS, Napoli N, Nielsen MF, Burden AM, et al
    Real-world persistence and dose titration of GLP-1 receptor agonists in type 2 diabetes: A UK population-based cohort study by obesity and cardiovascular disease status.
    Diabetes Obes Metab. 2026 Feb 17. doi: 10.1111/dom.70535.
    >> Share

  42. YAO K, Yang X, Lei S, Yin S, et al
    Trends and disparities in type 1 diabetes-related mortality in the United States, 1999-2023.
    Diabetes Obes Metab. 2026 Feb 12. doi: 10.1111/dom.70546.
    >> Share

  43. MINAKATA Y, Miura M, Nakatake N, Masuzawa M, et al
    Real-world effectiveness and safety of tirzepatide in Japanese patients with type 2 diabetes: A multi-site retrospective study.
    Diabetes Obes Metab. 2026 Feb 12. doi: 10.1111/dom.70550.
    >> Share

  44. PITT JP, Muller A, Nicholas C, McCarthy OM, et al
    Comparison of pharmacodynamics and pharmacokinetics of ultra-rapid-acting insulin aspart and rapid-acting insulin aspart around continuous moderate intensity exercise in adults with type 1 diabetes: A randomised controlled trial.
    Diabetes Obes Metab. 2026 Feb 10. doi: 10.1111/dom.70487.
    >> Share


  45. RETRACTION: Effects of GLP-1 Receptor Agonists on Cognitive Function in Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis Based on Randomized Controlled Trials.
    Diabetes Obes Metab. 2026 Feb 10. doi: 10.1111/dom.70552.
    >> Share

  46. O'NEAL DN, Sartoretto A, Holt BA, Abu Dayyeh BK, et al
    Safety, feasibility, and dose-dependent metabolic effects of endoscopic duodenal pulsed electric field therapy in adults with type 2 diabetes: Results from two multicentre proof-of-concept studies.
    Diabetes Obes Metab. 2026 Feb 9. doi: 10.1111/dom.70533.
    >> Share

  47. NGUYEN B, Quon S, Dhaliwal B, Warwas M, et al
    Early versus late initiation of long-acting insulin in paediatric and adult diabetic ketoacidosis: A systematic review and meta-analysis of randomised control trials.
    Diabetes Obes Metab. 2026 Feb 9. doi: 10.1111/dom.70542.
    >> Share

  48. VERKET M, Buitkamp LF, Kanna NDD, Thomas A, et al
    Effects of coaching with data management system intervention or usual care on glycemic control in patients with type 2 diabetes: A multicentre, randomised controlled trial.
    Diabetes Obes Metab. 2026 Feb 9. doi: 10.1111/dom.70534.
    >> Share

  49. GU JX, Huang J, Zhang AM, Wang ZW, et al
    Oxidised lipoproteins and the risk of type 2 diabetes mellitus: A 5-year cohort study on beta-cell dysfunction and prediabetes progression.
    Diabetes Obes Metab. 2026 Feb 9. doi: 10.1111/dom.70540.
    >> Share

  50. LAI CWY, Kwok HHY, Ye J, Ng CS, et al
    Effectiveness of behavioural economics-based financial incentives and social feedback on glycaemic control and physical activity in adults with newly diagnosed type 2 diabetes: A randomised control trial.
    Diabetes Obes Metab. 2026 Feb 9. doi: 10.1111/dom.70541.
    >> Share

  51. TAN JY, Nalbandian C, Moran C, Zhou Z, et al
    Single versus repeat diabetes testing in older adults: Observations from the STAREE clinical trial.
    Diabetes Obes Metab. 2026 Feb 6. doi: 10.1111/dom.70539.
    >> Share

  52. ARDAKANI J, Shahid I, Gullapelli R, Ahmed EN, et al
    Transportation noise exposure and incident type 2 diabetes: A retrospective cohort study in a large U.S. healthcare system.
    Diabetes Obes Metab. 2026 Feb 6. doi: 10.1111/dom.70499.
    >> Share

  53. LI XY, Jin Y, Feng XY, Wang RC, et al
    Prevalence and predictors of residual gastric content in patients with type 2 diabetes on GLP-1 receptor agonists: A prospective observational study.
    Diabetes Obes Metab. 2026 Feb 3. doi: 10.1111/dom.70537.
    >> Share

  54. KIM SR, Hong JH, Kim SG, Kim SK, et al
    Efficacy and safety of adding a fourth oral antidiabetic drug versus metformin dose escalation in patients with type 2 diabetes inadequately controlled on triple oral combination therapy (EFFORT): A 24-week, randomized, open-label, multicenter trial.
    Diabetes Obes Metab. 2026 Feb 3. doi: 10.1111/dom.70527.
    >> Share

  55. SHAO JW, Yang Y, Zhang YQ, Dai HY, et al
    Early detection of type 2 diabetes mellitus-associated cognitive dysfunction: The potential of amide proton transfer-weighted imaging.
    Diabetes Obes Metab. 2026 Feb 2. doi: 10.1111/dom.70468.
    >> Share


  56. Correction to "Continuous glucose monitoring in early gestational diabetes improves maternal and neonatal outcomes-The Steady Sugar trial".
    Diabetes Obes Metab. 2026 Feb 2. doi: 10.1111/dom.70544.
    >> Share

  57. KUGATHASAN L, Tsoukas MA, Nardone M, Sridhar VS, et al
    Semaglutide and cardiovascular risk in type 1 diabetes: A predictive modelling analysis in a double-blind, randomised, placebo-controlled cross-over trial.
    Diabetes Obes Metab. 2026 Feb 2. doi: 10.1111/dom.70525.
    >> Share

  58. JANUSZEWSKI AS, Snaith JR, Kowalski GM, Bruce CR, et al
    Interactive online calculator for estimation of muscle and hepatic insulin sensitivity in adults with Type 1 diabetes using clinical and research biomarkers.
    Diabetes Obes Metab. 2026 Feb 2. doi: 10.1111/dom.70517.
    >> Share

  59. MCKAY B, El Chaar D, Paquette M, Vallis M, et al
    Rationale and design of a parallel randomised trial of a plant-based intensive lifestyle intervention for diabetes remission: The REmission of diabetes using a PlAnt-based weight loss InteRvention (REPAIR) trial.
    Diabetes Obes Metab. 2026 Feb 2. doi: 10.1111/dom.70510.
    >> Share

  60. WEI Y, Tian Y, Cui R, Wang Y, et al
    Associations of adipose tissue insulin resistance with fasting blood glucose and HbA1c in adults without diabetes.
    Diabetes Obes Metab. 2026 Feb 2. doi: 10.1111/dom.70513.
    >> Share

  61. SU Q, Huang WZ, Huang Y, Mo LR, et al
    Synergistic effects of hypertension and diabetes on cardiovascular risk in elderly: Comparative longitudinal analysis of CHARLS and HRS.
    Diabetes Obes Metab. 2026 Feb 2. doi: 10.1111/dom.70528.
    >> Share

  62. CHOU YC, Weng SH, Cheng FS, Tseng CH, et al
    Unintentional periconceptional exposure to glucagon-like peptide-1 receptor agonists and adverse pregnancy outcomes: A nationwide cohort study in Taiwan.
    Diabetes Obes Metab. 2026;28:1420-1430.
    >> Share

  63. XING X, Zhao L, Wang K, Wang Z, et al
    Therapeutic equivalence and switching between biosimilar and reference insulins: A systematic review and meta-analysis of randomised controlled trials.
    Diabetes Obes Metab. 2026;28:1371-1382.
    >> Share

  64. ANAGNOSTAKIS F, Kokkorakis M, Nagarajan S, Anastasiou G, et al
    Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists for incident dementia: A retrospective multicohort study.
    Diabetes Obes Metab. 2026;28:1443-1452.
    >> Share

  65. HEUBOECK E, Bhogal CS, Mandl M
    Heart matters: How glucose- and lipid-modulating drugs remodel epicardial adipose tissue accumulation, inflammatory patterns and browning.
    Diabetes Obes Metab. 2026;28:878-894.
    >> Share

  66. BANDURA M, Piotrowska-Mieczkowska M, Hennig M, Gliwinski M, et al
    Safety and efficacy of the therapy with CD4 + CD25highCD127-T regulatory cells: When paediatric patient becomes adult.
    Diabetes Obes Metab. 2026;28:1392-1402.
    >> Share

  67. VILSBOLL T, Stellfeld M, Aroda VR, Dandanell S, et al
    Assessment of thyroid cancer risk associated with glucagon-like peptide 1 receptor agonist use.
    Diabetes Obes Metab. 2026;28:1499-1507.
    >> Share

  68. RIVELINE JP, Julla JB, Bonnemaison E, Joubert M, et al
    A nationwide 12-month observatory of automated insulin delivery shows improved glucose control, sustained adoption, and reduced acute severe events.
    Diabetes Obes Metab. 2026;28:1179-1190.
    >> Share

  69. FERREIRA JP, Marques P, Anker SD, Butler J, et al
    Effects of SGLT2 inhibitors across the spectrum of albuminuria in cardiovascular-kidney-metabolic conditions: A pooled analysis of randomised trials.
    Diabetes Obes Metab. 2026;28:1105-1115.
    >> Share

  70. PINDER L, Rickwood S, Konrad M, Kostev K, et al
    Annual prevalence of the body mass index documentation in the UK primary care: A cross-sectional study using IQVIA medical research data.
    Diabetes Obes Metab. 2026;28:1482-1489.
    >> Share

  71. GUTIERREZ DE PINERES V, Tamayo-Torres CS, Ramirez-Cisneros A, Kavelidou M, et al
    Effects of liraglutide treatment for 18 days on metabolic parameters, regional body composition and the myostatin-activin-follistatin-IGF-1 axis: Results from an exploratory, randomized, placebo-controlled, crossover study.
    Diabetes Obes Metab. 2026;28:1258-1265.
    >> Share

  72. ZHAO M, Liu Y, Huang W, Song G, et al
    Long-term glycemic exposure, glycemic control stability and incident calcific aortic valve disease: A prospective cohort study.
    Diabetes Obes Metab. 2026;28:1081-1089.
    >> Share

  73. ALFONSO ARVEZ MJ, Tan GSQ, Ademi Z, Ilomaki J, et al
    Initiation of sodium-glucose cotransporter-2 inhibitors and the risk of infection-related hospitalisations: A population-based cohort study.
    Diabetes Obes Metab. 2026;28:1057-1067.
    >> Share

    January 2026
  74. GAO FM, Kishore K, Pandey D, Jahanabadi H, et al
    Effect of preoperative SGLT2 inhibitor use on postoperative acute kidney injury in patients with type 2 diabetes undergoing surgery: A causal inference study using routinely collected data.
    Diabetes Obes Metab. 2026 Jan 29. doi: 10.1111/dom.70509.
    >> Share

  75. LEI L, Li Y, Chen S, Zou Y, et al
    Peptidylarginine deiminase 4-mediated neutrophil extracellular trap formation aggravates beta-cell damage in type 1 diabetes: A multi-model study.
    Diabetes Obes Metab. 2026 Jan 29. doi: 10.1111/dom.70442.
    >> Share

  76. KEELS JN, LaPlante RD, Lee CS, Dwyer AA, et al
    Prevalence of new-onset diabetes following COVID-19 infection: A systematic review and meta-analysis.
    Diabetes Obes Metab. 2026 Jan 28. doi: 10.1111/dom.70508.
    >> Share

  77. ABDEL-RAHMAN SM, Al-Shiab R, Shah E, Guldan M, et al
    Efficacy and safety of GLP-1 receptor agonists and SGLT2 inhibitors as adjuncts to insulin in type 1 diabetes: Systematic review and meta-analysis.
    Diabetes Obes Metab. 2026 Jan 28. doi: 10.1111/dom.70506.
    >> Share

  78. NARDONE M, Moedt E, Heerspink HJL, Davies MJ, et al
    Effects of sotagliflozin on markers of volume status and sodium handling in patients with type 1 diabetes: A biomarker analysis of the inTandem3 clinical trial.
    Diabetes Obes Metab. 2026 Jan 27. doi: 10.1111/dom.70520.
    >> Share

  79. ZHU X, Lipscombe LL, Shulman R, Lovblom LE, et al
    Timing of insulin pump initiation among individuals with type 1 diabetes in Ontario, Canada.
    Diabetes Obes Metab. 2026 Jan 26. doi: 10.1111/dom.70514.
    >> Share

  80. PAVLOU P, Anandhakrishnan A, Athanasiadou KI, Brackenridge A, et al
    Discordant real-world glycaemic outcomes with Omnipod 5 and MiniMed 780G in adults with type 1 diabetes: Why validated measures matter.
    Diabetes Obes Metab. 2026 Jan 26. doi: 10.1111/dom.70480.
    >> Share

  81. DICEMBRINI I, Poggi CD, Del Vescovo GG, Marinelli C, et al
    Efficacy of telemedicine on glycaemic control in nursing home residents with type 2 diabetes on basal-bolus insulin therapy: A randomised controlled trial.
    Diabetes Obes Metab. 2026 Jan 26. doi: 10.1111/dom.70511.
    >> Share


  82. Correction to 'Early subcutaneous basal insulin with intravenous insulin infusion for diabetic ketoacidosis management: A systematic review and meta-analysis of randomised controlled trials'.
    Diabetes Obes Metab. 2026 Jan 26. doi: 10.1111/dom.70518.
    >> Share

  83. GU Z, Chen L, Zhan K, Xi X, et al
    Development of the health economic model for type 2 diabetes considering glycaemic variability.
    Diabetes Obes Metab. 2026 Jan 26. doi: 10.1111/dom.70451.
    >> Share

  84. SUN M, Wang X, Lu Z, Yang Y, et al
    GLP-1RAs versus metformin and Parkinson's risk in type 2 diabetes.
    Diabetes Obes Metab. 2026 Jan 26. doi: 10.1111/dom.70459.
    >> Share

  85. MORRISSEY PI, Clarke ED, Loh XT, Collins CE, et al
    Nutrition interventions for anxiety, depression, stress and/or diabetes-related distress in individuals with diabetes: A systematic review and meta-analysis of randomised controlled trials.
    Diabetes Obes Metab. 2026 Jan 26. doi: 10.1111/dom.70444.
    >> Share

  86. MAKINO H, Kasahara M, Takashima R, Kasama S, et al
    Effect of empagliflozin on urinary albumin excretion and hypoxic biomarkers in early diabetic kidney disease: A randomised double-blind, placebo-controlled trial.
    Diabetes Obes Metab. 2026 Jan 26. doi: 10.1111/dom.70485.
    >> Share

  87. LI N, Sun J, Li H, Li C, et al
    Drug-gene interactions and the risk of diabetic microvascular complications: A population-based cohort study.
    Diabetes Obes Metab. 2026 Jan 26. doi: 10.1111/dom.70501.
    >> Share

  88. BORLONGAN LAZ, Samante FLD, Ontingco AJM, Tilbe JPA, et al
    Impact of luseogliflozin on metabolic health, lipid profiles, and cardiovascular outcomes in patients with type II diabetes: A systematic review and network meta-analysis.
    Diabetes Obes Metab. 2026 Jan 25. doi: 10.1111/dom.70482.
    >> Share

  89. BOURRON O, Denimal D
    Efficacy and safety of once-weekly insulins in type 2 diabetes: A systematic review and meta-analysis.
    Diabetes Obes Metab. 2026 Jan 23. doi: 10.1111/dom.70497.
    >> Share

  90. AZEGAMI T, Kaneko H, Okada A, Suzuki Y, et al
    SGLT2 inhibitors and mortality in older adults with diabetic kidney disease: A target trial emulation study.
    Diabetes Obes Metab. 2026 Jan 23. doi: 10.1111/dom.70502.
    >> Share

  91. MARTENS T, Battelino T, Heller S, Bhargava A, et al
    CGM-derived efficacy and overall safety of once-weekly insulin efsitora alfa (efsitora) relative to day of administration in adults with type 2 diabetes.
    Diabetes Obes Metab. 2026 Jan 22. doi: 10.1111/dom.70419.
    >> Share

  92. LIU X, Liang Z, Liu C, Ma Y, et al
    Oral indole-3-propionic acid preserves beta-cell function and improves glucose homeostasis in diabetic mice via FOXA1-SGPP1-HSPA5 signalling.
    Diabetes Obes Metab. 2026 Jan 21. doi: 10.1111/dom.70471.
    >> Share

  93. TAKAHASHI Y, Hayashi M, Kato T, Horikawa Y, et al
    BALLAST study: A multicentre, open-label, randomized-controlled, 52-week clinical trial of the efficacy and safety of luseogliflozin in older Japanese adults with type 2 diabetes receiving leucine-enriched amino acid supplementation and physical exerc
    Diabetes Obes Metab. 2026 Jan 21. doi: 10.1111/dom.70494.
    >> Share

  94. ZHANG Z, Zhao L, Wang Z, Zhou X, et al
    Lipoprotein(a) is associated with ASCVD in individuals with non-diabetes, prediabetes, or diabetes independent of CRP.
    Diabetes Obes Metab. 2026 Jan 21. doi: 10.1111/dom.70491.
    >> Share

  95. MONNIER L, Owens D
    New paths to attenuate the burden of hypoglycaemia in type 1 diabetes.
    Diabetes Obes Metab. 2026 Jan 21. doi: 10.1111/dom.70512.
    >> Share

  96. WANG Y, Meng X, Zhang X, Li M, et al
    Longitudinal exposure to non-HDL-C and cardiovascular events, all-cause mortality in type 2 diabetes: A post hoc analysis of the ACCORD trial.
    Diabetes Obes Metab. 2026 Jan 21. doi: 10.1111/dom.70498.
    >> Share

  97. CROOS J, Shooshtarian AK, Stotesbury B, Gallen G, et al
    Clinical outcomes of adults with type 1 diabetes and comorbid depression and/or anxiety disorders using hybrid closed-loop: A retrospective study from a multidisciplinary tertiary centre.
    Diabetes Obes Metab. 2026 Jan 20. doi: 10.1111/dom.70432.
    >> Share

  98. PSCHERER S, Fritsche A, Anderten H, Pegelow K, et al
    Efficacy and safety of switching basal insulin to insulin glargine 300 U/mL in individuals with inadequately controlled type 2 diabetes on advanced insulin therapies: The Toujeo-Neo T2DM study.
    Diabetes Obes Metab. 2026 Jan 20. doi: 10.1111/dom.70417.
    >> Share

  99. CHEVALIER C, Rodrigues Oliveira A, Wargny M, Cloteau C, et al
    Methylglyoxal-glycated apolipoproteins A-I and A-II are associated with new-onset diabetes in individuals with prediabetes.
    Diabetes Obes Metab. 2026 Jan 20. doi: 10.1111/dom.70493.
    >> Share

  100. GARRE TI, Guedet CG, Alexandre-Heymann L, Messier V, et al
    Association between daily steps, diabetes management and health indicators in people living with type 1 diabetes: A cross-sectional study from the BETTER registry.
    Diabetes Obes Metab. 2026 Jan 20. doi: 10.1111/dom.70473.
    >> Share

  101. TATEWAKI T, Okada A, Kimura Y, Yasunaga H, et al
    Risk of acute pancreatitis with DPP-4 inhibitors versus SGLT2 inhibitors in medication-naive individuals with diabetes: A target trial emulation.
    Diabetes Obes Metab. 2026 Jan 20. doi: 10.1111/dom.70490.
    >> Share

  102. TIAN X, Wu S, Xia X, Xu Q, et al
    Cardiovascular outcomes under hypothetical blood-pressure-lowering intervention in type 2 diabetes: A target trial emulation.
    Diabetes Obes Metab. 2026 Jan 20. doi: 10.1111/dom.70472.
    >> Share

  103. VERMA A, Upadhyay A
    Diabetic kidney disease, biomarkers, and finerenone.
    Diabetes Obes Metab. 2026 Jan 19. doi: 10.1111/dom.70464.
    >> Share

  104. JONES AM, Hallworth P, Kendal H, Mottershead C, et al
    Preferences for basal insulin treatments in adults with type 2 diabetes: A discrete choice experiment in France and Spain.
    Diabetes Obes Metab. 2026 Jan 19. doi: 10.1111/dom.70422.
    >> Share

  105. AKMAL M, Tariq S, Mustafa M, Gulzar G, et al
    Efficacy of once-weekly insulin efsitora versus once-daily basal insulin in type 2 diabetes: A systematic review and meta-analysis.
    Diabetes Obes Metab. 2026 Jan 19. doi: 10.1111/dom.70399.
    >> Share

  106. CHAI C, Chen S, Guan G, Cui Q, et al
    Comparative prognostic value of nine cardiorenal biomarkers for mortality among adults with prediabetes and diabetes.
    Diabetes Obes Metab. 2026 Jan 13. doi: 10.1111/dom.70470.
    >> Share

  107. CHONG MY, Eussen SJPM, van der Velde JHPM, de Galan BE, et al
    Reallocating morning physical activity to later-day activity and its association with type 2 diabetes incidence: The Maastricht Study.
    Diabetes Obes Metab. 2026 Jan 13. doi: 10.1111/dom.70438.
    >> Share

  108. TSUR A, Hamtzany O, Pollack R, Cahn A, et al
    Risk of recurrent diabetic ketoacidosis following initiation of sodium-glucose co-transporter 2 inhibitors in patients with an insulin-deficient diabetes and prior diabetic ketoacidosis: An observational cohort study.
    Diabetes Obes Metab. 2026 Jan 13. doi: 10.1111/dom.70457.
    >> Share

  109. SACRE JW, Lundegard K, Mohammedi K, Carstensen B, et al
    Prediction of heart failure as the first major cardiovascular disease event in type 2 diabetes.
    Diabetes Obes Metab. 2026 Jan 13. doi: 10.1111/dom.70426.
    >> Share

  110. RAMIREZ-OBERMAYER A, Tripolt NJ, Pferschy PN, Kojzar H, et al
    Impact of intermittent fasting on self-regulatory behaviour and sleep in participants with insulin-treated type 2 diabetes: A secondary analysis of the INTERFAST-2 randomised controlled trial.
    Diabetes Obes Metab. 2026 Jan 12. doi: 10.1111/dom.70469.
    >> Share

  111. KATZ A, Shulkin A, Housni A, Roy-Fleming A, et al
    A systematic review of glucocorticoid use in type 1 diabetes: Glycaemic effects and clinical management strategies.
    Diabetes Obes Metab. 2026 Jan 12. doi: 10.1111/dom.70465.
    >> Share

  112. MESSIER V, Ramsay T, Rabasa-Lhoret R, Sun CJ, et al
    The spectrum of exogenous insulin requirement in people living with type 1 diabetes: A cross-sectional analysis.
    Diabetes Obes Metab. 2026 Jan 12. doi: 10.1111/dom.70467.
    >> Share

  113. BRILLINGER J, Filliter C, Salmasi S, Zapata-Bravo E, et al
    Long-acting insulin analogues and the risk of diabetic nephropathy among patients with type 2 diabetes: A population-based cohort study.
    Diabetes Obes Metab. 2026 Jan 12. doi: 10.1111/dom.70397.
    >> Share

  114. SUGIMOTO T, Omura T, Araki A, Haneda C, et al
    Long-term effects of a multidomain intervention on cognitive function and metabolic control in older adults with type 2 diabetes and mild cognitive impairment: A 42-month follow-up of the J-MIND-Diabetes study.
    Diabetes Obes Metab. 2026 Jan 8. doi: 10.1111/dom.70431.
    >> Share

  115. GIUGLIANO D, Longo M, Di Martino N, Scappaticcio L, et al
    GLP1-1RAs improve walking distance and reduce amputation in people with type 2 diabetes and peripheral artery disease: A systematic review and meta-analysis of randomised controlled trials and cohort studies.
    Diabetes Obes Metab. 2026 Jan 8. doi: 10.1111/dom.70454.
    >> Share

  116. MARIGLIANO M, Mozzillo E, Romanelli R, Passanisi S, et al
    Higher post-prandial glucose excursions in youth with type 1 diabetes and celiac disease: Time to change the bolus?
    Diabetes Obes Metab. 2026 Jan 8. doi: 10.1111/dom.70430.
    >> Share

  117. RIVELINE JP, Renard E, Aleppo G, Bode BW, et al
    Psychosocial outcomes among adults with type 1 diabetes using a tubeless automated insulin delivery system compared with sensor augmented pump therapy: A randomised, parallel-group clinical trial sub-study.
    Diabetes Obes Metab. 2026 Jan 8. doi: 10.1111/dom.70416.
    >> Share

  118. TAN X, Liang Y, Xie L, Harton J, et al
    Comparison of cardiovascular outcomes between once-weekly semaglutide and dulaglutide in adults with type 2 diabetes and established atherosclerotic cardiovascular disease in the United States.
    Diabetes Obes Metab. 2026 Jan 8. doi: 10.1111/dom.70440.
    >> Share

  119. ZAWADKA M, Taguiam E, Le ML, Sanjanwala R, et al
    Sex differences in trial representation and the cardiovascular effectiveness of newer glucose-lowering agents in patients with and without type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials.
    Diabetes Obes Metab. 2026 Jan 8. doi: 10.1111/dom.70411.
    >> Share

  120. OH R, Kim S, Cho SH, Kim JY, et al
    Elevated triglyceride-glucose index is associated with increased risk of chronic kidney disease and end-stage renal disease in type 1 diabetes: Nationwide cohort study.
    Diabetes Obes Metab. 2026 Jan 7. doi: 10.1111/dom.70455.
    >> Share

  121. HERMANNS N, Kittel P, Cerletti P, Kulzer B, et al
    Independent associations of mental health and diabetes complications with health-related quality of life: Evidence from a cross-sectional study.
    Diabetes Obes Metab. 2026 Jan 7. doi: 10.1111/dom.70434.
    >> Share

  122. TONG X, Zhang Y, Zhang L, Zhang L, et al
    Once-weekly insulin icodec versus once-daily insulin degludec for type 2 diabetes in China: A cost-utility and budget impact analysis.
    Diabetes Obes Metab. 2026 Jan 6. doi: 10.1111/dom.70435.
    >> Share

  123. KISHIMORI T, Kato T, Iwasaki Y, Shimada T, et al
    Oral semaglutide and survival in heart failure with preserved ejection fraction and type 2 diabetes.
    Diabetes Obes Metab. 2026 Jan 5. doi: 10.1111/dom.70433.
    >> Share

  124. CHEN L, Zhang Q, Duan B, Wu X, et al
    Effects of age and disease duration on the glycaemic outcomes and safety of insulin glargine 300 U/mL in people with type 2 diabetes in China: A post-hoc analysis of the INITIATION study.
    Diabetes Obes Metab. 2026 Jan 5. doi: 10.1111/dom.70420.
    >> Share

  125. KABYTAEV K, Maddaloni E, Ferm ML, Redondo MJ, et al
    C-peptide as an important biomarker in diabetes management: The need for standardization of its measurement.
    Diabetes Obes Metab. 2026 Jan 5. doi: 10.1111/dom.70447.
    >> Share

  126. TAJIMA T, Kaga H, Ito N, Kogai T, et al
    Dual action of imeglimin on insulin secretion and sensitivity in type 2 diabetes.
    Diabetes Obes Metab. 2026 Jan 5. doi: 10.1111/dom.70449.
    >> Share

  127. YEO YH, San BJ, Lim GK, Tan MC, et al
    Increasing cardiovascular mortality in young adults with diabetes mellitus as a contributing cause in the United States.
    Diabetes Obes Metab. 2026 Jan 5. doi: 10.1111/dom.70441.
    >> Share

  128. MORIERI ML, Vedovato M, Bonora BM, Fioretto P, et al
    The importance of treatment sequencing with SGLT2 inhibitors and GLP-1 receptor agonists combination for kidney function preservation in type 2 diabetes.
    Diabetes Obes Metab. 2026 Jan 2. doi: 10.1111/dom.70445.
    >> Share

  129. YANG C, Denig P, Chepulis L, Paul RG, et al
    Age disparities in SGLT2 inhibitor prescription among people with type 2 diabetes: The role of frailty and sex.
    Diabetes Obes Metab. 2026 Jan 2. doi: 10.1111/dom.70421.
    >> Share

  130. THIJS I, Siegelaar SE, Elhenawy YI 1st, Benhalima K, et al
    Challenges in glycaemic control among women with type 1 diabetes and the role of MiniMed 780G system: A narrative review.
    Diabetes Obes Metab. 2026 Jan 2. doi: 10.1111/dom.70377.
    >> Share

  131. HOOKER SA, Neugebauer RS, Schmittdiel JA, An J, et al
    Comparative safety of glucose-lowering medications on depression in adults with type 2 diabetes.
    Diabetes Obes Metab. 2026 Jan 2. doi: 10.1111/dom.70415.
    >> Share

  132. PURCELL AR, Zhen XM, Wong J, Glastras SJ, et al
    Glucagon-like peptide-1 receptor agonist treatment reduces body weight and improves glycaemic outcomes in patients with concurrent overweight/obesity and type 1 diabetes: A systematic review and meta-analysis.
    Diabetes Obes Metab. 2026;28:296-305.
    >> Share

  133. LE ROUX CW, Wharton S, Bozkurt B, Platz E, et al
    Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE-1).
    Diabetes Obes Metab. 2026;28:337-346.
    >> Share

  134. AOYAMA K, Okada A, Kaneko H, Azegami T, et al
    Evolving trends of antidiabetic agents stratified by age, kidney function and body mass index: Insights from a nationwide claims database.
    Diabetes Obes Metab. 2026;28:701-710.
    >> Share

  135. ALCIBAHY Y, Darwish R, Butler AE, Moin ASM, et al
    Pancreatic beta-cell turnover in health and disease.
    Diabetes Obes Metab. 2026;28:27-49.
    >> Share

  136. LAMBERT F, Guillon E, Gatta-Cherifi B, Soula H, et al
    Effectiveness and safety of GLP-1 receptor agonists in craniopharyngioma patients with obesity: A multicentre real-world study.
    Diabetes Obes Metab. 2026;28:443-451.
    >> Share

  137. SA B, Maristany A, Subramaniam A, Guillen R, et al
    Psychiatric effects of GLP-1 receptor agonists: A systematic review of emerging evidence.
    Diabetes Obes Metab. 2026;28:50-59.
    >> Share

  138. MILANOVIC S, Lew R, Xiong K, Casavant E, et al
    A double-blind study on ulotaront's impact on weight-related parameters in schizophrenia patients with metabolic syndrome and prediabetes: Part II.
    Diabetes Obes Metab. 2026;28:94-102.
    >> Share

  139. MILANOVIC S, Lew R, Xiong K, Casavant E, et al
    An open-label study on ulotaront's effects on insulin-glucose regulation in schizophrenia patients with metabolic syndrome and prediabetes: Part I.
    Diabetes Obes Metab. 2026;28:103-111.
    >> Share

  140. HISADA H, Ikeuchi K, Tsuji Y, Yamamichi N, et al
    Glucagon-like peptide-1 receptor agonist and respiratory complications after endoscopy: A Japanese nationwide cohort study.
    Diabetes Obes Metab. 2026;28:316-323.
    >> Share

  141. ALISSOU M, Demangeat T, Folope V, Van Elslande H, et al
    Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study.
    Diabetes Obes Metab. 2026;28:112-121.
    >> Share

  142. HENNEY AE, Riley DR, Heague M, Roberts CA, et al
    Relative efficacy of GLP-1 and GLP-1/GIP receptor agonists in the prevention of alcohol-use disorders using a target trial emulation approach.
    Diabetes Obes Metab. 2026;28:137-150.
    >> Share

  143. XU Z, Huang Q, Zhang X, Wang S, et al
    Reevaluating the causal link between liver fat and hyperglycaemia.
    Diabetes Obes Metab. 2026;28:231-241.
    >> Share

  144. STUPALKOWSKA W, Henney A, Sheu EG, Alam U, et al
    Metabolic bariatric surgery is associated with reduced adverse hepatic and extrahepatic outcomes, and lower all-cause mortality, in patients with steatotic liver disease.
    Diabetes Obes Metab. 2026;28:174-185.
    >> Share

  145. BASSET-SAGARMINAGA J, De Block C, Norgaard K, O'Neal DN, et al
    Safety and glycaemic control during exercise with the MiniMed 780G: A narrative review of evidence from lab to real world.
    Diabetes Obes Metab. 2026;28 Suppl 1.
    >> Share

    December 2025
  146. BHANDARI R, Rhee JW, Chen S, Pillai R, et al
    Association of clonal haematopoiesis and diabetes with outcomes after autologous haematopoietic cell transplantation.
    Diabetes Obes Metab. 2025 Dec 28. doi: 10.1111/dom.70406.
    >> Share

  147. TSAI HR, Hsu JZ, Lee YC, Loh CH, et al
    Risk of diabetic retinopathy and ophthalmic interventions in patients with diabetes mellitus taking different oral anticoagulants.
    Diabetes Obes Metab. 2025 Dec 28. doi: 10.1111/dom.70392.
    >> Share

  148. KONING S, Dekker P, Birnie E, van den Heuvel T, et al
    What is the impact of an advanced hybrid closed-loop system on weight control among people with type 1 diabetes?
    Diabetes Obes Metab. 2025 Dec 28. doi: 10.1111/dom.70410.
    >> Share

  149. HOE B, Heimburger SMN, Gasbjerg LS, Lanng AR, et al
    Glucose-dependent insulinotropic polypeptide reduces postprandial glucose excursions but does not protect from hypoglycaemia in persons with type 1 diabetes-A randomised placebo-controlled study.
    Diabetes Obes Metab. 2025 Dec 28. doi: 10.1111/dom.70373.
    >> Share

  150. FOO N, Chodapaneedi S, Gibson B, Koh HJW, et al
    Comparative effectiveness of glucose monitoring methods and glycaemic control in patients with type 2 diabetes: An umbrella review.
    Diabetes Obes Metab. 2025 Dec 28. doi: 10.1111/dom.70401.
    >> Share

  151. VOGT J, Benkhoff M, Schroder NH, Hu H, et al
    Defective high-density lipoprotein lipoprotection in type 2 diabetes during acute myocardial infarction is rescued by apolipoprotein M/sphingosine-1-phosphate loading.
    Diabetes Obes Metab. 2025 Dec 28. doi: 10.1111/dom.70409.
    >> Share

  152. WANG Y, Wang Y, Mu Y, Cheng Y, et al
    Effects of SGLT2 inhibitors on development and progression of kidney disease in Chinese patients with type 2 diabetes: A multicentre, prospective real-world study.
    Diabetes Obes Metab. 2025 Dec 28. doi: 10.1111/dom.70413.
    >> Share

  153. GAO JW, Wu YB, Huang ZG, Deng QR, et al
    Comprehensive risk factor control and its biomarker-mediated association with diabetic microvascular complications.
    Diabetes Obes Metab. 2025 Dec 25. doi: 10.1111/dom.70403.
    >> Share

  154. ZHENG C, Cao D, Ma R, Hao X, et al
    Current status of multi-target therapeutics for diabetic macular oedema: Mechanisms and outcomes from clinical trials.
    Diabetes Obes Metab. 2025 Dec 23. doi: 10.1111/dom.70405.
    >> Share

  155. MAHESH S, Anson M, Malik RA, Cuthbertson DJ, et al
    Real-world evaluation of teplizumab in type 1 diabetes: Progression to insulin requirement.
    Diabetes Obes Metab. 2025 Dec 22. doi: 10.1111/dom.70354.
    >> Share

  156. ZHOU T, Tang H, Zhang B, Zhang D, et al
    Association between glucagon-like peptide-1 receptor agonists and risk of dementia in older adults with type 2 diabetes: A target trial emulation.
    Diabetes Obes Metab. 2025 Dec 22. doi: 10.1111/dom.70384.
    >> Share

  157. SYED AS, Arani G, Macwan S, Koska J, et al
    Obesity and overweight-related differences in cardiometabolic risk factors in type 1 diabetes.
    Diabetes Obes Metab. 2025 Dec 22. doi: 10.1111/dom.70329.
    >> Share

  158. DEDEEPYA SD, Goel V, Desai NN
    Comment on "Associations between gestational diabetes and cardiovascular disease largely operate independently of postpartum causal pathways: A population-based cohort study in England".
    Diabetes Obes Metab. 2025 Dec 22. doi: 10.1111/dom.70402.
    >> Share

  159. HU H, Wang G, Liang Y, Liu Y, et al
    Spatiotemporal burden, risk factors, and genetic causality of non-alcoholic fatty liver disease and type 2 diabetes mellitus comorbidity in Europe: A multi-database analysis.
    Diabetes Obes Metab. 2025 Dec 22. doi: 10.1111/dom.70398.
    >> Share

  160. DUTTA D, Mahajan K, Kamrul-Hasan ABM, Mahajan N, et al
    Impact of glucagon-like peptide-1 receptor agonism-based therapies on limb outcomes in peripheral artery disease and type 2 diabetes: An updated systematic review and meta-analysis.
    Diabetes Obes Metab. 2025 Dec 22. doi: 10.1111/dom.70391.
    >> Share

  161. HE Y, Dai Z, Yu AP, Wong SH, et al
    Efficacy of a low-carbohydrate diet combined with exercise on glycemic control and metabolic health in type 2 diabetes mellitus: A systematic review and meta-analysis.
    Diabetes Obes Metab. 2025 Dec 19. doi: 10.1111/dom.70379.
    >> Share

  162. LEE SH, Han KA, Hong EG, Kang JG, et al
    Efficacy and safety of combining empagliflozin in people with type 2 diabetes mellitus uncontrolled with metformin and sitagliptin: A randomised, double-blind, multicentre, therapeutic confirmatory phase 3 clinical trial.
    Diabetes Obes Metab. 2025 Dec 19. doi: 10.1111/dom.70386.
    >> Share

  163. YANG B, Sun F, Poon ET, Wang J, et al
    Effects of exercise interventions on 24-h continuous glucose profiles in non-diabetic populations: A systematic review and meta-analysis.
    Diabetes Obes Metab. 2025 Dec 19. doi: 10.1111/dom.70368.
    >> Share

  164. SPEZANI R, Mandarim-de-Lacerda CA
    Beyond diabetes and obesity: GLP-1 receptor agonists in disrupting the vicious cycle of metabolic dysfunction and neuroinflammation.
    Diabetes Obes Metab. 2025 Dec 19. doi: 10.1111/dom.70400.
    >> Share

  165. MINSKY NC, Olshanskiy D, Aharon-Hananel G
    Effect of semaglutide add-on therapy for people living with type 1 diabetes and excess weight.
    Diabetes Obes Metab. 2025 Dec 19. doi: 10.1111/dom.70389.
    >> Share

  166. MALTONI G, Bernardini L, Scozzarella A, Candela E, et al
    High co-incidence of coeliac disease in paediatric type 1 diabetes: A call for systematic screening.
    Diabetes Obes Metab. 2025 Dec 19. doi: 10.1111/dom.70395.
    >> Share

  167. SANFILIPPO S, Thurm U, Renfordt M, Schierbauer J, et al
    Performance of three simultaneously used rtCGM systems around a physically active weekend camp in adults with type 1 diabetes: A prospective lab and real-world study.
    Diabetes Obes Metab. 2025 Dec 19. doi: 10.1111/dom.70369.
    >> Share

  168. ZHANG S, Zhang J, Yang Y, Zhu W, et al
    Global prevalence of chronic kidney disease in type 1 diabetes: A systematic review and meta-analysis.
    Diabetes Obes Metab. 2025 Dec 17. doi: 10.1111/dom.70378.
    >> Share

  169. LUI JNM, Wong KTC, Lau ESH, Chan SCS, et al
    Work productivity, associated risk factors and costs on presenteeism and absenteeism in Chinese patients with young-onset type-2 diabetes in Hong Kong.
    Diabetes Obes Metab. 2025 Dec 16. doi: 10.1111/dom.70352.
    >> Share

  170. DEFRONZO RA
    Chronically elevated sympathetic nervous system tone: A significant, common, and poorly realised contributor to cardiometabolic disease in type 2 diabetes.
    Diabetes Obes Metab. 2025 Dec 15. doi: 10.1111/dom.70347.
    >> Share

  171. CHUNG GE, Yu SJ, Park J, Kim YJ, et al
    Associations between steatotic liver disease subtypes and incident diabetes in young Korean adults: A nationwide cohort study.
    Diabetes Obes Metab. 2025 Dec 15. doi: 10.1111/dom.70381.
    >> Share

  172. TOURKMANI AM, Al-Harbi TJ, Alghamdi AA, Youzghadli IM, et al
    Literature-informed ensemble machine learning for three-year diabetic kidney disease risk prediction in type 2 diabetes: Development, validation, and deployment of the PSMMC NephraRisk model.
    Diabetes Obes Metab. 2025 Dec 15. doi: 10.1111/dom.70385.
    >> Share

  173. HARBI H, Carney G, Dormuth C, Stidsen JV, et al
    Use of sodium-glucose cotransporter-2 inhibitors among older adults with type 2 diabetes mellitus in British Columbia.
    Diabetes Obes Metab. 2025 Dec 12. doi: 10.1111/dom.70375.
    >> Share

  174. LEI M, Zhou Y, Ni Y, Lin Z, et al
    Impact of stepwise diabetes technology advances in older adults with type 1 diabetes: A systematic review and meta-analysis of randomised trials.
    Diabetes Obes Metab. 2025 Dec 12. doi: 10.1111/dom.70355.
    >> Share

  175. CHENG AYY, Anil G, Canani L, Vinther S, et al
    Efficacy and hypoglycaemia outcomes of once-weekly insulin icodec versus once-daily basal insulin comparators across baseline HbA1c, BMI and duration of type 2 diabetes subgroups: A post hoc analysis of ONWARDS 1-5.
    Diabetes Obes Metab. 2025 Dec 12. doi: 10.1111/dom.70358.
    >> Share

  176. BHADURI G, Samajdar SS, Bandyopadhyay S, Mukherjee S, et al
    Effectiveness and safety of saroglitazar in managing dyslipidaemia and liver enzymes in patients with type 2 diabetes, MASLD, and Stage 3 chronic kidney disease: A 12-month observational study.
    Diabetes Obes Metab. 2025 Dec 10. doi: 10.1111/dom.70370.
    >> Share

  177. JAIN A, Kristensen PN, Wasehuus RS, Kruse C, et al
    Clinical implications of intentional weight loss in people living with type 2 diabetes: A real-world database study.
    Diabetes Obes Metab. 2025 Dec 10. doi: 10.1111/dom.70350.
    >> Share


  178. Correction to "An SGLT2 inhibitor, canagliflozin, reduces blood glucose level in the renal capillaries and protects the capillary network in the diabetic rats".
    Diabetes Obes Metab. 2025 Dec 9. doi: 10.1111/dom.70372.
    >> Share

  179. DRAI R, Galstyan G, Karonova T, Protsenko E, et al
    Immunogenicity, efficacy and safety of a biosimilar insulin glulisine compared with originator in adults with type 1 diabetes mellitus: A phase III randomised clinical trial.
    Diabetes Obes Metab. 2025 Dec 9. doi: 10.1111/dom.70360.
    >> Share

  180. YEN FS, Wei JC, Lu WY, Yen YH, et al
    Income-related inequities in the progression from gestational to type 2 diabetes: Findings from Taiwan's maternal and child health database.
    Diabetes Obes Metab. 2025 Dec 9. doi: 10.1111/dom.70367.
    >> Share

  181. STIMSON RH, Crane MS, Dover AR, Forbes S, et al
    CGM-derived average glucose is more strongly associated with microvascular complications than HbA1c in type 1 diabetes.
    Diabetes Obes Metab. 2025 Dec 9. doi: 10.1111/dom.70365.
    >> Share

  182. DHIPPAYOM T, Meraz M, Lee H, Hur C, et al
    GLP-1 receptor agonists for treating obesity without diabetes: A systematic review and meta-analysis of economic evaluations.
    Diabetes Obes Metab. 2025 Dec 9. doi: 10.1111/dom.70322.
    >> Share

  183. RUSSELL-JONES D, Smout V, Roy S, Myers G, et al
    A novel glucose beta-hydroxybutyrate combination improves hypoglycaemia recovery and patient-reported outcomes in type 1 diabetes.
    Diabetes Obes Metab. 2025 Dec 8. doi: 10.1111/dom.70323.
    >> Share

  184. JANSSON AK, Schumacher TL, Oldmeadow C, Grotowski M, et al
    The impact of telehealth-delivered Medical Nutrition Therapy on diabetes outcomes in rural general practice: A secondary analysis of the Healthy Rural Hearts randomised controlled trial.
    Diabetes Obes Metab. 2025 Dec 5. doi: 10.1111/dom.70339.
    >> Share

  185. RAHMAN MH, Selim S, Afsana F, Hoque MA, et al
    Safety and effectiveness of tirzepatide during Ramadan fasting: Real-world evidence from patients with type 2 diabetes in Bangladesh.
    Diabetes Obes Metab. 2025 Dec 4. doi: 10.1111/dom.70343.
    >> Share

  186. WANG Y, Wang S, Wang W, Li X, et al
    Low immunogenicity of insulin efsitora alfa in participants with type 1 and type 2 diabetes mellitus.
    Diabetes Obes Metab. 2025 Dec 4. doi: 10.1111/dom.70325.
    >> Share

  187. BARRAUD S, Aguayo GA, Cosson E, Amouyal C, et al
    Severity of complications is associated with impaired health-related quality of life in people with type 1 diabetes.
    Diabetes Obes Metab. 2025 Dec 2. doi: 10.1111/dom.70306.
    >> Share

  188. MONAMI M, Ragghianti B, Zuffanelli A, Bordoni L, et al
    Further efficacy and safety data on bio-absorbable antibiotic delivery in calcium sulphate granules for diabetic foot osteomyelitis: Extension of the BIG D-FOOT Study.
    Diabetes Obes Metab. 2025 Dec 2. doi: 10.1111/dom.70332.
    >> Share

  189. CARTER P, Simo R, Lovestam-Adrian M, Pearce I, et al
    Addressing the risk of ocular complications of GLP-1RAs; a multi-disciplinary expert consensus.
    Diabetes Obes Metab. 2025;27:7535-7543.
    >> Share

  190. CHOUDHARY P, Kao K, Quadri F, Balogh E, et al
    Contributions of intermittently scanned continuous glucose monitoring frequency and bolus insulin dosing on time in range: Analysis of data from CGM and connected insulin pens.
    Diabetes Obes Metab. 2025;27:7570-7577.
    >> Share

  191. NEFF GW
    Shared mechanistic pathways of glucagon signalling: Unlocking its potential for treating obesity, metabolic dysfunction-associated steatotic liver disease, and other cardio-kidney-metabolic conditions.
    Diabetes Obes Metab. 2025;27:6869-6883.
    >> Share

  192. WRUBLEWSKY S, Bickelmann C, Messmer LS, Wilden C, et al
    Boosting the engraftment of subcutaneously transplanted pancreatic islets by nanofat.
    Diabetes Obes Metab. 2025;27:7258-7274.
    >> Share

  193. YANG X, Tang W, Chan H, Wang M, et al
    Genetic evidence for repurposing GLP-1 receptor agonists in chronic kidney disease and IgA nephropathy: Metabolic and anti-inflammatory pathways beyond glycaemic control.
    Diabetes Obes Metab. 2025;27:7395-7407.
    >> Share

  194. JIA W, Jiang F, Xu Y, Li Y, et al
    Efficacy and safety of Efsubaglutide Alfa in "overrun" patients in the SUPER2 trial: A post-hoc analysis for comprehensive evaluation.
    Diabetes Obes Metab. 2025;27:7123-7132.
    >> Share

  195. MAQSOOD S, Sarwar MA, Belousoviene E, Maskeliunas R, et al
    GlucoNet-MM: A multimodal attention-based multi-task learning framework with decision transformer for personalised and explainable blood glucose forecasting.
    Diabetes Obes Metab. 2025;27:7416-7430.
    >> Share

  196. WITTHAUER L, Mendez C, Garcia-Tirado J, Eichenlaub M, et al
    Discrepancies between current displayed and auto-logged glucose values in FreeStyle Libre 3: Implications for clinical interpretation.
    Diabetes Obes Metab. 2025;27:7367-7373.
    >> Share

  197. DEUSCH K, Deboek A, Sina C, Capo-Velez C, et al
    Coated glucose microbeads stimulate enteric hormone release and improve glucose tolerance in Phase 1 and 2 clinical trials.
    Diabetes Obes Metab. 2025;27:7344-7354.
    >> Share

  198. FENG W, Zhu S, Kong L, Zhang W, et al
    Deletion of RalGAPbeta protects pancreatic beta cells and improves glycemic control.
    Diabetes Obes Metab. 2025;27:7323-7343.
    >> Share

  199. KIM J, Raggi P, Carreau AM, Wharton S, et al
    A review of multidisciplinary care in metabolic dysfunction-associated steatohepatitis and cardiometabolic disease, with a focus on Canada.
    Diabetes Obes Metab. 2025;27:6831-6846.
    >> Share

  200. SIDDIQUI HF, Ali D, Sajid M, Qureshi S, et al
    Sex differences in the efficacy of GLP-1 receptor agonists: A systematic review and meta-analysis of cardiovascular and renal outcome trials.
    Diabetes Obes Metab. 2025;27:6847-6856.
    >> Share

  201. XIAO YJ, Yu S, Zhang YL, Chen J, et al
    Efficacy and safety of survodutide on glycemic control and weight loss in adults: A systematic review and meta-analysis.
    Diabetes Obes Metab. 2025;27:7062-7074.
    >> Share

  202. KONG W, Fang B, Xing W
    Efficacy and safety of liraglutide in non-alcoholic fatty liver disease with or without type 2 diabetes: A systematic review and meta-analysis.
    Diabetes Obes Metab. 2025 Dec 1. doi: 10.1111/dom.70301.
    >> Share

    November 2025
  203. ERIKSSON JW, Fanni G, Lundqvist MH, Jansson S, et al
    SGLT2 inhibitor or metformin as standard treatment in early-stage type 2 diabetes? Baseline data in SMARTEST, a novel, decentralised, register-based randomised trial on prevention of diabetic complications.
    Diabetes Obes Metab. 2025 Nov 28. doi: 10.1111/dom.70320.
    >> Share

  204. EDD S, Laron-Hirsch M, Castaneda J, van den Heuvel T, et al
    A narrative review of meal management with the MiniMed 780G system: Evolution of dietary management in type 1 diabetes.
    Diabetes Obes Metab. 2025 Nov 28. doi: 10.1111/dom.70310.
    >> Share

  205. ELBADAWI H, Albalkhi N, Al Kadhim I, Elsadig A, et al
    PIONEER REAL Saudi Arabia: A multicentre, prospective, real-world study of once-daily oral semaglutide use in adults with type 2 diabetes in Saudi Arabia.
    Diabetes Obes Metab. 2025 Nov 27. doi: 10.1111/dom.70317.
    >> Share

  206. HAN G, Zhang X, Ye Y, Wang C, et al
    Cost-effectiveness of continuous glucose monitoring in Chinese adults with uncontrolled type 2 diabetes: A modelling study stratified by baseline HbA(1c).
    Diabetes Obes Metab. 2025 Nov 27. doi: 10.1111/dom.70333.
    >> Share

  207. CUNNINGHAM H, Apostolopoulos J, Ngan J, Jones H, et al
    Feasibility study of a combined insulin-delivery and glucose sensor system worn over 7 days in persons with type 1 diabetes.
    Diabetes Obes Metab. 2025 Nov 25. doi: 10.1111/dom.70331.
    >> Share

  208. LI Q, Li X, Bi Y, Lu J, et al
    Sensory network dysregulation in type 2 diabetes: Linking olfactory, visual, and cognitive function.
    Diabetes Obes Metab. 2025 Nov 25. doi: 10.1111/dom.70309.
    >> Share

  209. IWAMOTO Y, Iwamoto H, Kimura T, Kubo M, et al
    Correlation between diabetes complications severity index and actual complication severity and diabetic medication in Japanese patients with type 2 diabetes mellitus.
    Diabetes Obes Metab. 2025 Nov 25. doi: 10.1111/dom.70321.
    >> Share

  210. WINN M, Pauleck S, Richardson S, Viskochil R, et al
    New-onset prediabetes/diabetes worsens overall survival in patients with cancer: A real-world retrospective cohort study.
    Diabetes Obes Metab. 2025 Nov 24:10.1111/dom.70311. doi: 10.1111/dom.70311.
    >> Share

  211. LEWIS GA, Hughes DM, Irving G, Wilding J, et al
    Diabetes self-management education and its association with hospital admissions and premature mortality: A scoping review and meta-analysis.
    Diabetes Obes Metab. 2025 Nov 24. doi: 10.1111/dom.70296.
    >> Share

  212. PAN C, Jiang H, Feng Y, Wang S, et al
    Efficacy and safety of bi-weekly cofrogliptin treatment replacing daily dipeptidyl peptidase-4 inhibitors in Chinese patients with type 2 diabetes mellitus: A multicenter, open-label, randomized controlled phase 2 trial.
    Diabetes Obes Metab. 2025 Nov 20. doi: 10.1111/dom.70305.
    >> Share

  213. SCARAMUZZA AE, Marigliano M, Moser O, Abate Daga F, et al
    Optimising the CamAPS FX automated insulin delivery system for exercise and complex meals in adolescents with type 1 diabetes: A prospective interventional study in a camp setting.
    Diabetes Obes Metab. 2025 Nov 20. doi: 10.1111/dom.70295.
    >> Share

  214. YEO D, Jo Y, Jeong J, Jeong YD, et al
    Efficacy and safety of glucagon-like peptide 1 receptor agonists across all health outcomes in type 2 diabetes: An umbrella review and evidence map of randomised controlled trials.
    Diabetes Obes Metab. 2025 Nov 19. doi: 10.1111/dom.70298.
    >> Share

  215. LI S, Chen L, Han Y, Jiang S, et al
    National trends in catastrophic health expenditures among US adults with diabetes aged 18-64 years: 2012-2021.
    Diabetes Obes Metab. 2025 Nov 18. doi: 10.1111/dom.70304.
    >> Share

  216. WU Z, Alexandre-Heymann L, Lebbar M, Talbo MK, et al
    Despite lower haemoglobin A1c with second-generation automated insulin delivery systems, mental burden remains high for all adults with type 1 diabetes: A BETTER registry analysis.
    Diabetes Obes Metab. 2025 Nov 18. doi: 10.1111/dom.70299.
    >> Share

  217. ROSS MM, Mulnick S, Boye KS, Samuelson A, et al
    The value and impact of weight reduction from the perspective of people with type 2 diabetes in the United States.
    Diabetes Obes Metab. 2025 Nov 18. doi: 10.1111/dom.70290.
    >> Share

  218. POSTEMA A, Gaspersz J, Baak BN, Huisman EL, et al
    Real-world evaluation of clinical outcomes in Dutch patients with type 2 diabetes treated with oral semaglutide: A retrospective, observational cohort study using the PHARMO data network.
    Diabetes Obes Metab. 2025 Nov 17. doi: 10.1111/dom.70251.
    >> Share

  219. CHEN L, Wang L, Fu A, Yang J, et al
    Nomogram-based prediction of hypoglycemia risk in elderly community-dwelling patients with type 2 diabetes: Development and validation in a multicentre real-world cohort.
    Diabetes Obes Metab. 2025 Nov 17. doi: 10.1111/dom.70297.
    >> Share

  220. BHISE MR, Bhajipale NS, Babu RH, Tare MS, et al
    Comment on "Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes".
    Diabetes Obes Metab. 2025 Nov 17. doi: 10.1111/dom.70294.
    >> Share

  221. SEO DH, Min KW, Sohn HS, Kim SY, et al
    Lobeglitazone improves glycaemic control as add-on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double-blind, randomised, placebo-controlled trial.
    Diabetes Obes Metab. 2025 Nov 14. doi: 10.1111/dom.70257.
    >> Share

  222. WENG CH, Bennett CL, Magagnoli J, Chou CC, et al
    Concerns regarding "GLP-1RA and the risk of non-arteritic anterior ischaemic optic neuropathy in patients with type 2 diabetes".
    Diabetes Obes Metab. 2025 Nov 14. doi: 10.1111/dom.70293.
    >> Share

  223. ADAMS J, Saha S, Fleetwood KJ, Blackbourn LAK, et al
    Prescribing of glucose-lowering medication to adults with type 2 diabetes by severe mental illness status in Scotland: A cohort study.
    Diabetes Obes Metab. 2025 Nov 14. doi: 10.1111/dom.70278.
    >> Share

  224. COLEMAN RL, Adler AI, Clarke PM, McGuire DK, et al
    Estimating the risk of cardiovascular outcomes and all-cause mortality in individuals with type 2 diabetes: Validation of the UKPDS outcomes model using TECOS and EXSCEL data.
    Diabetes Obes Metab. 2025 Nov 12. doi: 10.1111/dom.70280.
    >> Share

  225. HARLEY M, Rentsch CT, Williamson E, Shah ASV, et al
    Ethnic differences in the comparative effectiveness of second-line type 2 diabetes medications in preventing cardiovascular disease.
    Diabetes Obes Metab. 2025 Nov 12. doi: 10.1111/dom.70273.
    >> Share

  226. LIU S, Liu B, Zhang Y, Qiu X, et al
    Longitudinal trajectories of fasting plasma glucose predicting cardiovascular disease risk in Chinese patients with type 2 diabetes under health management.
    Diabetes Obes Metab. 2025 Nov 12. doi: 10.1111/dom.70277.
    >> Share

  227. BOYE KS, Neff LM, Perez-Nieves M, Lage MJ, et al
    Medical events and costs associated with metabolic bariatric surgery among adults with type 2 diabetes: A retrospective, matched cohort study.
    Diabetes Obes Metab. 2025 Nov 11. doi: 10.1111/dom.70226.
    >> Share

  228. WHARTON S, le Roux CW, Bozkurt B, Platz E, et al
    Baseline characteristics in the SYNCHRONIZE-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes.
    Diabetes Obes Metab. 2025 Nov 11. doi: 10.1111/dom.70263.
    >> Share

  229. SUN R, Wang Y, Shu H, Li L, et al
    Biweekly dosing of efsubaglutide alfa maintains glycaemic and continuous glucose monitoring control in type 2 diabetes: A randomised multicentre trial.
    Diabetes Obes Metab. 2025 Nov 10. doi: 10.1111/dom.70262.
    >> Share

  230. ANAGNOSTOPOULOU L, Liarakos AL, Ntanasis-Stathopoulos I, Briasoulis A, et al
    Continuous glucose monitoring and microvascular complications in diabetes: Bridging glycemic metrics with clinical outcomes.
    Diabetes Obes Metab. 2025 Nov 10. doi: 10.1111/dom.70288.
    >> Share

  231. YU W, Chen Y, Yuan M, Liang A, et al
    The global burden of early-onset type 2 diabetes (1990-2050): An age-period-cohort analysis of incidence, disparities, and projections.
    Diabetes Obes Metab. 2025 Nov 10. doi: 10.1111/dom.70287.
    >> Share

  232. BOSE R, Gupta R
    Letter to the Editor in response to "Management of metabolic dysfunction-associated steatotic liver disease (MASLD)-An expert consensus statement from Indian diabetologists' perspective".
    Diabetes Obes Metab. 2025 Nov 10. doi: 10.1111/dom.70284.
    >> Share

  233. ANDERSEN ES, Foghsgaard S, Vedtofte L, Pedersen MH, et al
    Five years liraglutide treatment improves glucose tolerance in women with previous gestational diabetes mellitus-Results from a randomised controlled trial.
    Diabetes Obes Metab. 2025 Nov 10. doi: 10.1111/dom.70286.
    >> Share

  234. THAMMAKOSOL K, Vongtangton P, Numthavaj P, Auttara-Atthakorn A, et al
    Early subcutaneous basal insulin with intravenous insulin infusion for diabetic ketoacidosis management: A systematic review and meta-analysis of randomised controlled trials.
    Diabetes Obes Metab. 2025 Nov 10. doi: 10.1111/dom.70276.
    >> Share

  235. TANG WC, Reynier P, Douros A, Yu OHY, et al
    Sodium glucose co-transporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors and the risk of ventricular arrhythmia among patients with type 2 diabetes: A population-based cohort study.
    Diabetes Obes Metab. 2025 Nov 10. doi: 10.1111/dom.70264.
    >> Share

  236. SUN F, Zhang M, Pan Q, Shen P, et al
    The association between glycaemic control, normal weight and long-term macrovascular outcomes in people with type 2 diabetes in China: A retrospective study.
    Diabetes Obes Metab. 2025 Nov 10. doi: 10.1111/dom.70237.
    >> Share

  237. ESMANN FVL, Heerfordt IM, Windfeld-Mathiasen J, Horwitz A, et al
    Anabolic androgenic steroid use and risk of diabetes mellitus in males.
    Diabetes Obes Metab. 2025 Nov 10. doi: 10.1111/dom.70283.
    >> Share

  238. BELL DSH, Jerkins TW
    Diabetic distal symmetric polyneuropathy: More than just "tingling in the feet".
    Diabetes Obes Metab. 2025 Nov 6. doi: 10.1111/dom.70235.
    >> Share

  239. ASTBURY NM, Ripullone K, Ramakrishnan R, Woodwood M, et al
    Associations between gestational diabetes and cardiovascular disease largely operate independently of postpartum causal pathways: A population-based cohort study in England.
    Diabetes Obes Metab. 2025 Nov 5. doi: 10.1111/dom.70210.
    >> Share

  240. LAN Y, Wu D, Feng B, Ding X, et al
    Acute inflammation amplifies the diabetogenic effect of excess adiposity: Evidence from a real-life, prospective cohort.
    Diabetes Obes Metab. 2025 Nov 5. doi: 10.1111/dom.70274.
    >> Share

  241. HONG S, Kim WJ, Kim S, Park JH, et al
    Efficacy and safety of switching to ezetimibe 10 mg/rosuvastatin 2.5 mg in Korean patients with type 2 diabetes mellitus and dyslipidaemia: A multicentre, prospective study (EROICA study).
    Diabetes Obes Metab. 2025 Nov 5. doi: 10.1111/dom.70258.
    >> Share

  242. SHEN J, Zeng T, Li X, Zheng C, et al
    Safety and efficacy of hybrid closed-loop insulin pump therapy in adolescents and adults with type 1 diabetes in China.
    Diabetes Obes Metab. 2025 Nov 5. doi: 10.1111/dom.70227.
    >> Share

  243. DONNELLY LA, Singh K, McCrimmon RJ, Pearson ER, et al
    One-year usage patterns of SGLT-2 inhibitors and GLP-1 receptor agonists in individuals with type 2 diabetes in a real-world population.
    Diabetes Obes Metab. 2025 Nov 4. doi: 10.1111/dom.70269.
    >> Share

  244. KETEMA DB, Joshi R, Hailu W, Gallagher M, et al
    Availability and readiness of health facilities for chronic kidney disease, diabetes and cardiovascular disease in Ethiopia: Evidence from service provision assessment data.
    Diabetes Obes Metab. 2025 Nov 3. doi: 10.1111/dom.70268.
    >> Share

  245. RATZKI-LEEWING A, Black JE, Bhatti J, Ryan BL, et al
    Real-world incidence and risk factors of level 3 (severe) hypoglycaemia in adults with type 1 or 2 diabetes (iNPHORM, United States).
    Diabetes Obes Metab. 2025 Nov 3. doi: 10.1111/dom.70252.
    >> Share

  246. LIU X, Chen X, Yang W, Ding G, et al
    Cardiorespiratory fitness and type 2 diabetes risk: A prospective cohort study with mediation analysis of biological aging in the UK Biobank.
    Diabetes Obes Metab. 2025 Nov 3. doi: 10.1111/dom.70261.
    >> Share

  247. AIMELET V, Holst JJ
    Pharmacological intervention: Challenges and promising outcomes for fat loss and preservation of lean body mass in the treatment of overweight and type 2 diabetes.
    Diabetes Obes Metab. 2025 Nov 3. doi: 10.1111/dom.70229.
    >> Share

  248. LANDGRAF W, Owens DR, Frier BM, Bolli GB, et al
    Importance of targeting post-prandial hyperglycaemia to achieve HbA1c goals in insulin glargine-treated subphenotypes of type 2 diabetes.
    Diabetes Obes Metab. 2025 Nov 3. doi: 10.1111/dom.70231.
    >> Share

  249. SCILLETTA S, Welsh P, Di Pino A, Sattar N, et al
    Progressive increases in adiposity and ectopic fat surrogates across glycaemic states highlight weight reduction as a key target for type 2 diabetes prevention, especially in younger people.
    Diabetes Obes Metab. 2025 Nov 3. doi: 10.1111/dom.70248.
    >> Share

  250. HENNEY AE, Heague M, Riley DR, Hydes TJ, et al
    Synergistic associations of metformin and GLP-1 receptor agonist use with adiposity-related cancer incidence in people living with type 2 diabetes.
    Diabetes Obes Metab. 2025 Nov 3. doi: 10.1111/dom.70267.
    >> Share

  251. PATHAK A, Hardin MB, Girard M, Davies MJ, et al
    Impact of sotagliflozin on glomerular hyperfiltration in people with type 1 diabetes: A post hoc analysis of the inTandem3 trial.
    Diabetes Obes Metab. 2025 Nov 3. doi: 10.1111/dom.70266.
    >> Share

  252. ELKIND-HIRSCH K, Armatta M, Griffen C, Welsh JB, et al
    Continuous glucose monitoring in early gestational diabetes improves maternal and neonatal outcomes-The Steady Sugar trial.
    Diabetes Obes Metab. 2025 Nov 3. doi: 10.1111/dom.70254.
    >> Share

  253. MANTOVANI A, Lombardi R, Dalbeni A, Morandin R, et al
    Two-tier screening approach for liver fibrosis stratification in outpatients with type 2 diabetes mellitus: A multicenter cross-sectional study.
    Diabetes Obes Metab. 2025 Nov 2. doi: 10.1111/dom.70245.
    >> Share

  254. SMOLDEREN KG, Mena-Hurtado C, Zhao Z, Michalak W, et al
    Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real-world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World).
    Diabetes Obes Metab. 2025;27:6691-6704.
    >> Share

  255. SAIDI AN, Konings LAM, Dietvorst CAW, de Jong VD, et al
    Assessing the effects of naltrexone-bupropion on hepatic steatosis and fibrosis in patients with T2DM and overweight or obesity: Insights from a placebo-controlled trial.
    Diabetes Obes Metab. 2025;27:6624-6631.
    >> Share

  256. TANG H, Lu Y, Zhang B, Zhou T, et al
    Cardiovascular and kidney outcomes of GLP-1 receptor agonists in adults with obesity: A target trial emulation study.
    Diabetes Obes Metab. 2025;27:6527-6536.
    >> Share

  257. HUA R, Yang A, Gao L, Chow E, et al
    Social determinants of health and progression to cardio-renal-metabolic multimorbidity and mortality in people with prediabetes: A prospective cohort study.
    Diabetes Obes Metab. 2025;27:6605-6614.
    >> Share

  258. AZEGAMI T, Kaneko H, Okada A, Suzuki Y, et al
    Gender differences in the prescription of SGLT2 inhibitors in chronic kidney disease: A real-world database study.
    Diabetes Obes Metab. 2025;27:6294-6303.
    >> Share

  259. BRAMLAGE P, Vijayan A, Varghese TP, Melepurakkal Sadanandan D, et al
    Comparative analysis on renal and cardiovascular outcomes of antidiabetic treatment in chronic kidney disease patients-A systematic review and network meta-analysis.
    Diabetes Obes Metab. 2025;27:6254-6263.
    >> Share

  260. GAO FM, Kishore K, Pandey D, Jahanabadi H, et al
    Ketosis and ketoacidosis in hospitalized patients receiving SGLT2 inhibitor therapy.
    Diabetes Obes Metab. 2025;27:6367-6374.
    >> Share

  261. CRUTCHLOW M, Liu J, Hernandez-Illas M, Zhang H, et al
    Combined GPR40 and GPR119 full agonism with K-757 and K-833 results in robust glucose lowering and modest weight loss in overweight/obese subjects with T2DM.
    Diabetes Obes Metab. 2025;27:6264-6274.
    >> Share

  262. WONG S, Le GH, Dri CE, Teopiz KM, et al
    Evaluating biased agonism of glucagon-like peptide-1 (GLP-1) receptors to improve cellular bioenergetics: A systematic review.
    Diabetes Obes Metab. 2025;27:6105-6115.
    >> Share

    October 2025
  263. BOWE A, Hayes M, John I, Diaz M, et al
    Glucagon-like peptide-1 receptor agonist versus sodium-glucose cotransporter-2 inhibitor persistence in Medicare Advantage beneficiaries with type 2 diabetes, cardiovascular risk, and obesity.
    Diabetes Obes Metab. 2025 Oct 30. doi: 10.1111/dom.70219.
    >> Share

  264. GLATZ U, Muller A, Moser O, Aberer F, et al
    Acute and prolonged effects of aerobic endurance training on N-lactoyl-phenylalanine and inflammatory markers in individuals with type 1 diabetes: An exploratory analysis of the ULTRAFLEXI-1 study.
    Diabetes Obes Metab. 2025 Oct 29. doi: 10.1111/dom.70236.
    >> Share

  265. GOLDENBERG RM
    An indirect treatment comparison of tirzepatide 10 and 15 mg versus high-dose semaglutide 7.2 mg in people with obesity and type 2 diabetes.
    Diabetes Obes Metab. 2025 Oct 29. doi: 10.1111/dom.70253.
    >> Share

  266. MEFFEN A, Tyrer F, Mbah Mbahnjeck J, Khunti K, et al
    Blood pressure and adverse cardiovascular outcomes in older people with type 2 diabetes and chronic kidney disease: Findings based on the Clinical Practice Research Datalink databases in England.
    Diabetes Obes Metab. 2025 Oct 28. doi: 10.1111/dom.70234.
    >> Share

  267. LIN R, Hsu CL, Shih MC, Chien KL, et al
    Comparison of the renal outcomes of novel antidiabetic agents in patients with type 2 diabetes with chronic kidney disease: A systematic review and network meta-analysis of randomized controlled trials.
    Diabetes Obes Metab. 2025 Oct 28. doi: 10.1111/dom.70224.
    >> Share

  268. YANG W, Cai X, Ji Q, Tong N, et al
    Control of the cardiovascular risk factors in patients with type 2 diabetes mellitus in China in 2023-2024.
    Diabetes Obes Metab. 2025 Oct 27. doi: 10.1111/dom.70222.
    >> Share

  269. CHAUDHRY A, Thompson DM, Chanoine JP
    Diabetes management in maternally inherited diabetes and deafness (MIDD): A review and a proposed treatment algorithm.
    Diabetes Obes Metab. 2025 Oct 27. doi: 10.1111/dom.70240.
    >> Share

  270. LAN H, Xu S, Li H, Guo R, et al
    Plasma proteomics identifies potential drug targets for diabetic polyneuropathy: Evidence from prospective cohorts and genetic analysis.
    Diabetes Obes Metab. 2025 Oct 27. doi: 10.1111/dom.70239.
    >> Share

  271. PASQUA MR, Tsoukas MA, Haidar A
    Changes to insulin requirements over time with semaglutide in adults with type 1 diabetes on insulin pump therapy: A post-hoc analysis of a double-blinded, randomised, crossover trial.
    Diabetes Obes Metab. 2025 Oct 27. doi: 10.1111/dom.70213.
    >> Share

  272. YONEDA M, Takeuchi M, Oura T, Nakajima A, et al
    Decreased fatty liver index with tirzepatide treatment in Japanese patients with type 2 diabetes: A SURPASS J-mono post hoc analysis.
    Diabetes Obes Metab. 2025 Oct 27. doi: 10.1111/dom.70225.
    >> Share

  273. DE MEULEMEESTER J, Valgaerts L, Tenoutasse S, Gies I, et al
    One-year effectiveness and safety in young children aged 2-6 years with type 1 diabetes using an automated insulin delivery system: A real-world prospective cohort study.
    Diabetes Obes Metab. 2025 Oct 27. doi: 10.1111/dom.70228.
    >> Share

  274. KATO S, Ozu N, Yamakage H, Kato H, et al
    Antidiabetic agents and dementia risk in type 2 diabetes: A systematic review and network meta-analysis.
    Diabetes Obes Metab. 2025 Oct 22. doi: 10.1111/dom.70182.
    >> Share

  275. LIU Q, Guo S, Tong Y, Qiu L, et al
    Renal lipotoxicity in diabetic and obesity-associated kidney diseases: Molecular mechanisms and therapeutic targeting.
    Diabetes Obes Metab. 2025 Oct 22. doi: 10.1111/dom.70220.
    >> Share

  276. HIGHTON PJ, Funnell MP, Tziannou A, Rowlands AV, et al
    Structured group education programme and accompanying mHealth intervention to promote physical activity in women with a history of gestational diabetes (Baby Steps): 4-year follow-up of a randomised controlled trial.
    Diabetes Obes Metab. 2025 Oct 21. doi: 10.1111/dom.70199.
    >> Share

  277. YU M
    iGlarLixi: A titrateable fixed-ratio combination of basal insulin + GLP-1 receptor agonist-An effective type 2 diabetes treatment option in China.
    Diabetes Obes Metab. 2025 Oct 20. doi: 10.1111/dom.70192.
    >> Share

  278. ZHANG J, Wang Y, Lu Z, Yang Y, et al
    Baseline HbA1c and dementia risk at SGLT2i initiation in type 2 diabetes.
    Diabetes Obes Metab. 2025 Oct 20. doi: 10.1111/dom.70223.
    >> Share

  279. DESHMUKH H, Wilmot EG, Ssemmondo E, Barnes D, et al
    Exploring the interaction between ethnicity, deprivation and the use of CGM on diabetes outcomes-A study from the Association of British Clinical Diabetologists.
    Diabetes Obes Metab. 2025 Oct 17. doi: 10.1111/dom.70206.
    >> Share

  280. WAN S, Yan H, Sun QY, Zhu JQ, et al
    Effects of GLP-1 receptor agonists on cognitive function in patients with type 2 diabetes: A systematic review and meta-analysis based on randomized controlled trials.
    Diabetes Obes Metab. 2025 Oct 17. doi: 10.1111/dom.70201.
    >> Share

  281. TESFAYE H, Paik JM, Wexler DJ, Hathaway JT, et al
    GLP-1RA and the risk of non-arteritic anterior ischaemic optic neuropathy in patients with type 2 diabetes: A population-based study.
    Diabetes Obes Metab. 2025 Oct 17. doi: 10.1111/dom.70200.
    >> Share

  282. ZHOU H, Wang Y, Song X, Xu T, et al
    Independent and joint association of fat-to-muscle mass ratio and cardiorespiratory fitness with type 2 diabetes mellitus incidence: A prospective cohort study.
    Diabetes Obes Metab. 2025 Oct 16. doi: 10.1111/dom.70217.
    >> Share

  283. KOUFAKIS T, Sarafidis P, Tsapas A, Doumas M, et al
    Pursuing remission in type 2 diabetes: Competing strategies or complementary paths?
    Diabetes Obes Metab. 2025 Oct 16. doi: 10.1111/dom.70212.
    >> Share

  284. WEINREICH AA, Bagger JI, Jorgensen JT, Kristensen PL, et al
    Efficacy and safety of oral semaglutide treatment in a Danish type 2 diabetes outpatient clinic: Real-world evidence.
    Diabetes Obes Metab. 2025 Oct 16. doi: 10.1111/dom.70208.
    >> Share

  285. NI J, Chen L, Su H, Cai J, et al
    Low serum 1,5-anhydroglucitol is associated with increased risk of all-cause and cardiovascular mortality in type 2 diabetes: A real-world cohort study.
    Diabetes Obes Metab. 2025 Oct 15. doi: 10.1111/dom.70214.
    >> Share

  286. HTOO PT, Tesfaye H, Schneeweiss S, Wexler DJ, et al
    Comparative healthcare resource utilization and costs of empagliflozin and GLP-1 receptor agonists in type 2 diabetes.
    Diabetes Obes Metab. 2025 Oct 15. doi: 10.1111/dom.70195.
    >> Share

  287. ZAKY A, Nguyen LT, Shi Y, Hou M, et al
    The effect of sugarcane extract supplementation on glycemic control in a mouse model of type 1 diabetes.
    Diabetes Obes Metab. 2025 Oct 14. doi: 10.1111/dom.70183.
    >> Share

  288. YU M, Wang T, Xu C, Bi Y, et al
    Triple oral therapy with metformin, DPP-4 inhibitor, and SGLT2 inhibitor for adults with type 2 diabetes: Consensus recommendations of a Chinese expert panel (version 2025).
    Diabetes Obes Metab. 2025 Oct 14. doi: 10.1111/dom.70197.
    >> Share

  289. GU W, Wu X, Zhang M, Wang X, et al
    Efficacy and safety of iGlarLixi versus IDegAsp by baseline beta-cell function in Chinese people with type 2 diabetes: Exploratory analyses of the Soli-D study.
    Diabetes Obes Metab. 2025 Oct 14. doi: 10.1111/dom.70181.
    >> Share

  290. SKOP V, Lankova I, Antalova S, Miskova I, et al
    Partial non-adherence to antidiabetic therapy undermines diabetes management and correlates with treatment complexity: A cross-sectional study using blood plasma analysis.
    Diabetes Obes Metab. 2025 Oct 10. doi: 10.1111/dom.70174.
    >> Share

  291. PASQUA MR, Tsoukas MA, Haidar A
    Semaglutide withdrawal in adults with type 1 diabetes on pump therapy: A post-hoc analysis from a double-blinded randomized controlled trial.
    Diabetes Obes Metab. 2025 Oct 8. doi: 10.1111/dom.70185.
    >> Share

  292. BANERJEE M, Pal R, Pal S
    Histological efficacy of anti-diabetic agents in MASH and the mediating role of weight loss: A network meta-analysis.
    Diabetes Obes Metab. 2025 Oct 8. doi: 10.1111/dom.70187.
    >> Share

  293. ZHONG X, Zheng Y, Wang L, Ouyang B, et al
    Evaluating global epidemiology of type 2 diabetes mellitus among the working-age population: A 60-year study by interpretable machine learning framework.
    Diabetes Obes Metab. 2025 Oct 8. doi: 10.1111/dom.70155.
    >> Share

  294. POHLMANN J, Smith-Palmer J, Serne EH, Tuomaala AK, et al
    A systematic literature review and meta-analysis of real-world evidence on commercially available automated insulin delivery systems in people with type 1 diabetes.
    Diabetes Obes Metab. 2025 Oct 8. doi: 10.1111/dom.70161.
    >> Share

  295. TUTTLE KR, Ji L, Mathieu C, Rosen J, et al
    Addressing unmet needs for chronic kidney disease treatment in type 1 diabetes: A review.
    Diabetes Obes Metab. 2025 Oct 6. doi: 10.1111/dom.70180.
    >> Share

  296. ALGHAMDI M, Dihoum A, Hakami K, Bhattacharjee A, et al
    Dapagliflozin reduces epicardial adipose tissue in patients with heart failure and type 2 diabetes.
    Diabetes Obes Metab. 2025 Oct 6. doi: 10.1111/dom.70164.
    >> Share

  297. MONNIER L, Colette C, Benhamou PY, Owens D, et al
    Should glycaemic variability and times spent in levels 1 and 2 hypoglycaemia be revised downward in type 1 diabetes treated with advanced systems of insulin delivery?
    Diabetes Obes Metab. 2025 Oct 6. doi: 10.1111/dom.70179.
    >> Share

  298. DI GIOIA L, Di Molfetta S, Caruso I, Caporusso M, et al
    Efficacy and safety of once-weekly basal insulin therapy in people with type 1 diabetes: A systematic review and meta-analysis.
    Diabetes Obes Metab. 2025 Oct 6. doi: 10.1111/dom.70176.
    >> Share

  299. SCARAMUZZA AE, Cherubini V
    The 'awareness effect': A crucial, un-modelleld economic benefit of national type 1 diabetes screening.
    Diabetes Obes Metab. 2025 Oct 6. doi: 10.1111/dom.70184.
    >> Share

  300. AL OZAIRI E, Irshad M, Alkandari J, Sojan L, et al
    Weight loss in people with type 1 diabetes over 12 months: Real-world data comparing tirzepatide, semaglutide and liraglutide.
    Diabetes Obes Metab. 2025 Oct 6. doi: 10.1111/dom.70172.
    >> Share

  301. MATHIESEN DS, Hansen JV, Hock A, Nielsen CK, et al
    Repurposing colchicine for reduction of residual inflammatory risk in type 1 diabetes: Design and rationale of the REC1TE trial.
    Diabetes Obes Metab. 2025 Oct 6. doi: 10.1111/dom.70139.
    >> Share

  302. PAN Y, Zhang W, Dai Y, Liu Y, et al
    Association between accelerometer-measured physical activity, genetic risk, and incident type 2 diabetes: A prospective cohort study.
    Diabetes Obes Metab. 2025 Oct 3. doi: 10.1111/dom.70166.
    >> Share

  303. MANCHANDA Y, Jones B, Carrat G, Ramchunder Z, et al
    Binding kinetics, bias, receptor internalization and effects on insulin secretion in vitro and in vivo of a novel GLP-1R/GIPR dual agonist, HISHS-2001.
    Diabetes Obes Metab. 2025;27:5938-5949.
    >> Share

  304. LIN YL, Hung YJ, Chen JH, Sung JY, et al
    Protective effect of metformin against dementia in patients with obesity: Results from a global federated health network analysis.
    Diabetes Obes Metab. 2025;27:5899-5909.
    >> Share

  305. FERNANDEZ C, Nacher M, Rivera K, Marin-Canas S, et al
    Loss of beta-cell identity in human islets treated with glibenclamide.
    Diabetes Obes Metab. 2025;27:5782-5792.
    >> Share

  306. WANG Z, Jin Z, Xiong Z
    Research progress of epidermal growth factor receptor in metabolic dysfunction-associated steatotic liver disease and related diseases.
    Diabetes Obes Metab. 2025;27:5418-5431.
    >> Share

  307. WEN Y, Lemen D, Lin Y, Chen YQ, et al
    Decreases in circulating ANGPTL3/8 concentrations following retatrutide treatment parallel reductions in serum lipids.
    Diabetes Obes Metab. 2025;27:5985-5995.
    >> Share

  308. AKINRIMISI OI, Koning M, Scheijen JLJM, Meijnikman AS, et al
    Higher plasma dicarbonyl levels are associated with liver fibrosis in obese individuals.
    Diabetes Obes Metab. 2025;27:5878-5888.
    >> Share

  309. ZHOU J, Husain M, Li Y, Liu W, et al
    Effect of semaglutide versus placebo on cardiorenal outcomes by prior cardiovascular disease and baseline body mass index: Pooled post hoc analysis of SUSTAIN 6 and PIONEER 6.
    Diabetes Obes Metab. 2025;27:5706-5715.
    >> Share

  310. CARLIER L, De Ponthaud C, Jacqueminet S, Phan F, et al
    Perioperative use and accuracy of continuous glucose monitoring: A systematic review.
    Diabetes Obes Metab. 2025;27:5393-5408.
    >> Share

  311. SATTAR N, Garcia-Perez LE, Rodriguez A, Kapoor R, et al
    Tirzepatide and cardiometabolic parameters in obesity: Summary of current evidence.
    Diabetes Obes Metab. 2025;27:5386-5392.
    >> Share

    September 2025
  312. DI MOLFETTA S, Di Gioia L, Caruso I, Caporusso M, et al
    Glycaemic control and variability with different commercially available hybrid closed loop systems in people with type 1 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Diabetes Obes Metab. 2025 Sep 29. doi: 10.1111/dom.70150.
    >> Share

  313. CHANG Y, Hsieh MH, Ju PC, Chang CC, et al
    Risk of depression with GLP-1 receptor agonists use in overweight or obese adults with type 2 diabetes: A new-user, active-comparator cohort study.
    Diabetes Obes Metab. 2025 Sep 29. doi: 10.1111/dom.70175.
    >> Share

  314. CHEN MH, Lin LY, Hung TY, Lin TC, et al
    Comparative cardiovascular risk of sulfonylureas with low- and high-affinities for cardiac mitochondrial adenosine triphosphate-sensitive potassium channels versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: A cohort study.
    Diabetes Obes Metab. 2025 Sep 29. doi: 10.1111/dom.70157.
    >> Share

  315. ZHOU Z, Gao N, Liu J, Ma X, et al
    An interpretable machine learning model for predicting metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes.
    Diabetes Obes Metab. 2025 Sep 29. doi: 10.1111/dom.70168.
    >> Share

  316. HANKOSKY ER, Lebrec J, Lee CJ, Dimitriadis GK, et al
    Tirzepatide and the 10-year predicted risk of cardiovascular disease and type 2 diabetes in adults with obesity and prediabetes: A post hoc analysis from the three-year SURMOUNT-1 trial.
    Diabetes Obes Metab. 2025 Sep 29. doi: 10.1111/dom.70143.
    >> Share

  317. FADINI GP, Longato E, Poletto S, Giaccari A, et al
    Effectiveness of oral semaglutide versus empagliflozin for the management of type 2 diabetes. PIONEER-2 trial emulation with real-world data.
    Diabetes Obes Metab. 2025 Sep 24. doi: 10.1111/dom.70151.
    >> Share

  318. CASTRILLON F, Carter B, McClure A, Welk B, et al
    The impact of semaglutide on peri-operative cardiovascular outcomes in diabetes.
    Diabetes Obes Metab. 2025 Sep 24. doi: 10.1111/dom.70145.
    >> Share

  319. CHENG J, Yu H, Gu Y, Ma C, et al
    Diabetes remission and diabetic complications of bariatric surgery vs. medical management in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
    Diabetes Obes Metab. 2025 Sep 24. doi: 10.1111/dom.70152.
    >> Share

  320. ZHANG L, Wang J, Zheng W, Yuan X, et al
    Probiotics and dietary fibre fermented milk supplementation initiated in the first trimester to prevent gestational diabetes mellitus in overweight and obese pregnant women: A randomized controlled trial.
    Diabetes Obes Metab. 2025 Sep 24. doi: 10.1111/dom.70158.
    >> Share

  321. BELAND-BONENFANT S, Denimal D, Pais-de-Barros JP, Choubley H, et al
    Plasma sphingolipids predict advanced liver fibrosis development in patients with type 2 diabetes.
    Diabetes Obes Metab. 2025 Sep 24. doi: 10.1111/dom.70156.
    >> Share

  322. SUN Y, Li H, Yan X, Ma G, et al
    Unveiling urinary diagnostic biomarkers for diabetic kidney disease using metabolomics and machine learning approaches.
    Diabetes Obes Metab. 2025 Sep 21. doi: 10.1111/dom.70138.
    >> Share

  323. MURUGAVEL S, Retnakaran R, Feig DS, Zinman B, et al
    Empagliflozin for the preservation of beta-cell function in women with recent gestational diabetes: A randomized placebo-controlled trial.
    Diabetes Obes Metab. 2025 Sep 18. doi: 10.1111/dom.70146.
    >> Share

  324. GURUNG RL, Zheng H, Tan JLI, Liu S, et al
    Integrative metabolomic and proteomic analysis of diabetic kidney disease progression with younger-onset type 2 diabetes.
    Diabetes Obes Metab. 2025 Sep 18. doi: 10.1111/dom.70153.
    >> Share

  325. RITTENHOUSE BE, Alolayan S, Segal AR, Eguale T, et al
    Reply to "A comment on 'Metformin in the Diabetes Prevention Program 3-year trial: The cost-effectiveness that never was'".
    Diabetes Obes Metab. 2025 Sep 18. doi: 10.1111/dom.70149.
    >> Share

  326. DIONNE V, Iglesies-Grau J, Latour E, Besnier F, et al
    Optimizing cardiovascular health with a type 2 diabetes remission program: Ultraprocessed food-intake reduction, Mediterranean diet, chrononutrition and physical training-The DIABEPIC-2 pilot study.
    Diabetes Obes Metab. 2025 Sep 18. doi: 10.1111/dom.70142.
    >> Share

  327. QU HQ, Hakonarson H
    Sex as a modifier of genetic risk for type 1 diabetes.
    Diabetes Obes Metab. 2025 Sep 18. doi: 10.1111/dom.70124.
    >> Share

  328. LEE BW, Lee CB, Lim S, Kim SG, et al
    Efficacy and safety in tirzepatide-treated Korean adults with type 2 diabetes-A post hoc analysis of SURPASS-AP-combo and SURPASS-3.
    Diabetes Obes Metab. 2025 Sep 15. doi: 10.1111/dom.70111.
    >> Share

  329. HOO JX, Yang YF, Lau ESH, Ibrahim L, et al
    A 7-year prospective analysis of sustained benefits of multicomponent risk assessment and data-driven care in patients with type 2 diabetes: The Malaysian JADE Program.
    Diabetes Obes Metab. 2025 Sep 15. doi: 10.1111/dom.70125.
    >> Share

  330. XUE X, Li J, Zheng W, Zhang B, et al
    Contributions of 2-h post-load glucose, fasting blood glucose and glycosylated haemoglobin elevations to the prevalence of diabetes and pre-diabetes in adults: A systematic analysis of global data.
    Diabetes Obes Metab. 2025 Sep 15. doi: 10.1111/dom.70130.
    >> Share

  331. LI X, Zhang Y, Bi Y, Lu J, et al
    Dapagliflozin restores odour-induced functional integration of primary olfactory cortex circuit but not olfactory-related regional brain activation in patients with type 2 diabetes: A 16-week randomised comparative study.
    Diabetes Obes Metab. 2025 Sep 15. doi: 10.1111/dom.70132.
    >> Share

  332. CRUTCHLOW M, Liu J, Romero C, Watkins E, et al
    Combined agonism of nutrient receptors GPR40 and GPR119 with K-757 and K-833 results in weight loss and blood pressure reductions in obese subjects without type 2 diabetes mellitus.
    Diabetes Obes Metab. 2025 Sep 15. doi: 10.1111/dom.70120.
    >> Share

  333. LI J, Liu Y, Xing W, Jiang Y, et al
    Blood glucose trajectories in diabetes patients receiving CAPDCA model of personalised patient education: A cluster randomised controlled trial.
    Diabetes Obes Metab. 2025 Sep 14. doi: 10.1111/dom.70119.
    >> Share

  334. LI W, Huang L, Wang R, Peng P, et al
    Comparative efficacy and safety of Glucagon-like pepetide-1 receptor agonists with metformin in Asian versus non-Asian patients with type 2 diabetes: A systematic review and meta-analysis.
    Diabetes Obes Metab. 2025 Sep 11. doi: 10.1111/dom.70084.
    >> Share

  335. LEE YT, Wu JY, Chang TW, Hung CH, et al
    Impact of SGLT2 inhibitors on the risk of age-related ocular diseases in patients with type 2 diabetes mellitus: A target trial emulation study.
    Diabetes Obes Metab. 2025 Sep 11. doi: 10.1111/dom.70131.
    >> Share

  336. CHENG X, Fu Z, Chen Y, Wang J, et al
    Semaglutide attenuates diabetic retinopathy progression via ameliorating retinal vasculopathy and oxidative stress in vivo and in vitro.
    Diabetes Obes Metab. 2025 Sep 10. doi: 10.1111/dom.70107.
    >> Share

  337. ZHANG A, Zhichen B, Kidoguchi S, Nishiyama A, et al
    An SGLT2 inhibitor, canagliflozin, reduces blood glucose level in the renal capillaries and protects the capillary network in the diabetic rats.
    Diabetes Obes Metab. 2025 Sep 10. doi: 10.1111/dom.70118.
    >> Share

  338. LIU A, Shao Y, Chen J, Ng CS, et al
    The healthcare and economic burden associated with inadequate risk factor control for type 2 diabetes in Hong Kong: A population-based modelling study.
    Diabetes Obes Metab. 2025 Sep 10. doi: 10.1111/dom.70081.
    >> Share

  339. HASEBE M, Su CY, Keidai Y, Minamino H, et al
    Cardiovascular risk reduction with glucagon-like peptide-1 receptor agonists is proportional to HbA1c lowering in type 2 diabetes: An updated meta-regression analysis incorporating FLOW and SOUL trials.
    Diabetes Obes Metab. 2025 Sep 9. doi: 10.1111/dom.70121.
    >> Share

  340. JOUBERT M, Meyer L, Bekka S, Rakotoarisoa L, et al
    Hypoglycemia incidence and behavioural adjustments during free-living unstructured physical activity in adults with type 1 diabetes using AID systems: Results from the RAPPID study.
    Diabetes Obes Metab. 2025 Sep 9. doi: 10.1111/dom.70122.
    >> Share

  341. GUAN H, Jiang H, Yuan H, Sun J, et al
    Long-term efficacy and safety of tirzepatide in participants with type 2 diabetes with inadequate glycaemic control on metformin and/or sulfonylurea: Post-hoc analysis of SURPASS-4.
    Diabetes Obes Metab. 2025 Sep 9. doi: 10.1111/dom.70047.
    >> Share

  342. SCHIERBAUER J, Sanfilippo S, Wachsmuth N, Moser O, et al
    Association between glycated haemoglobin A(1c) and total haemoglobin mass in adults with type 1 diabetes mellitus. A proof-of-concept study.
    Diabetes Obes Metab. 2025 Sep 8. doi: 10.1111/dom.70007.
    >> Share

  343. FJAELDSTAD AW, Norman K, Bjerg L
    Subjective smell- and taste loss in diabetes-A questionnaire-based study on 47 011 individuals with diabetes and matched controls.
    Diabetes Obes Metab. 2025 Sep 8. doi: 10.1111/dom.70099.
    >> Share

  344. ZHANG Y, Zhou J, Chen X, Huang H, et al
    Optimal type and dose of exercise to improve glycated haemoglobin in individuals with type 1 diabetes: A systematic review and Bayesian dose-response network meta-analysis of RCTs.
    Diabetes Obes Metab. 2025 Sep 8. doi: 10.1111/dom.70115.
    >> Share

  345. DAVIDSEN L, Jensen MH, Drewes AM, Knop FK, et al
    Declining incidence of hypoglycaemia in diabetes secondary to chronic pancreatitis: A nationwide cohort study from 2003 to 2022.
    Diabetes Obes Metab. 2025 Sep 8. doi: 10.1111/dom.70106.
    >> Share

  346. RABBONE I, Tinti D, Rigamonti A, Mossetto C, et al
    Comparable glycemic outcomes with insulin glargine and insulin degludec during exercise in adolescents with type 1 diabetes using a standardized management protocol.
    Diabetes Obes Metab. 2025 Sep 8. doi: 10.1111/dom.70108.
    >> Share

  347. SHARMA A, Ali Baig S, Thayakaran R, Rengarajan L, et al
    Clinical characteristics and outcomes of diabetes-related ketoacidosis (DKA) in sodium-glucose co-transporter-2 inhibitor (SGLT2i) users with type 2 diabetes.
    Diabetes Obes Metab. 2025 Sep 8. doi: 10.1111/dom.70098.
    >> Share

  348. KANU C, Boye KS, Poon JL, Goetz I, et al
    Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study.
    Diabetes Obes Metab. 2025 Sep 8. doi: 10.1111/dom.70097.
    >> Share

  349. PENG Y, Li J, Deng Y, Zhou Z, et al
    The protective role of TIGIT+ B cells in attenuating type 1 diabetes progression.
    Diabetes Obes Metab. 2025 Sep 5. doi: 10.1111/dom.70092.
    >> Share

  350. CHAO Y, Tong X, Zhang B, Yang H, et al
    Olfactory training improves cognition and modifies brain networks in type 2 diabetes patients with mild cognitive impairment: A 16-week randomised controlled trial.
    Diabetes Obes Metab. 2025 Sep 5. doi: 10.1111/dom.70103.
    >> Share

  351. SOLA C, Lundemose SB, McCarthy OM, Norgaard K, et al
    Post-exercise glycaemic control for 24 h: Fasted morning exercise with and without glucagon in adults with type 1 diabetes using automated insulin delivery.
    Diabetes Obes Metab. 2025 Sep 4. doi: 10.1111/dom.70085.
    >> Share

  352. IPAYE T, Goldney J, Wilkinson TJ, Zaccardi F, et al
    Weight loss interventions and obesity-associated cancers in people with type 2 diabetes and overweight/obesity: A real-world observational study.
    Diabetes Obes Metab. 2025 Sep 3. doi: 10.1111/dom.70090.
    >> Share

  353. THAMMAKOSOL K, Jantarapootirat M, Traiwanatham S, Sriphrapradang C, et al
    Early insulin degludec with continuous intravenous insulin infusion in the management of diabetic ketoacidosis: A randomized controlled trial.
    Diabetes Obes Metab. 2025 Sep 3. doi: 10.1111/dom.70101.
    >> Share

  354. XIAO Q, Zhang C, Jiang Y, Suo C, et al
    Identification of subtypes of type 2 diabetes in the Chinese population and their distinct complication risk profiles.
    Diabetes Obes Metab. 2025 Sep 3. doi: 10.1111/dom.70056.
    >> Share

  355. ARD J, Lee CJ, Gudzune K, Addison B, et al
    Weight reduction over time in tirzepatide-treated participants by early weight loss response: Post hoc analysis in SURMOUNT-1.
    Diabetes Obes Metab. 2025;27:5064-5071.
    >> Share

  356. WANG J, Lin C, Cai X, Wang Y, et al
    Glucagon-like peptide-1 receptor agonist treatment associated weight fluctuation and influencing factors in patients with overweight or obesity.
    Diabetes Obes Metab. 2025;27:5042-5051.
    >> Share

  357. TANS R, Schipper A, de Vaan E, Kusters R, et al
    A personalized approach to classify the degree of liver insulin resistance in children with obesity.
    Diabetes Obes Metab. 2025;27:5225-5234.
    >> Share

  358. MOCHIZUKI K, Fuchigami A, Hirose T, Uchino H, et al
    Impact of baseline alanine aminotransferase levels on the efficacy of dapagliflozin and sitagliptin: Latent class analysis from the DIVERSITY-CVR study.
    Diabetes Obes Metab. 2025;27:5099-5107.
    >> Share

  359. BERGET C, Cobry E, Escobar E, Towers L, et al
    Sustained improvements in glycaemic and psychosocial outcomes for youth and caregivers using Omnipod 5 AID for 12 months.
    Diabetes Obes Metab. 2025;27:4942-4949.
    >> Share

  360. SIMENTAL-MENDIA LE, Simental-Mendia M, Barragan-Zuniga LJ, Arce-Quinones M, et al
    Effect of saroglitazar on glycaemic parameters: A systematic review and meta-analysis of randomized controlled trials.
    Diabetes Obes Metab. 2025;27:4627-4642.
    >> Share

  361. GUO R, Pandey A, Chandramouli C, Wu MZ, et al
    The effect of sodium-glucose cotransporter 2 inhibitors on HbA1c variability and cardiovascular and renal adverse outcome in patients with T2DM.
    Diabetes Obes Metab. 2025;27:4720-4728.
    >> Share

  362. CHO Y, Jhee JH, Jhee JH, Park HS, et al
    Beyond BMI: The role of diabetes and central obesity in fracture risk-Insights from the UK biobank.
    Diabetes Obes Metab. 2025 Sep 1. doi: 10.1111/dom.70074.
    >> Share

  363. ALHAMAR G, Fallucca S, Richardson SJ, Torabi F, et al
    Raised levels of Interleukin-8 and myeloperoxidase in patients with recent onset type 1 diabetes.
    Diabetes Obes Metab. 2025 Sep 1. doi: 10.1111/dom.70048.
    >> Share

  364. SSEMMONDO E, Newham M, Deshmukh H, Wilmot EG, et al
    Baseline clinical factors associated with diabetes distress in dialysis patients: Insights from the ABCD audit data.
    Diabetes Obes Metab. 2025 Sep 1. doi: 10.1111/dom.70076.
    >> Share

  365. YU B, Li J, Yu Y, Sun Y, et al
    Proteomics-enabled learning machine algorithms enhance the prediction of cardiovascular diseases in patients with type 2 diabetes mellitus.
    Diabetes Obes Metab. 2025 Sep 1. doi: 10.1111/dom.70064.
    >> Share

  366. WANG B, Liu KSN, Mak IL, Choi EPH, et al
    Impact of onset age of type 2 diabetes mellitus on risk of renal complications compared to age-matched non-diabetic patients: Two cohort studies in the United Kingdom and Hong Kong.
    Diabetes Obes Metab. 2025 Sep 1. doi: 10.1111/dom.70061.
    >> Share

  367. WEI J, Wu H, Wang N, Zhu J, et al
    Integrative proteomic analysis provides novel therapeutic insights for etiological subtypes of diabetes.
    Diabetes Obes Metab. 2025 Sep 1. doi: 10.1111/dom.70088.
    >> Share


  368. Correction to "Effects of dipeptidyl peptidase-4 inhibitor linagliptin versus sulphonylurea glimepiride on systemic haemodynamics in overweight patients with type 2 diabetes: A secondary analysis of an 8-week, randomized, controlled, double-blind tria
    Diabetes Obes Metab. 2025 Sep 1. doi: 10.1111/dom.70086.
    >> Share

  369. HOLMAN N, Young B, Gregg EW, Wareham N, et al
    Trends in mortality and hospitalisations for cardiovascular, kidney and liver disease in people with type 2 diabetes in England, 2009-2019.
    Diabetes Obes Metab. 2025 Sep 1. doi: 10.1111/dom.70025.
    >> Share

    August 2025
  370. NUYUJUKIAN DS, Zhou JJ, Koska J, Reaven PD, et al
    Triglyceride variability and risk of heart failure events in type 2 diabetes: Results from the ACCORD trial.
    Diabetes Obes Metab. 2025 Aug 28. doi: 10.1111/dom.70083.
    >> Share

  371. WEN Y, Zeng S
    Advancing AI-driven biomarker discovery in diabetic nephropathy: A framework for robustness and interpretability.
    Diabetes Obes Metab. 2025 Aug 28. doi: 10.1111/dom.70087.
    >> Share

  372. ADOLFSSON P, Guerci B, Hartvig NV, Kaas A, et al
    Glycaemic control after connected insulin pen initiation in people living with diabetes: Results from a real-world setting.
    Diabetes Obes Metab. 2025 Aug 28. doi: 10.1111/dom.70051.
    >> Share

  373. YAU YK, Li M, Quan J, Grepin KA, et al
    Disrupted specialist outpatient services and alternative modes of service for patients with diabetes mellitus: A population-based, retrospective cohort study in Hong Kong.
    Diabetes Obes Metab. 2025 Aug 28. doi: 10.1111/dom.70069.
    >> Share

  374. LAVENS A, De Block C, Oriot P, Philips JC, et al
    Impact of the era of diabetes onset in a national care system on the prevalence of retinopathy and microalbuminuria in people living with type 1 diabetes 15 years post-diagnosis: A cross-sectional, real-world observational study.
    Diabetes Obes Metab. 2025 Aug 28. doi: 10.1111/dom.70049.
    >> Share

  375. KANAZAWA K, Hayashi K, Xinyi C, Hijikata M, et al
    Effectiveness and predictors of weight reduction with low-dose tirzepatide in Japanese patients with type 2 diabetes: A pilot retrospective cohort study.
    Diabetes Obes Metab. 2025 Aug 28. doi: 10.1111/dom.70062.
    >> Share

  376. GIANGRECO F, Tura A, Parenti M, Cappelli S, et al
    GLP-1 receptor agonist therapy for relapsed diabetes following 6q24-related transient neonatal diabetes due to paternal uniparental disomy: A case report.
    Diabetes Obes Metab. 2025 Aug 27. doi: 10.1111/dom.70065.
    >> Share

  377. JI L, Huang D, Lin X, Dong X, et al
    Efficacy and safety benefits of HR17031, a fixed-ratio combination of INS068 and noiiglutide, versus its components alone in Chinese patients with type 2 diabetes uncontrolled on oral antidiabetic drug(s): A phase 2, multicentre, open-label, randomise
    Diabetes Obes Metab. 2025 Aug 27. doi: 10.1111/dom.70036.
    >> Share

  378. VARGAS KG, Siemes B, Rutten T, Brockmeyer M, et al
    Assessment of precision medicine potential in diabetes mellitus: A meta-regression analysis of dose-dependent glycaemic control data from 44 randomised controlled trials.
    Diabetes Obes Metab. 2025 Aug 27. doi: 10.1111/dom.70066.
    >> Share

  379. YEN FS, Wang SI, Hung YM, Hsu CC, et al
    Impact of glucagon-like peptide-1 receptor agonists on the incidence of inflammatory bowel disease in people with type 2 diabetes.
    Diabetes Obes Metab. 2025 Aug 27. doi: 10.1111/dom.70034.
    >> Share

  380. COSSU L, Facchinetti A, Bally L
    CGM profiling in Roux-en-Y gastric bypass, type 1 diabetes and healthy adults: Unmasking deviations from normoglycaemia.
    Diabetes Obes Metab. 2025 Aug 26. doi: 10.1111/dom.70059.
    >> Share

  381. AL-OZAIRI E, Al-Awadhi A, Mashankar A, Alroudhan D, et al
    Association of device-based measurement of physical activity with liver fat and stiffness in type 2 diabetes and obesity.
    Diabetes Obes Metab. 2025 Aug 26. doi: 10.1111/dom.70038.
    >> Share

  382. CAO Y, Widyahening I, Sun X, Li S, et al
    Pathophysiology of type 2 diabetes: A focus on the metabolic differences among southeast Asian, Chinese and Indian populations and how this impacts treatment.
    Diabetes Obes Metab. 2025 Aug 26. doi: 10.1111/dom.70060.
    >> Share

  383. ANANDHAKRISHNAN A, Liarakos AL, Dhatariya K, Gallen G, et al
    Hybrid closed-loop systems in UK type 1 diabetes care: National survey of healthcare professional awareness, confidence, and training needs.
    Diabetes Obes Metab. 2025 Aug 22. doi: 10.1111/dom.70027.
    >> Share

  384. JI L, Yuan G, Liu J, Zhang B, et al
    Efficacy and safety of oral semaglutide in Chinese participants with type 2 diabetes: Subgroup analyses by baseline characteristics in the PIONEER 11 and 12 randomised controlled trials.
    Diabetes Obes Metab. 2025 Aug 22. doi: 10.1111/dom.70031.
    >> Share

  385. SARABHAI T, Kostev K
    SGLT2 inhibitor therapy and lower incidence of iron deficiency anaemia in patients with type 2 diabetes: A retrospective cohort study from Germany.
    Diabetes Obes Metab. 2025 Aug 22. doi: 10.1111/dom.70057.
    >> Share

  386. CAI Z, Du M, Chen M, Ni G, et al
    An MRI study of pancreatic atrophy in children with type 1 diabetes: Heterogeneity, disease duration effects, and progression prediction models.
    Diabetes Obes Metab. 2025 Aug 22. doi: 10.1111/dom.70055.
    >> Share

  387. KANG S, Chen S, Lin Z, Zhang M, et al
    Association between Chinese visceral adiposity index and heart failure in diabetic patients.
    Diabetes Obes Metab. 2025 Aug 22. doi: 10.1111/dom.70053.
    >> Share

  388. LOGAN BK, Larsen R, Sacre JW, Cohen ND, et al
    Interrupting prolonged sitting reduces postprandial GIP but not GLP-1 responses in type 2 diabetes.
    Diabetes Obes Metab. 2025 Aug 22. doi: 10.1111/dom.70046.
    >> Share

  389. SHEU WH, Lee CY, Wang YW, Liao CS, et al
    Glycaemic responses to metformin monotherapy by SNP clusters in patients with type 2 diabetes.
    Diabetes Obes Metab. 2025 Aug 22. doi: 10.1111/dom.70023.
    >> Share

  390. GAO L, Ji L, Yan X, Cheng Z, et al
    Efficacy and safety of chiglitazar add-on to metformin in type 2 diabetes mellitus (RECAM study).
    Diabetes Obes Metab. 2025 Aug 22. doi: 10.1111/dom.70009.
    >> Share

  391. LIU Y, Wang Q
    Increased risk of type 1 diabetes in patients with autoimmune conditions-Further nuance needed.
    Diabetes Obes Metab. 2025 Aug 20. doi: 10.1111/dom.70041.
    >> Share

  392. LI X, Zhao W, Zhao L, Sun T, et al
    Cardiovascular disease risk estimates for primary prevention in the US prediabetes and diabetes population using the PREVENT equation.
    Diabetes Obes Metab. 2025 Aug 20. doi: 10.1111/dom.70043.
    >> Share

  393. WU B, Nieman K, Sandoval R
    High-intensity statin therapy is associated with reduced coronary inflammation on CT in patients with type 2 diabetes mellitus.
    Diabetes Obes Metab. 2025 Aug 18. doi: 10.1111/dom.70032.
    >> Share

  394. TREVINO-ALVAREZ AM, Cabeza de Baca T, Stinson EJ, Gluck ME, et al
    Acidosis is associated with lower insulin sensitivity and incident type 2 diabetes in indigenous Americans: A prospective cohort study.
    Diabetes Obes Metab. 2025 Aug 18. doi: 10.1111/dom.70037.
    >> Share

  395. WANG D, Morton JI, Magliano DJ, Shaw JE, et al
    Comparison of subcutaneous, visceral, liver and muscle fat depots in relation to prevalent and incident diabetes.
    Diabetes Obes Metab. 2025 Aug 18. doi: 10.1111/dom.70021.
    >> Share

  396. LI CE, Yang DW, Guo QQ
    Cardiac repolarization in type 1 diabetes: Considerations beyond the clamp.
    Diabetes Obes Metab. 2025 Aug 14. doi: 10.1111/dom.70042.
    >> Share

  397. ROSENSTOCK J, Robins DA, Duffin KL, Wilson JM, et al
    Orforglipron, an oral non-peptide glucagon-like peptide-1 receptor agonist, improves markers of beta-cell function and insulin sensitivity in type 2 diabetes.
    Diabetes Obes Metab. 2025 Aug 14. doi: 10.1111/dom.70022.
    >> Share

  398. DEPOORTER L, Laghrib Y, De Fijter JW, Hellemans R, et al
    Diabetes screening in dialysis populations with a glucose challenge test and continuous glucose monitoring-DIGEST study.
    Diabetes Obes Metab. 2025 Aug 14. doi: 10.1111/dom.16656.
    >> Share

  399. CHO YK, Cho JH, Hong SM, Park JH, et al
    Efficacy and safety of pioglitazone, empagliflozin and glimepiride as third-line agents in patients with type 2 diabetes inadequately controlled with metformin and DPP-4 inhibitors: A multicentre, phase 4 randomized controlled trial.
    Diabetes Obes Metab. 2025 Aug 14. doi: 10.1111/dom.70030.
    >> Share

  400. BAJAJ HS, Bennedsen LV, Donatsky AM, Martiny JHJ, et al
    Adherence to app-based dose guidance for once-weekly insulin icodec in insulin-naive individuals with type 2 diabetes: Post hoc analysis of ONWARDS 5.
    Diabetes Obes Metab. 2025 Aug 13. doi: 10.1111/dom.16597.
    >> Share

  401. ANDERSEN JA, Suvitaival T, Trost K, Romero-Lado MJ, et al
    Metabolomic risk predictors of diabetic foot complications: A longitudinal observational study in type 1 diabetes.
    Diabetes Obes Metab. 2025 Aug 12. doi: 10.1111/dom.70001.
    >> Share

  402. CARUSO I, Giordano F, Matichecchia II, Di Gioia L, et al
    Effectiveness of GLP-1RA according to different type 2 diabetes phenotypes: A retrospective study.
    Diabetes Obes Metab. 2025 Aug 11. doi: 10.1111/dom.70005.
    >> Share

  403. CHANG H, Wang R
    Screening for type 1 diabetes in patients with celiac or thyroid disease: Practical considerations.
    Diabetes Obes Metab. 2025 Aug 11. doi: 10.1111/dom.70018.
    >> Share

  404. GEORGIANOS PI, Koufakis T, Arampatzis S, Liakopoulos V, et al
    CONFIDENCE in the safety and efficacy of dual therapy with an SGLT-2 inhibitor and finerenone in patients with chronic kidney disease and type 2 diabetes.
    Diabetes Obes Metab. 2025 Aug 11. doi: 10.1111/dom.70026.
    >> Share

  405. MALIK RA, Anderson J, Russo G, Amani MEA, et al
    Long-term effectiveness of iGlarLixi treatment in people with type 2 diabetes in the United States: The soli-durability 24-month observational study.
    Diabetes Obes Metab. 2025 Aug 11. doi: 10.1111/dom.16591.
    >> Share

  406. PICO ML, Maindal HT, Grunnet LG, Damm P, et al
    Prevalence and concordance of cardiometabolic risk markers and health behaviour among couples after a gestational diabetes mellitus-affected pregnancy.
    Diabetes Obes Metab. 2025 Aug 8. doi: 10.1111/dom.70017.
    >> Share

  407. BRYANT CLN, Colbert K, Hompesch M, Chaves S, et al
    GLY-200, an oral pharmacologic duodenal exclusion drug, resulted in positive effects on glucose, lipids and bodyweight in patients with type 2 diabetes: Results of a randomized, double-blind placebo-controlled trial.
    Diabetes Obes Metab. 2025 Aug 6. doi: 10.1111/dom.16664.
    >> Share

  408. CHAKRAVARTHY MV, Elliott MA, Acosta L, Sonnenberg GE, et al
    Efficacy and safety of CT-868, a novel, fully biased, dual glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor agonist, in type 2 diabetes: A double-blind, randomized placebo controlled phase 2 trial.
    Diabetes Obes Metab. 2025 Aug 5. doi: 10.1111/dom.70006.
    >> Share

  409. TATSUMI T, Takatsuna Y, Ishibashi R, Koshizaka M, et al
    Sodium-glucose co-transporter 2 inhibitors reduce the intravitreal anti-VEGF treatment necessity in eyes with early diabetic macular oedema: A post-hoc analysis focusing on the fellow eye of the COMET trial.
    Diabetes Obes Metab. 2025 Aug 4. doi: 10.1111/dom.16636.
    >> Share

  410. ARONSON R, Abitbol A, Bajaj HS, Cheng AYY, et al
    Continuous glucose monitoring in noninsulin-treated type 2 diabetes: A critical review of reported trials with an updated systematic review and meta-analysis of randomised controlled trials.
    Diabetes Obes Metab. 2025 Aug 4. doi: 10.1111/dom.70008.
    >> Share

  411. WANG HW, Tsai MH, Fang YW, Lu KC, et al
    Association between sodium-glucose cotransporter 2 inhibitor use and clinical outcomes in patients with type 2 diabetes after urinary tract infection.
    Diabetes Obes Metab. 2025 Aug 4. doi: 10.1111/dom.70003.
    >> Share

  412. MOLANI-GOL R, Rafraf M, Asghari Jafarabadi M, Aftabi-Yousefabad S, et al
    The interaction of vitamin D supplementation with Omentin-1 gene polymorphism on metabolic biomarkers, omentin-1 levels and anthropometric measures in women with prediabetes: A double-blind randomized controlled trial.
    Diabetes Obes Metab. 2025;27:4522-4536.
    >> Share

  413. PAN Q, Ai W, Chen Y, Shen Z, et al
    CHIP mediates glucagon action on hepatic glucose production via regulating Smad3 ubiquitination.
    Diabetes Obes Metab. 2025;27:4499-4510.
    >> Share

  414. SILVERII GA, Marinelli C, Bettarini C, Del Vescovo GG, et al
    GLP-1 receptor agonists and the risk for cancer: A meta-analysis of randomized controlled trials.
    Diabetes Obes Metab. 2025;27:4454-4468.
    >> Share

  415. ALAMMARI N, Alshehri A, Al Khalaf A, Alamri RA, et al
    Effects of GLP-1 receptor agonists on incidence and outcomes of ischemic stroke and myocardial infarction: A systematic review and meta-analysis.
    Diabetes Obes Metab. 2025;27:4387-4400.
    >> Share

  416. CONNOLLY EL, Liu AH, Woodman RJ, Shafaei A, et al
    Cruciferous vegetables improve glycaemic control compared to root/squash vegetables in a randomized, controlled, crossover trial: The VEgetableS for vaScular hEaLth (VESSEL) study.
    Diabetes Obes Metab. 2025;27:4300-4310.
    >> Share

  417. SCHEEN AJ
    Glucagon-like peptide-1 receptor agonists and alcohol use disorders: An emerging unexpected beneficial effect.
    Diabetes Obes Metab. 2025;27:4083-4091.
    >> Share

  418. PARKER CH, Slattery C, Brennan DJ, le Roux CW, et al
    Glucagon-like peptide 1 (GLP-1) receptor agonists' use during pregnancy: Safety data from regulatory clinical trials.
    Diabetes Obes Metab. 2025;27:4102-4108.
    >> Share

  419. AAMODT KI, Powers AC
    The pathophysiology, presentation and classification of Type 1 diabetes.
    Diabetes Obes Metab. 2025;27 Suppl 6.
    >> Share

  420. HORVATH L, Novodvorsky P, Haluzik M
    Practical limitations of complex insulin therapies in type 2 diabetes: Focus on therapy simplification using fixed-ratio combinations of basal insulin and a glucagon-like peptide-1 receptor agonist.
    Diabetes Obes Metab. 2025;27 Suppl 7.
    >> Share

  421. FRIAS JP
    What is the 'real-world' experience with fixed-ratio combination therapy (insulin + GLP-1 receptor agonist) in routine clinical practice? Take-home messages for clinicians regarding key outcomes.
    Diabetes Obes Metab. 2025;27 Suppl 7.
    >> Share

    July 2025
  422. VILSBOLL T, Malecki MT, Sharma P, Thieu VT, et al
    HbA1c reduction with tirzepatide in people with type 2 diabetes: The contribution of weight loss assessed by a mediation analysis.
    Diabetes Obes Metab. 2025 Jul 31. doi: 10.1111/dom.16592.
    >> Share

  423. HAGELQVIST PG, Schwarz CR, Maytham K, Hamid YH, et al
    The impact of plasma glucose decline rate on cardiac repolarisation in individuals with type 1 diabetes.
    Diabetes Obes Metab. 2025 Jul 31. doi: 10.1111/dom.16607.
    >> Share

  424. O'CONNOR E, Kiely C, Gildea N, O'Shea D, et al
    Effects of pioglitazone with and without exercise training on cardiorespiratory fitness and oxygen uptake kinetics in type 2 diabetes.
    Diabetes Obes Metab. 2025 Jul 30. doi: 10.1111/dom.16648.
    >> Share

  425. AL ASHI S, Shah R, Iftikhar N, Lingvay I, et al
    Association of GLP1-receptor agonist use with liver disease progression, major cardiovascular events, and mortality in people with hepatic steatosis and diabetes.
    Diabetes Obes Metab. 2025 Jul 30. doi: 10.1111/dom.16657.
    >> Share

  426. SARWAL A, Singh R, Wei G, Shen J, et al
    Glycemic therapies and the risk of gastrointestinal adverse events in veterans with type 2 diabetes.
    Diabetes Obes Metab. 2025 Jul 30. doi: 10.1111/dom.16642.
    >> Share

  427. MA J, Fan W
    Towards precision obesity management in diabetes: methodological considerations and future directions.
    Diabetes Obes Metab. 2025 Jul 29. doi: 10.1111/dom.16655.
    >> Share

  428. STOUGAARD EB, Andersen MR, Bagger JI, Sondergaard E, et al
    The Steno 1 study: Multifactorial intervention to reduce cardiovascular disease in type 1 diabetes-rationale and protocol of the prospective, randomized, open-labelled multicentre study.
    Diabetes Obes Metab. 2025 Jul 29. doi: 10.1111/dom.16606.
    >> Share

  429. HONG EG, Min KW, Chun S, Chung CH, et al
    Efficacy and safety of lobeglitazone added to metformin and sitagliptin combination therapy in patients with type 2 diabetes: A 52-week, multicentre, randomized, placebo-controlled, phase III clinical trial.
    Diabetes Obes Metab. 2025 Jul 29. doi: 10.1111/dom.16625.
    >> Share

  430. KIM J, Kim YS, Hwang YC, Yim JE, et al
    Comparative efficacy and safety of Evogliptin in type 2 diabetes patients above and below 65 years.
    Diabetes Obes Metab. 2025 Jul 29. doi: 10.1111/dom.16659.
    >> Share

  431. LIU J, Liu Y, Xu W, Zhang M, et al
    Evaluation of efficacy of iGlarLixi versus IDegAsp using derived time-in-ranges in Chinese adults with Type 2 diabetes: A post hoc analysis of the Soli-D study.
    Diabetes Obes Metab. 2025 Jul 25. doi: 10.1111/dom.16646.
    >> Share

  432. PETERMANN-ROCHA F, Diaz-Toro F, Nazar G, Apolinar-Jimenez E, et al
    Diabetes is one of the main drivers of mortality in Mexico: A latent class analysis of chronic diseases using the Mexico City Prospective Study.
    Diabetes Obes Metab. 2025 Jul 25. doi: 10.1111/dom.16644.
    >> Share

  433. DE HOOGH IM, Snel T, Kamstra RJM, Krone T, et al
    Differential effects of lifestyle interventions on continuous glucose monitoring metrics in persons with type 2 diabetes: Potential for personalised treatment.
    Diabetes Obes Metab. 2025 Jul 25. doi: 10.1111/dom.16654.
    >> Share

  434. GALINDO RJ, Lee CJ, Allen SE, Dib A, et al
    Improvement in body mass index category was associated with improved cardiometabolic measures and patient-reported outcomes in adults with type 2 diabetes treated with tirzepatide.
    Diabetes Obes Metab. 2025 Jul 24. doi: 10.1111/dom.16620.
    >> Share

  435. GONG JY, Salim A, Magliano DJ, Shaw JE, et al
    Impact of eligibility for diabetes remission on response to intensive lifestyle intervention in overweight and obese people with type 2 diabetes: The Look AHEAD trial.
    Diabetes Obes Metab. 2025 Jul 24. doi: 10.1111/dom.16650.
    >> Share

  436. PASHA R, Kamath A, Linn Z, Kalteniece A, et al
    Statin therapy and neuropathy in type 1 diabetes: A cross-sectional study.
    Diabetes Obes Metab. 2025 Jul 24. doi: 10.1111/dom.16617.
    >> Share

  437. QUINN LM, Boiko O, Elliott J, Randell M, et al
    Treatment acceptability for disease-modifying therapy for type 1 diabetes (T1D)-Views from parents of children with presymptomatic T1D.
    Diabetes Obes Metab. 2025 Jul 23. doi: 10.1111/dom.16639.
    >> Share

  438. OLSEN MT, Jensen SH, Rasmussen LM, Klarskov CK, et al
    The association between inflammation and glucose levels in hospitalised patients with type 2 diabetes.
    Diabetes Obes Metab. 2025 Jul 23. doi: 10.1111/dom.16640.
    >> Share

  439. JANG SA, Kwon SJ, Kim CS, Park SW, et al
    Exploring the value of ChatGPT in selecting antidiabetic agents for type 2 diabetes.
    Diabetes Obes Metab. 2025 Jul 23. doi: 10.1111/dom.16630.
    >> Share

  440. PAN Y, Li Y, Cui M, He G, et al
    Global, regional and national burden of blindness and vision loss attributable to diabetic retinopathy, 1990-2021: A systematic analysis for the Global Burden of Disease Study 2021.
    Diabetes Obes Metab. 2025 Jul 22. doi: 10.1111/dom.16588.
    >> Share

  441. HUGHES MS, Morgan M, Liu YT, Lee MY, et al
    Diabetes technology use in U.S. hospitals: A survey of user experiences.
    Diabetes Obes Metab. 2025 Jul 22. doi: 10.1111/dom.16634.
    >> Share

  442. NAJA K, Elashi AA, Anwardeen N, Razzaq A, et al
    N-lactoyl amino acids are potential biomarkers for insulin resistance and diabetic complications.
    Diabetes Obes Metab. 2025 Jul 22. doi: 10.1111/dom.16633.
    >> Share

  443. LEE D, Seo G, Kim Y, Min JY, et al
    Clinical features and outcomes of diabetic ketoacidosis in patients using SGLT2 inhibitors: A systematic review and meta-analysis.
    Diabetes Obes Metab. 2025 Jul 21. doi: 10.1111/dom.16635.
    >> Share

  444. LOW JL, Hesketh K, Falkenhain K, Jung ME, et al
    Improved glycemic regulation on exercise compared to non-exercise days in a real-world setting in individuals recently diagnosed with type 2 diabetes: A secondary analysis of the MOTIVATE T2D randomised controlled trial.
    Diabetes Obes Metab. 2025 Jul 21. doi: 10.1111/dom.16623.
    >> Share

  445. BOLLI GB, Porcellati F, Lucidi P, Fanelli CG, et al
    An overview of randomized clinical trials of fixed-ratio combinations of basal insulin plus GLP-1RA (injectable therapy): Lessons for advancing therapy in people with type 2 diabetes.
    Diabetes Obes Metab. 2025 Jul 17. doi: 10.1111/dom.16616.
    >> Share

  446. HAN S, Hu X, Zhang Z, Li Y, et al
    Cognitive reserve, genetic risk, and lifestyle in the incidence and progression of type 2 diabetes: A large community-based longitudinal study.
    Diabetes Obes Metab. 2025 Jul 17. doi: 10.1111/dom.16622.
    >> Share

  447. CHERUBINI V, Scaramuzza AE, Agrimi U, Bonfanti R, et al
    Initial observations on the frequency of diabetic ketoacidosis following pilot screening for type 1 diabetes in the general Italian population.
    Diabetes Obes Metab. 2025 Jul 17. doi: 10.1111/dom.16611.
    >> Share

  448. WERKMAN NCC, Nielen JTH, Tapia-Galisteo J, Somolinos-Simon FJ, et al
    Prediction of glycaemic control and quality of life in people with type 2 diabetes using glucose-lowering drugs with machine learning-The Maastricht study.
    Diabetes Obes Metab. 2025 Jul 17. doi: 10.1111/dom.16598.
    >> Share

  449. WALLACE H, Wick J, Neuen BL, Buizen L, et al
    Prevalence of SGLT2 inhibitor and GLP1 receptor agonist prescriptions in type 2 diabetes patients with and without chronic kidney disease: Analysis of an Australian primary care dataset.
    Diabetes Obes Metab. 2025 Jul 16. doi: 10.1111/dom.16608.
    >> Share

  450. KLEPSER NS, Weber ES, Li L, Fleischmann KE, et al
    Adherence to GLP-1 receptor agonists and SGLT2 inhibitors by out-of-pocket spending among Medicare beneficiaries with diabetes.
    Diabetes Obes Metab. 2025 Jul 16. doi: 10.1111/dom.16619.
    >> Share

  451. WHYTE MB, Heald AH
    Could continuous subcutaneous glucose sensors (CGMS) be repurposed to diagnose diabetes in equivocal or challenging cases?
    Diabetes Obes Metab. 2025 Jul 15. doi: 10.1111/dom.16624.
    >> Share

  452. SUGIMOTO T, Omura T, Araki A, Haneda C, et al
    Differential effects of a multidomain intervention on cognitive decline in older adults with type 2 diabetes according to white matter hyperintensity status: A secondary analysis of the J-MIND-Diabetes.
    Diabetes Obes Metab. 2025 Jul 14. doi: 10.1111/dom.16605.
    >> Share

  453. HUANG C, Chen Y, Britton A
    Changes in adiposity indices over 10 years and risk of type 2 diabetes: The Whitehall II cohort study.
    Diabetes Obes Metab. 2025 Jul 14. doi: 10.1111/dom.16615.
    >> Share

  454. NEVES JS, Vale C, Leite AR, Ferreira JP, et al
    Cardiorenal outcomes and mortality with GLP-1 receptor agonists combined with SGLT2 inhibitors in type 2 diabetes: An updated systematic review and meta-analysis.
    Diabetes Obes Metab. 2025 Jul 14. doi: 10.1111/dom.16603.
    >> Share

  455. AL OZAIRI E, Irshad M, Alkandari J, Taghadom E, et al
    Association of device measured physical activity with liver fat and stiffness in people with type 1 diabetes.
    Diabetes Obes Metab. 2025 Jul 14. doi: 10.1111/dom.16584.
    >> Share

  456. GOYAL A, Kubihal S, Gupta Y, Shalimar, et al
    Hepatic steatosis index for prediction of metabolic dysfunction-associated steatotic liver disease (MASLD) among young Indian women with gestational diabetes and normoglycaemia during index pregnancy.
    Diabetes Obes Metab. 2025 Jul 14. doi: 10.1111/dom.16595.
    >> Share

  457. DE WIT DF, Fuhri Snethlage CM, Minab R, Rampanelli E, et al
    Persisting plasma proinsulin levels in a cohort of 482 individuals with long-standing type 1 diabetes mellitus.
    Diabetes Obes Metab. 2025 Jul 14. doi: 10.1111/dom.16604.
    >> Share

  458. STOCHL J, Clarke N, Green D, Comins J, et al
    Psychometric evaluation of the Adelphi Adherence Questionnaire (ADAQ(c)) in a type 2 diabetes mellitus population as a new measure of adherence and the complex factors influencing adherence in routine care.
    Diabetes Obes Metab. 2025 Jul 14. doi: 10.1111/dom.16551.
    >> Share

  459. SVENSSON CH, Fabricius TW, Verhulst C, Tack CJ, et al
    Association between recent real-life exposure to hypoglycaemia and cognitive function during hypoglycaemia in people with type 1 diabetes: Findings from the Hypo-RESOLVE clamp study.
    Diabetes Obes Metab. 2025 Jul 11. doi: 10.1111/dom.16587.
    >> Share

  460. ANANDHAKRISHNAN A, Pender S, Johnston T, Hyslop R, et al
    Ethnicity and socioeconomic status do not influence glycaemic outcomes of a tubeless hybrid closed-loop system (Omnipod(R) 5) in adults with type 1 diabetes.
    Diabetes Obes Metab. 2025 Jul 9. doi: 10.1111/dom.16553.
    >> Share

  461. CARUSO P, Angelino S, Matrone R, Scappaticcio L, et al
    Association of semaglutide with less limb events in people with type 2 diabetes and peripheral artery disease or foot ulcers: An observational study comparing matched cohorts.
    Diabetes Obes Metab. 2025 Jul 7. doi: 10.1111/dom.16594.
    >> Share

  462. ALGUWAIHES AM, Alotaibi MS, Alqumaidi H, Batais MA, et al
    Potential benefits of hybrid closed-loop systems for managing moderate- to high-risk individuals with type 1 diabetes during Ramadan fasting.
    Diabetes Obes Metab. 2025 Jul 7. doi: 10.1111/dom.16573.
    >> Share

  463. LEE HA
    Sex- and age-specific determinants of diabetes: Insights from BKMR and cox modelling of metabolic and lifestyle risk factors in a Korean cohort.
    Diabetes Obes Metab. 2025 Jul 2. doi: 10.1111/dom.16577.
    >> Share

  464. TRBOVICH M, Hoekstra S, Gastaldelli A, Salehi M, et al
    Reduced prandial insulin secretion contributes to prandial hyperglycaemia in non-diabetic individuals with spinal cord injury.
    Diabetes Obes Metab. 2025 Jul 2. doi: 10.1111/dom.16563.
    >> Share

  465. VOSS EA, Yuan Z, Ali SR, Bosan R, et al
    A study on the utilization of canagliflozin in type 1 diabetes mellitus using real-world data from four European countries.
    Diabetes Obes Metab. 2025 Jul 2. doi: 10.1111/dom.16574.
    >> Share

  466. GETHER IM, Gilliam-Vigh H, Kliim-Hansen V, Hartmann B, et al
    Oxytocin mRNA is expressed throughout the small intestine in individuals with and without type 2 diabetes, and circulating neurophysin I declines after Roux-en-Y gastric bypass surgery.
    Diabetes Obes Metab. 2025 Jul 2. doi: 10.1111/dom.16571.
    >> Share

  467. WANG S, Fan D, Yao Q, Sun X, et al
    The cost-utility and budget impact analyses of Tirzepatide versus once-weekly Semaglutide as add-on therapy to metformin in patients with type 2 diabetes mellitus in China.
    Diabetes Obes Metab. 2025 Jul 2. doi: 10.1111/dom.16580.
    >> Share

  468. YU C, Zhou Z, Neumann JT, Lin T, et al
    Genomic risk prediction for type 2 diabetes in Australian individuals aged 70 years and older.
    Diabetes Obes Metab. 2025 Jul 2. doi: 10.1111/dom.16579.
    >> Share

  469. FADINI GP, Longato E, Morieri ML, Broglio F, et al
    Long-term preservation of kidney function with SGLT-2 inhibitors versus comparator drugs in people with type 2 diabetes and chronic kidney disease.
    Diabetes Obes Metab. 2025 Jul 2. doi: 10.1111/dom.16569.
    >> Share

  470. SHAO X, Xu H, Chen L, Bai P, et al
    Multi-modal models using fMRI, urine and serum biomarkers for classification and risk prognosis in diabetic kidney disease.
    Diabetes Obes Metab. 2025 Jul 2. doi: 10.1111/dom.16572.
    >> Share

  471. BEEN RA, van Helsdingen MRX, Zammit D, Grzegorczyk M, et al
    The efficacy of intermittent scanning continuous glucose monitoring in the elderly: A case-control study.
    Diabetes Obes Metab. 2025;27:3882-3890.
    >> Share

  472. KO HY, Jung K, Cho Y, Bea S, et al
    Association between the body mass index and risk of cardiovascular events in sodium-glucose cotransporter 2 inhibitor users compared with dipeptidyl-peptidase 4 inhibitor users: A nationwide cohort study in Korea.
    Diabetes Obes Metab. 2025;27:3869-3881.
    >> Share

  473. MURRAY-THOMAS T, Dcruz JM, Harder-Lauridsen NM, Olsen AH, et al
    Real-world use of liraglutide for weight management according to label in the United Kingdom: A cohort study using the Clinical Practice Research Datalink primary care databases.
    Diabetes Obes Metab. 2025;27:3705-3713.
    >> Share

  474. RICHARDSON KM, Schembre SM, Jospe MR, Widmer A, et al
    The influence of the glucagon-like peptide-1 receptor agonist, liraglutide, on dietary patterns and nutrient intakes in patients with obesity and prediabetes: A secondary analysis of a randomized controlled trial.
    Diabetes Obes Metab. 2025;27:3725-3735.
    >> Share

  475. KANG YM, Punov V, Lim S, Nauck MA, et al
    Comparative efficacy and tolerability of currently approved incretin mimetics: A systematic analysis of placebo-controlled clinical trials.
    Diabetes Obes Metab. 2025;27:3736-3746.
    >> Share

  476. SUN M, Wang X, Lu Z, Yang Y, et al
    Sodium-glucose cotransporter-2 inhibitors and subtype-specific dementia risk: A multinational and multiethnic cohort study.
    Diabetes Obes Metab. 2025;27:3766-3779.
    >> Share

  477. O'HARA DV, Jardine MJ
    A review of the safety of sodium-glucose co-transporter-2 inhibitors.
    Diabetes Obes Metab. 2025;27:3598-3606.
    >> Share

  478. MCEWAN P, Evans M
    The health economics of insulin therapy: How do we address the rising demands, costs, inequalities and barriers to achieving optimal outcomes.
    Diabetes Obes Metab. 2025;27 Suppl 5.
    >> Share

  479. YANG A, Yu J, Cheung JTK, Chan JCN, et al
    Real world evidence of insulin and biosimilar insulin therapy-Opportunities to improve adherence, outcomes and cost-effectiveness.
    Diabetes Obes Metab. 2025;27 Suppl 5.
    >> Share

  480. HEISE T, DeVries JH
    Biosimilar insulins: Narrative review of the regulatory framework and registration studies.
    Diabetes Obes Metab. 2025;27 Suppl 5.
    >> Share

  481. HOME PD
    An overview of insulin therapy for the non-specialist.
    Diabetes Obes Metab. 2025;27 Suppl 5.
    >> Share

  482. ABITBOL A, Chu L
    What do the guidelines say about use of biosimilar insulin therapy? Simple practical considerations to guide clinicians in different patient subgroups-Sharing Canadian perspectives.
    Diabetes Obes Metab. 2025;27 Suppl 5:36-44.
    >> Share

  483. JANUSZEWSKI AS, Snaith JR, Grzelka-Wozniak A, Simonsen JRA, et al
    No evidence from euglycaemic-hyperinsulinaemic clamp studies for greater insulin sensitivity in adults with type 1 diabetes using insulin pump versus multiple daily insulin injections-Post hoc meta-analysis.
    Diabetes Obes Metab. 2025 Jul 1. doi: 10.1111/dom.16487.
    >> Share

    June 2025
  484. VALLIVAARA HL, Leppanen HA, Mustonen J, Saari A, et al
    Long-term health economic evaluation of automated insulin delivery system compared with continuous subcutaneous insulin infusion pumps and CGM in a real-world setting in Finnish paediatric and adult individuals with type 1 diabetes.
    Diabetes Obes Metab. 2025 Jun 27. doi: 10.1111/dom.16520.
    >> Share

  485. MORRISON DJ, Vogrin S, Zaharieva DP, Manos G, et al
    Glycaemic impact of the pre-exercise timing of an elevated glucose target implemented using an automated insulin delivery system in adults with type 1 diabetes.
    Diabetes Obes Metab. 2025 Jun 25. doi: 10.1111/dom.16567.
    >> Share

  486. DIALLO A, Villard O, Carlos-Bolumbu M, Duc P, et al
    Blood glucose and body weight reduction for the prevention of clinical events and mortality in patients with type 2 diabetes: A meta-analysis and meta-regression of 44 randomized controlled trials.
    Diabetes Obes Metab. 2025 Jun 25. doi: 10.1111/dom.16561.
    >> Share

  487. FRANC S, Charpentier G
    Emotional distress as a therapeutic target against persistent poor glycaemic control in subjects with type 1 diabetes: A systematic review.
    Diabetes Obes Metab. 2025 Jun 25. doi: 10.1111/dom.16540.
    >> Share

  488. JUN JE, Choi SH, Moon MK, Ko SH, et al
    EffiCacy and safety of ANagliptin when added to iNsulin and metformin therapy in patients with uncontrolled type 2 diAbetes; randomized, placebo-controlled, double-blind, multicentre trial (CANNA study).
    Diabetes Obes Metab. 2025 Jun 25. doi: 10.1111/dom.16557.
    >> Share

  489. BORG MJ, Xie C, Chen C, Bound MJ, et al
    Metformin slows intestinal glucose absorption in type 2 diabetes, irrespective of the timing of its administration.
    Diabetes Obes Metab. 2025 Jun 24. doi: 10.1111/dom.16570.
    >> Share

  490. SOLIMAN Y, Everett K, Shulman R, Austin PC, et al
    Impact of social disadvantage on clinical and health care use indicators in adults with type 1 diabetes using insulin pumps in Ontario, Canada.
    Diabetes Obes Metab. 2025 Jun 24. doi: 10.1111/dom.16547.
    >> Share

  491. JAMIOLKOWSKA-SZTABKOWSKA M, Noiszewska K, Polkowska A, Zasim A, et al
    Get ahead of the disease: Islet cell autoimmunity and preclinical phase of type 1 diabetes in general population of 1-9 year-old children in the north-eastern region of Poland-A summary of the first 18 months of the study.
    Diabetes Obes Metab. 2025 Jun 24. doi: 10.1111/dom.16560.
    >> Share

  492. REWERS M
    Health economic considerations of screening for early type 1 diabetes.
    Diabetes Obes Metab. 2025 Jun 24. doi: 10.1111/dom.16522.
    >> Share

  493. DELGADO ALVAREZ E, Morales Portillo C, Abreu Padin C, Aliaga Verdugo A, et al
    PIONEER REAL Spain: A multicentre, prospective, real-world study of oral semaglutide use in adults with type 2 diabetes.
    Diabetes Obes Metab. 2025 Jun 24. doi: 10.1111/dom.16523.
    >> Share

  494. GHARIBZADEH S, Lee J, Highton P, Greenlaw N, et al
    Risk factors for development of diabetic foot ulcer disease in two large contemporary UK cohorts.
    Diabetes Obes Metab. 2025 Jun 24. doi: 10.1111/dom.16519.
    >> Share

  495. KIM MJ, Cho YK, Kim S, Moon JY, et al
    Efficacy and safety of combination therapy using SGLT2 and DPP4 inhibitors to treat type 2 diabetes: An updated systematic review and meta-analysis with focus on an Asian subpopulation.
    Diabetes Obes Metab. 2025 Jun 24. doi: 10.1111/dom.16550.
    >> Share

  496. LI K, Tang H, Wang Y, Wang X, et al
    Identification of hub genes involved in the pathogenesis of diabetic nephropathy: A multi-omics study integrating machine learning, mendelian randomization and mediation analysis.
    Diabetes Obes Metab. 2025 Jun 24. doi: 10.1111/dom.16536.
    >> Share

  497. MUSTAFA S, Mayo C, Paul R, Rodrigues M, et al
    Inequity in adherence to empagliflozin and dulaglutide for type 2 diabetes in Aotearoa New Zealand.
    Diabetes Obes Metab. 2025 Jun 24. doi: 10.1111/dom.16558.
    >> Share

  498. NI W, Chen Z, Zhu M, Li Y, et al
    Gestational diabetes risk associated with early pregnancy blood pressure characteristics and trajectories: A Chinese prospective cohort study.
    Diabetes Obes Metab. 2025 Jun 19. doi: 10.1111/dom.16555.
    >> Share

  499. CIUDIN A, Johansson E, Zimner-Rapuch S, Dimitriadis GK, et al
    Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes.
    Diabetes Obes Metab. 2025 Jun 19. doi: 10.1111/dom.16508.
    >> Share

  500. DE LEIJER JF, Pham SDT, Vissers TACM, Exalto LG, et al
    Association between retinal microvasculature and cerebral small vessel function in type 2 diabetes: An ultrahigh field MRI study.
    Diabetes Obes Metab. 2025 Jun 19. doi: 10.1111/dom.16546.
    >> Share

  501. TSUR A, Leibowitz G, Cohen MJ, Cahn A, et al
    Predictors of diabetic ketoacidosis in patients with insulin-deficient diabetes phenotype initiating SGLT2 inhibitors.
    Diabetes Obes Metab. 2025 Jun 19. doi: 10.1111/dom.16545.
    >> Share

  502. BELL KJ, Lain SJ
    The Changing Epidemiology of Type 1 Diabetes: A Global Perspective.
    Diabetes Obes Metab. 2025 Jun 19. doi: 10.1111/dom.16501.
    >> Share

  503. STEENS ILM, Schram MT, Houben AJHM, Berendschot TTJM, et al
    Type 2 diabetes and depression via microvascular dysfunction, neurodegeneration, inflammation, advanced glycation end products (AGEs), arterial stiffness.
    Diabetes Obes Metab. 2025 Jun 19. doi: 10.1111/dom.16527.
    >> Share

  504. LEKVA T, Roland MCP, Qvigstad E, Khan Y, et al
    Oxidative stress, senescence and mRNA decay in peripheral blood mononuclear cells of women with gestational diabetes mellitus-link to increased cardiovascular disease risk.
    Diabetes Obes Metab. 2025 Jun 17. doi: 10.1111/dom.16521.
    >> Share

  505. GUO Y, Zhang X, Li W, Zhou Y, et al
    Trajectories of body mass index and diabetes mellitus risk among elderly Chinese adults: A 10-year longitudinal study.
    Diabetes Obes Metab. 2025 Jun 17. doi: 10.1111/dom.16530.
    >> Share

  506. LEI M, Ling P, Lin B, Lv J, et al
    Efficacy and safety of a tubeless open-source hybrid automated insulin delivery use at home among adults with type 1 diabetes mellitus: Results from a 26-week, free-living, randomized crossover trial.
    Diabetes Obes Metab. 2025 Jun 17. doi: 10.1111/dom.16505.
    >> Share

  507. ADAMS RN, Athinarayanan SJ, Zoller AR, McKenzie AL, et al
    Sustained metabolic improvements in a remotely delivered ketogenic nutrition programme for veterans with type 2 diabetes: A 3-year observational study.
    Diabetes Obes Metab. 2025 Jun 16. doi: 10.1111/dom.16525.
    >> Share

  508. INOUE M, Kusunoki Y, Ohigashi M, Osugi K, et al
    Continuous glucose monitoring-derived time in range is associated with changes in cognitive function test scores in Japanese patients with type 2 diabetes mellitus.
    Diabetes Obes Metab. 2025 Jun 16. doi: 10.1111/dom.16511.
    >> Share

  509. SCHMEDT N, Alhamdow A, Tskhvarashvili G, Saarelainen L, et al
    Post-authorisation safety study to assess the risk of urinary tract cancer in people with type 2 diabetes initiating empagliflozin: A multi-country European study.
    Diabetes Obes Metab. 2025 Jun 13. doi: 10.1111/dom.16477.
    >> Share

  510. COWART K, Carris NW
    Current treatment guidelines and glycated haemoglobin goals for type 2 diabetes: Which patients are most likely to benefit from fixed-ratio basal insulin glucagon-like peptide-1 receptor agonist combinations?
    Diabetes Obes Metab. 2025 Jun 11. doi: 10.1111/dom.16502.
    >> Share

  511. SUN CJ, Lochnan H, Sorisky A, Shaw J, et al
    A simplified protocol based on a standardized meal-stimulated beta-cell response to stratify people living with non-insulin-treated type 2 diabetes.
    Diabetes Obes Metab. 2025 Jun 11. doi: 10.1111/dom.16528.
    >> Share

  512. HIGHTON P, Abdala R, Evley R, Balasubramanian V, et al
    The use of SGLT2 inhibitors in people with diabetes-related foot disease: A Delphi-based consensus study.
    Diabetes Obes Metab. 2025 Jun 11. doi: 10.1111/dom.16498.
    >> Share

  513. SU H, Ni J, Peng D, He X, et al
    Association of time in tight range and 1,5-anhydroglucitol in type 2 diabetes.
    Diabetes Obes Metab. 2025 Jun 9. doi: 10.1111/dom.16515.
    >> Share

  514. YAMAUCHI T, Asakura T, Shingaki T, Oura T, et al
    Efficacy and safety of once-weekly tirzepatide in Japanese participants with type 2 diabetes who have obesity or overweight: Subpopulation analysis of the SURMOUNT-2 trial.
    Diabetes Obes Metab. 2025 Jun 9. doi: 10.1111/dom.16500.
    >> Share

  515. DUBSKY M, Sojakova D, Husakova J, Nemcova A, et al
    Long-term efficacy of autologous cell therapy, repeated PTA and conservative treatment in people with diabetes and chronic limb-threatening ischaemia.
    Diabetes Obes Metab. 2025 Jun 9. doi: 10.1111/dom.16510.
    >> Share

  516. ASSALIA NAFFA M, Ayada G, Zolotov S, Shehadeh N, et al
    Glucagon-like peptide-1 receptor agonists in adults with cystic fibrosis-related diabetes: Rationale and emerging evidence.
    Diabetes Obes Metab. 2025 Jun 9. doi: 10.1111/dom.16516.
    >> Share

  517. WEI X, Zhao J, Zhu P, Niu W, et al
    Association between estimated glucose disposal rate and lower extremity arterial disease in type 2 diabetes: A nationwide cross-sectional study from China.
    Diabetes Obes Metab. 2025 Jun 9. doi: 10.1111/dom.16514.
    >> Share

  518. ALIYU U, Umlai UI, Al-Thani NM, Toor SM, et al
    Genetic risk and polygenic risk score assessment of prediabetes and progression to type 2 diabetes.
    Diabetes Obes Metab. 2025 Jun 5. doi: 10.1111/dom.16490.
    >> Share

  519. RETNAKARAN R, Pu J, Hanley AJ, Zinman B, et al
    A1c versus oral glucose tolerance test for chronic glycemic surveillance in women with previous gestational diabetes.
    Diabetes Obes Metab. 2025 Jun 5. doi: 10.1111/dom.16513.
    >> Share

  520. CUI K, Fu R, Yang J, Xu H, et al
    Haemoglobin glycation index and in-hospital mortality after acute myocardial infarction in patients with/without diabetes: A prospective, nationwide and multicentre registry.
    Diabetes Obes Metab. 2025 Jun 3. doi: 10.1111/dom.16495.
    >> Share

  521. LUEDDE M, Sedighi J, Hippe HJ, Sossalla S, et al
    SGLT2 inhibitors are associated with a reduced incidence of atrial fibrillation in type 2 diabetes mellitus.
    Diabetes Obes Metab. 2025 Jun 3. doi: 10.1111/dom.16494.
    >> Share

  522. ZARGAR AH, Bhansali A, Majumdar A, Maheshwari A, et al
    Management of metabolic dysfunction-associated steatotic liver disease (MASLD)-An expert consensus statement from Indian diabetologists' perspective.
    Diabetes Obes Metab. 2025 Jun 2. doi: 10.1111/dom.16496.
    >> Share

  523. TANG M, Shi L, Guan D, Winberg D, et al
    Long-term cost-effectiveness of tirzepatide for individuals with type 2 diabetes and comorbid obesity.
    Diabetes Obes Metab. 2025 Jun 2. doi: 10.1111/dom.16466.
    >> Share

  524. NANNA MG, Doan QV, Fabricatore A, Faurby M, et al
    Population-level impact of semaglutide 2.4 mg in patients with obesity or overweight and cardiovascular disease: A modelling study based on the SELECT trial.
    Diabetes Obes Metab. 2025;27:3442-3452.
    >> Share

  525. BERGET C, Annan SF, Biester T, Choudhary P, et al
    Practical considerations for using the Omnipod(R) 5 Automated Insulin Delivery System: Clinical experience from the United States and Europe.
    Diabetes Obes Metab. 2025;27:2909-2919.
    >> Share

  526. TEOH KW, Baek Y, Ademi Z, Lee SWH, et al
    A cost-effectiveness analysis alongside trial of a digital health-supported and community pharmacy-based prediabetes management programme (PRIME Programme) in Malaysia.
    Diabetes Obes Metab. 2025;27:3324-3334.
    >> Share

  527. IGARASHI A, Capucci S, Ota R, Wada S, et al
    Impact of weight loss on obesity-related complications and direct healthcare costs in Japan: A modelling study.
    Diabetes Obes Metab. 2025;27:3017-3024.
    >> Share

  528. SIMONSEN E, Lund LC, Ernst MT, Hjellvik V, et al
    Use of semaglutide and risk of non-arteritic anterior ischemic optic neuropathy: A Danish-Norwegian cohort study.
    Diabetes Obes Metab. 2025;27:3094-3103.
    >> Share

  529. WITT C, Renfroe LG, Lyons TS
    Discordance between serum cholesterol concentration and atherogenic lipoprotein particle number in people with metabolic disease: A systematic review.
    Diabetes Obes Metab. 2025;27:2940-2954.
    >> Share

  530. BERGMAN BK, Rosenstock J, Garvey WT, Batterham RL, et al
    Time spent in glycaemic control with sustained body weight reduction with tirzepatide: A post hoc analysis of the SURPASS clinical trial programme.
    Diabetes Obes Metab. 2025;27:3223-3232.
    >> Share

  531. SASAKI N, Ueno Y, Ozono R, Nakano Y, et al
    Insulin resistance in adipose tissue and fatty liver, but not fat mass, are involved in worsening glycaemic status: The Hiroshima study on glucose metabolism and cardiovascular diseases.
    Diabetes Obes Metab. 2025;27:3025-3035.
    >> Share

  532. HUA R, Shi M, Chow E, Yang A, et al
    Genetic evidence for the effects of glucokinase activation on frailty-related outcomes: A Mendelian randomisation study.
    Diabetes Obes Metab. 2025;27:3072-3083.
    >> Share

  533. LIM BSY, Chen M, Li HY, Li LJ, et al
    Metformin use in prediabetes: A review of evidence and a focus on metabolic features among peri-menopausal women.
    Diabetes Obes Metab. 2025;27 Suppl 3.
    >> Share

  534. SAADATI S, Mason T, Godini R, Vanky E, et al
    Metformin use in women with polycystic ovary syndrome (PCOS): Opportunities, benefits, and clinical challenges.
    Diabetes Obes Metab. 2025;27 Suppl 3.
    >> Share

  535. MAYADUNNE T, Saadati S, Asmelash D, Mason T, et al
    Long-term effects of metformin on offspring health: A review of current evidence and future directions.
    Diabetes Obes Metab. 2025;27 Suppl 3.
    >> Share

  536. MCEVOY RP, Newman C, Egan AM, Dunne FP, et al
    A narrative review of metformin in pregnancy: Navigating benefit and uncertainty.
    Diabetes Obes Metab. 2025;27 Suppl 3.
    >> Share

  537. LIN L, Chen P, Zhang Y, Long J, et al
    Burden of type 2 diabetes mellitus and risk factor attribution among older adults: A global, regional, and national analysis from 1990 to 2021, with projections up to 2040.
    Diabetes Obes Metab. 2025 Jun 1. doi: 10.1111/dom.16471.
    >> Share

  538. MAVROMATIS LA, Surapaneni A, Mehta S, Xu Y, et al
    Glucagon-like peptide-1 receptor agonists and incidence of obesity-related cancer in adults with diabetes: A target-trial emulation study.
    Diabetes Obes Metab. 2025 Jun 1. doi: 10.1111/dom.16445.
    >> Share

    May 2025
  539. BEERNINK JM, Jongs N, Mosterd CM, Scholtes RA, et al
    Effects of dapagliflozin on sodium excretion, blood pressure and volume status in patients with type 2 diabetes and/or chronic kidney disease: The DAPASALT trial.
    Diabetes Obes Metab. 2025 May 30. doi: 10.1111/dom.16478.
    >> Share

  540. LIU JJ, Liu S, Lee J, Zheng H, et al
    Plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) and the risk of chronic kidney disease progression in patients with type 2 diabetes.
    Diabetes Obes Metab. 2025 May 29. doi: 10.1111/dom.16486.
    >> Share

  541. EDELMAN SV, Agardh D, Cui N, Hao L, et al
    Risk of new-onset type 1 diabetes in individuals with celiac disease and thyroid disease-An observational study.
    Diabetes Obes Metab. 2025 May 28. doi: 10.1111/dom.16454.
    >> Share

  542. KONANTAMBIGI A, Wang W, Boggild D, Rana A, et al
    Real-world evaluation of automated insulin delivery therapy in type 1 diabetes: A multicentre study across regional and metropolitan Queensland, Australia.
    Diabetes Obes Metab. 2025 May 28. doi: 10.1111/dom.16485.
    >> Share

  543. TOUZOT M, Voican A, Potier L, Beaussier H, et al
    Efficacy and tolerance of liraglutide for weight loss in obese, type 2 diabetes and haemodialysis patients.
    Diabetes Obes Metab. 2025 May 28. doi: 10.1111/dom.16484.
    >> Share

  544. ZHANG Y, Gao W, Li B, Liu Y, et al
    The association between the visceral obesity indices and the future diabetes mellitus risk: A prospective cohort study.
    Diabetes Obes Metab. 2025 May 28. doi: 10.1111/dom.16492.
    >> Share

  545. YIN M, Fan W, Yu Y, Liu Z, et al
    Disparities in diabetes burden in China and globally, with projections to 2050: A systematic analysis for the Global Burden of Disease Study 2021.
    Diabetes Obes Metab. 2025 May 28. doi: 10.1111/dom.16482.
    >> Share

  546. COLLIER JJ, Wasserfall CH, Brehm MA, Karlstad MD, et al
    Partial remission of type 1 diabetes: Do immunometabolic events define the honeymoon period?
    Diabetes Obes Metab. 2025 May 28. doi: 10.1111/dom.16480.
    >> Share

  547. FAN W, Deng C, Xu R, Liu Z, et al
    Fully automated insulin delivery systems in type 1 diabetes: A systematic review and meta-analysis.
    Diabetes Obes Metab. 2025 May 28. doi: 10.1111/dom.16499.
    >> Share

  548. WU D, Wang X, Liu Q, Luo X, et al
    Comparative efficacy and safety of oral hypoglycaemic drugs as adjunctive therapy in the management of type 1 diabetes mellitus: A systematic review and meta-analysis.
    Diabetes Obes Metab. 2025 May 23. doi: 10.1111/dom.16474.
    >> Share

  549. HAN X, Pang L, Zhang X, Gao H, et al
    Impact of bariatric surgery on glycaemic and metabolic outcomes in people with obesity and type 2 diabetes mellitus: A meta-analysis.
    Diabetes Obes Metab. 2025 May 23. doi: 10.1111/dom.16475.
    >> Share

  550. DALY T, Okholm S, Imbimbo BP
    Beyond diabetes: Testing long-term metformin adherence for dementia prevention.
    Diabetes Obes Metab. 2025 May 23. doi: 10.1111/dom.16472.
    >> Share

  551. CARROLL OU, Bidulka P, Basu A, Adler AI, et al
    Long-term outcomes following alternative second-line oral glucose-lowering treatments: Results from the real-world progression in type 2 diabetes mellitus United Kingdom (RAPIDS-UK) model.
    Diabetes Obes Metab. 2025 May 21. doi: 10.1111/dom.16447.
    >> Share

  552. SU HY, Chew KY, Graves N, Ou HT, et al
    Cost-effectiveness of ON101 with general wound care for diabetic foot ulcers among patients with type 2 diabetes in Singapore: Analysis of a multi-ethnic country in Asia.
    Diabetes Obes Metab. 2025 May 21. doi: 10.1111/dom.16473.
    >> Share

  553. WASEHUUS V, Smeijer JD, Ambery P, Greasley PJ, et al
    Effects of combined treatment with zibotentan and dapagliflozin compared to dapagliflozin alone in patients with diabetic and non-diabetic chronic kidney disease.
    Diabetes Obes Metab. 2025 May 21. doi: 10.1111/dom.16468.
    >> Share

  554. HAUGHTON S, Riley D, Berry S, Arshad MF, et al
    The impact of insulin pump therapy compared to multiple daily injections on complications and mortality in type 1 diabetes: A real-world retrospective cohort study.
    Diabetes Obes Metab. 2025 May 19. doi: 10.1111/dom.16455.
    >> Share

  555. HEALEY E, Morato C, Murillo J, Kohane I, et al
    Heterogeneity of continuous glucose monitoring features and their clinical associations in a type 2 diabetes population.
    Diabetes Obes Metab. 2025 May 19. doi: 10.1111/dom.16432.
    >> Share

  556. OKADA A, Otsuka Y, Inoue R, Hashimoto Y, et al
    Adherence to physician visits for diabetes care and cardiovascular disease risk: A retrospective cohort study using an administrative claims database.
    Diabetes Obes Metab. 2025 May 19. doi: 10.1111/dom.16479.
    >> Share

  557. NOKIHARA M, Fujihara K, Yaguchi Y, Takizawa H, et al
    The associations of body mass index and waist circumference with the risk of diabetic complications in people with type 2 diabetes mellitus.
    Diabetes Obes Metab. 2025 May 16. doi: 10.1111/dom.16461.
    >> Share

  558. CARDOSO P, Young KG, Hopkins R, Mateen BA, et al
    Evaluating prediction of short-term tolerability of five type 2 diabetes drug classes using routine clinical features: UK population-based study.
    Diabetes Obes Metab. 2025 May 16. doi: 10.1111/dom.16470.
    >> Share

  559. MAUVAIS FX, van Endert PM
    Type 1 Diabetes: A Guide to Autoimmune Mechanisms for Clinicians.
    Diabetes Obes Metab. 2025 May 15. doi: 10.1111/dom.16460.
    >> Share

  560. ANTAKLY HANON Y, Moeuf Y, Garcon P, Kalaydjian A, et al
    Progression of cardiac dysfunction in patients with type 2 diabetes without overt cardiovascular disease: A three-year follow-up echocardiographic study (DIACAR).
    Diabetes Obes Metab. 2025 May 14. doi: 10.1111/dom.16457.
    >> Share

  561. CAI Y, Liu J, Wang Q, Ren X, et al
    Mechanisms of vascular endothelial cell injury triggered by blood glucose changes in gestational diabetes mellitus.
    Diabetes Obes Metab. 2025 May 13. doi: 10.1111/dom.16450.
    >> Share

  562. GIULIO F, Andrea R, Riccardo B
    Letter to the editor to "Sick days glycaemic outcomes in a cohort of children and adolescents with type 1 diabetes using an AID system".
    Diabetes Obes Metab. 2025 May 9. doi: 10.1111/dom.16459.
    >> Share

  563. CHEN LL, Tohit NM, Ludin AFM, Manaf ZA, et al
    Efficacy of diabetes-specific partial meal replacement on glycemic and weight control in type 2 diabetes: A randomized controlled trial.
    Diabetes Obes Metab. 2025 May 9. doi: 10.1111/dom.16446.
    >> Share

  564. SUN M, Wang X, Lu Z, Yang Y, et al
    Long-term delirium and survival outcomes in patients treated with GLP-1 receptor agonists versus metformin in type 2 diabetes: A population-based cohort study.
    Diabetes Obes Metab. 2025 May 7. doi: 10.1111/dom.16434.
    >> Share

  565. ZHAO J, Zhang J, Xuan Y, Huang C, et al
    Clinical observation and experimental study on the role of choroid-to-retina volume ratio in diabetic retinopathy.
    Diabetes Obes Metab. 2025 May 7. doi: 10.1111/dom.16444.
    >> Share

  566. REHNI AK, Cho S, Liu A, Lo J, et al
    Recurrent hypoglycemia exposure increases the risk of platelet activation and thrombosis in insulin-treated diabetic rats.
    Diabetes Obes Metab. 2025 May 7. doi: 10.1111/dom.16440.
    >> Share

  567. DUNN TJ, Tan X, Harton J, Kim S, et al
    Macrovascular and microvascular complications in US Medicare enrollees with type 2 diabetes with and without atherosclerotic cardiovascular disease.
    Diabetes Obes Metab. 2025 May 7. doi: 10.1111/dom.16441.
    >> Share

  568. ZHAO L, Tao F, Cheng Z, Lu Y, et al
    Predicting 10-year risk of type 2 diabetes in Chinese people with overweight or obesity treated with Tirzepatide: Post hoc analysis of SURMOUNT-CN trial.
    Diabetes Obes Metab. 2025 May 6. doi: 10.1111/dom.16439.
    >> Share

  569. VAN BAAR MJB, Muskiet MHA, Scholtes RA, Touw DJ, et al
    Fasting and postprandial kidney haemodynamic effects of empagliflozin and linagliptin in mono- and combination therapy compared to gliclazide in overweight people with type 2 diabetes (RACELINES): A randomised, double-blind trial.
    Diabetes Obes Metab. 2025 May 6. doi: 10.1111/dom.16431.
    >> Share

  570. TINTI D, Castorani V, Nobili C, Felappi B, et al
    Omnipod 5 in children and adolescents with type 1 diabetes: Improved outcomes with fewer boluses.
    Diabetes Obes Metab. 2025 May 5. doi: 10.1111/dom.16436.
    >> Share

  571. HANKOSKY ER, He X, Malik R, Fraseur Brumm J, et al
    Tirzepatide 10 and 15 mg versus semaglutide 2.4 mg in people with obesity or overweight with type 2 diabetes: An indirect treatment comparison.
    Diabetes Obes Metab. 2025 May 5. doi: 10.1111/dom.16401.
    >> Share

  572. PANCHAL K, Lawson CA, Shabnam S, Khunti K, et al
    Mortality risk following ischaemic and non-ischaemic heart failure in people with type 2 diabetes: Observational study in England, 2000-2021.
    Diabetes Obes Metab. 2025 May 2. doi: 10.1111/dom.16413.
    >> Share

  573. GU W, Lu Y, Ye X, Yuan G, et al
    Efficacy and safety of once-weekly semaglutide 2.4 mg for weight management in participants from China: A prespecified analysis of the STEP 7 randomized clinical trial.
    Diabetes Obes Metab. 2025;27:2540-2551.
    >> Share

  574. ZHANG Z, Wang C, Zhao L, Wang Z, et al
    Association of depression, traditional risk factor control and genetic risk with incident cardiovascular disease among individuals with prediabetes: A population-based prospective study from UK biobank.
    Diabetes Obes Metab. 2025;27:2833-2843.
    >> Share

  575. KARAKASIS P, Patoulias D, Rizzo M, Fragakis N, et al
    Association between remnant cholesterol and chronic kidney disease: Systematic review and meta-analysis.
    Diabetes Obes Metab. 2025;27:2573-2583.
    >> Share

  576. CAMPBELL K, Ashton N, Peddie MC, Ma'ia'i K, et al
    A DiRECT approach to weight loss in a culturally diverse, low-income population: Pilot randomised controlled trial and meta-analysis of similar interventions.
    Diabetes Obes Metab. 2025;27:2442-2453.
    >> Share

  577. WOLPERT H, Rodbard D, Xue J, Johnson J, et al
    Characterizing insulin dosing behaviour and glycaemic excursions: Development of metrics using connected insulin pen and continuous glucose monitoring.
    Diabetes Obes Metab. 2025;27:2507-2514.
    >> Share

  578. ZHUO L, Zhang B, Yin Y, Sun Y, et al
    Use of sodium-glucose cotransporter-2 inhibitors and risk of dementia: A population-based cohort study.
    Diabetes Obes Metab. 2025;27:2430-2441.
    >> Share

    April 2025
  579. YU N, Xu W, Guo X, Xu M, et al
    Fotagliptin add-on therapy to metformin in patients with uncontrolled type 2 diabetes: A randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.
    Diabetes Obes Metab. 2025 Apr 30. doi: 10.1111/dom.16427.
    >> Share

  580. KHODABANDEHLOO P, Fakembe P, Senga J, Shulman R, et al
    Social disadvantage and technology use among adults with type 1 diabetes in Quebec: A cross-sectional study using data from the Canadian T1D (BETTER) Registry.
    Diabetes Obes Metab. 2025 Apr 29. doi: 10.1111/dom.16426.
    >> Share

  581. FIELD BCT
    The BIG D-FOOT randomized, double-blinded, controlled trial of bio-absorbable antibiotic delivery in calcium sulphate granules for the treatment of diabetic foot osteomyelitis.
    Diabetes Obes Metab. 2025 Apr 29. doi: 10.1111/dom.16423.
    >> Share

  582. MONAMI M, Mannucci E
    Reply to Dr. Field on 'The BIG D-FOOT randomized, double-blinded, controlled trial of bio-absorbable antibiotic delivery in calcium sulphate granules for the treatment of diabetic foot osteomyelitis'.
    Diabetes Obes Metab. 2025 Apr 29. doi: 10.1111/dom.16428.
    >> Share

  583. HE J
    Remnant cholesterol trajectories and diabetes risk: A letter to the editor commenting on "Changes in remnant cholesterol and the incidence of diabetes: Results from two large prospective cohort studies".
    Diabetes Obes Metab. 2025 Apr 28. doi: 10.1111/dom.16430.
    >> Share

  584. SNOEK F, Galstyan G, Khan N, Tirosh A, et al
    Clinically meaningful improvements in treatment satisfaction in insulin-naive people with type 2 diabetes post initiation of insulin glargine 300 U/mL: A post hoc analysis of real-world ATOS study.
    Diabetes Obes Metab. 2025 Apr 28. doi: 10.1111/dom.16415.
    >> Share

  585. CARUSO P, Maiorino MI, Longo M, Maio A, et al
    Liraglutide improves peripheral perfusion and markers of angiogenesis and inflammation in people with type 2 diabetes and peripheral artery disease: An 18-month follow-up of a randomized clinical trial.
    Diabetes Obes Metab. 2025 Apr 25. doi: 10.1111/dom.16419.
    >> Share

  586. ZHANG Z, Huang Z, Xi Y, Han S, et al
    Association between adherence to the EAT-Lancet diet and risk of microvascular complications in type 2 diabetes: A cohort study.
    Diabetes Obes Metab. 2025 Apr 23. doi: 10.1111/dom.16414.
    >> Share

  587. LEE CMY, Gibson AA, Nassar N, Colagiuri S, et al
    Long-term adherence to glucose-lowering medications in adults with diabetes: A data linkage study.
    Diabetes Obes Metab. 2025 Apr 23. doi: 10.1111/dom.16408.
    >> Share


  588. Correction to "A micro-randomized pilot study to examine the impact of just-in-time nudging on after-dinner snacking in adults with type 2 diabetes: A study protocol".
    Diabetes Obes Metab. 2025 Apr 21. doi: 10.1111/dom.16412.
    >> Share

  589. DE RUITER SC, Tschiderer L, Grobbee DE, Ruigrok YM, et al
    Diabetes, glycaemic traits and cardiovascular disease in females and males: Observational and Mendelian randomisation analyses in the UK Biobank.
    Diabetes Obes Metab. 2025 Apr 21. doi: 10.1111/dom.16406.
    >> Share

  590. HAMAMOTO Y, Usui R
    Imeglimin and DPP-4 inhibitors: A promising therapeutic strategy for type 2 diabetes individuals with reduced insulin secretion.
    Diabetes Obes Metab. 2025 Apr 21. doi: 10.1111/dom.16397.
    >> Share

  591. GUO Z, Wallace AS, Rooney MR, Wang D, et al
    Ultra-processed food consumption among adults with prediabetes and diabetes, 2001-2018.
    Diabetes Obes Metab. 2025 Apr 21. doi: 10.1111/dom.16411.
    >> Share

  592. YANO Y, Okami S, Kanegae H, Oberprieler NG, et al
    Transitional changes in medication-initiator cohort profiles in persons with chronic kidney disease and type 2 diabetes-A hospital-based cohort study in Japan.
    Diabetes Obes Metab. 2025 Apr 21. doi: 10.1111/dom.16394.
    >> Share

  593. LI MN, Jin FX, Zhao JJ, Wang Y, et al
    Recurrent hypoglycaemia leads to impairment in glucagon-mediated hepatic glycogenolysis in type 1 diabetic mice.
    Diabetes Obes Metab. 2025 Apr 20. doi: 10.1111/dom.16409.
    >> Share

  594. FANG X, Zhang Y, Huang X, Miao R, et al
    Gut microbiome research: Revealing the pathological mechanisms and treatment strategies of type 2 diabetes.
    Diabetes Obes Metab. 2025 Apr 15. doi: 10.1111/dom.16387.
    >> Share

  595. REN Y, Chen Y, Zheng W, Kong W, et al
    The effect of GLP-1 receptor agonists on circulating inflammatory markers in type 2 diabetes patients: A systematic review and meta-analysis.
    Diabetes Obes Metab. 2025 Apr 15. doi: 10.1111/dom.16366.
    >> Share

  596. EVANS-MOLINA C, Oram RA
    Type 1 diabetes presenting in adults: Trends, diagnostic challenges and unique features.
    Diabetes Obes Metab. 2025 Apr 15. doi: 10.1111/dom.16402.
    >> Share

  597. GONZALEZ-VIDAL T, Rivas-Otero D, Ramos-Ruiz G, Agueria-Cabal P, et al
    Duration of type 1 diabetes and glycaemic control in adults: A nonlinear relationship.
    Diabetes Obes Metab. 2025 Apr 14. doi: 10.1111/dom.16392.
    >> Share

  598. LO SW, Ko A, Lin J, Tu YF, et al
    Comments on 'Propensity score matching methodology in Riley et al.'s study on type 2 diabetes and obstructive sleep apnoea'.
    Diabetes Obes Metab. 2025 Apr 14. doi: 10.1111/dom.16396.
    >> Share

  599. PAL A, Rawat D, Sadananda S, Goyal A, et al
    Pregnancy and postpartum cardiometabolic outcomes among women with overt diabetes compared to women with normoglycaemia, gestational diabetes and pre-existing diabetes: A systematic review and meta-analysis.
    Diabetes Obes Metab. 2025 Apr 11. doi: 10.1111/dom.16400.
    >> Share

  600. LATRES E, Plum-Moerschel L, Murugesan SMN, Lou O, et al
    An open-label, multiple ascending dose trial of orally administered insulin Tregopil in patients with type 1 diabetes mellitus to evaluate its pharmacokinetics, pharmacodynamics, safety and tolerability.
    Diabetes Obes Metab. 2025 Apr 10. doi: 10.1111/dom.16327.
    >> Share


  601. Correction to "Cumulative risk of diabetic foot complications in risk groups of type 1 and type 2 diabetes: Real-world evidence from a 22-year follow-up study".
    Diabetes Obes Metab. 2025 Apr 8. doi: 10.1111/dom.16381.
    >> Share

  602. ZHOU X, Chen S, Savitz B, Yu N, et al
    Comparative efficacy of different functional hydrogel dressings in healing diabetic foot ulcer: A systematic review and network meta-analysis.
    Diabetes Obes Metab. 2025 Apr 8. doi: 10.1111/dom.16367.
    >> Share

  603. XIE R, Li T, Gao H, Xie C, et al
    Single-cell transcriptional profiling reveals cellular senescence and inflammatory persistence as key features of type 1 diabetes partial remission.
    Diabetes Obes Metab. 2025 Apr 4. doi: 10.1111/dom.16384.
    >> Share

  604. JEON J, Lee K, Lee JE, Huh W, et al
    Frequency and sequence of proteinuria positivity and clinical outcomes in patients with diabetes: A nationwide cohort study.
    Diabetes Obes Metab. 2025 Apr 4. doi: 10.1111/dom.16345.
    >> Share

  605. ROSAS-GUZMAN J, Navarro-Lara A, Sanudo-Maury ME, Anguiano L, et al
    Safety and clinical effectiveness of iGlarLixi in people with type 2 diabetes mellitus in Mexico.
    Diabetes Obes Metab. 2025 Apr 4. doi: 10.1111/dom.16357.
    >> Share

  606. SHAO Y, Li Z, Sun M, Wu Q, et al
    Changes in remnant cholesterol and the incidence of diabetes: Results from two large prospective cohort studies.
    Diabetes Obes Metab. 2025 Apr 4. doi: 10.1111/dom.16383.
    >> Share

  607. MODY R, Desai K, Teng CC, Reznor G, et al
    Association of tirzepatide with glycaemic control and weight loss in a real world cohort of patients with type 2 diabetes from the United States.
    Diabetes Obes Metab. 2025 Apr 4. doi: 10.1111/dom.16372.
    >> Share

  608. HOME P, Lauand F, Djaballah K, Li XT, et al
    Efficacy and safety of iGlarLixi versus IDegAsp in people with type 2 diabetes inadequately controlled with basal insulin: A systematic literature review and network meta-analysis of non-Asian studies.
    Diabetes Obes Metab. 2025 Apr 2. doi: 10.1111/dom.16360.
    >> Share

  609. TINTI D, Nobili C, Bettin G, Roggero E, et al
    Sick days glycaemic outcomes in a cohort of children and adolescents with type 1 diabetes using an AID system-A preliminary report.
    Diabetes Obes Metab. 2025 Apr 2. doi: 10.1111/dom.16377.
    >> Share

  610. LIU J, Shang X, Zhang X, Chen Y, et al
    Metabolomic network reveals novel biomarkers for type 2 diabetes mellitus in the UK Biobank study.
    Diabetes Obes Metab. 2025 Apr 2. doi: 10.1111/dom.16351.
    >> Share

  611. CENGIZ A, Wu CC, Lawley SD
    Alternative dosing regimens of GLP-1 receptor agonists may reduce costs and maintain weight loss efficacy.
    Diabetes Obes Metab. 2025;27:2251-2258.
    >> Share

  612. AN X, Sun W, Wen Z, Duan L, et al
    Comparison of the efficacy and safety of GLP-1 receptor agonists on cardiovascular events and risk factors: A review and network meta-analysis.
    Diabetes Obes Metab. 2025;27:1735-1751.
    >> Share

  613. JO S, Jing G, Chen J, Xu G, et al
    Oral TIX100 protects against obesity-associated glucose intolerance and diet-induced adiposity.
    Diabetes Obes Metab. 2025;27:2223-2231.
    >> Share

  614. IMMANUEL J, Kongbrailatpam T, Rajagopal R, Simmons D, et al
    Evaluation of the analytical and clinical accuracy of four blood glucose meters in pregnant women with hyperglycaemia.
    Diabetes Obes Metab. 2025;27:2131-2137.
    >> Share

  615. HAYMAN MME, Jones W, Aman A, Ward J, et al
    Association of GLP1R locus with mental ill-health endophenotypes and cardiometabolic traits: A trans-ancestry study in UK Biobank.
    Diabetes Obes Metab. 2025;27:1845-1858.
    >> Share

  616. XU M, Lv D, Wei H, Li Z, et al
    Effects of antidiabetic agents on lipid metabolism of skeletal muscle: A narrative review.
    Diabetes Obes Metab. 2025;27:1693-1707.
    >> Share

  617. HIRAYAMA K, Koshizaka M, Ishibashi R, Shoji M, et al
    Effects of the SGLT2 inhibitor ipragliflozin and metformin on hepatic steatosis and liver fibrosis: Sub-analysis of a randomized controlled study.
    Diabetes Obes Metab. 2025;27:2059-2069.
    >> Share

  618. SIRIWARDANA A, Buizen L, Jun M, Kotwal S, et al
    Cardiovascular, kidney and safety outcomes with canagliflozin in older adults: A combined analysis from the CANVAS Program and CREDENCE trial.
    Diabetes Obes Metab. 2025;27:1972-1979.
    >> Share

  619. THOMSEN RW, Mailhac A, Lohde JB, Pottegard A, et al
    Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies.
    Diabetes Obes Metab. 2025;27 Suppl 2.
    >> Share

  620. BLUHER M
    An overview of obesity-related complications: The epidemiological evidence linking body weight and other markers of obesity to adverse health outcomes.
    Diabetes Obes Metab. 2025;27 Suppl 2.
    >> Share

  621. FORST T, De Block C, Del Prato S, Frias J, et al
    Novel pharmacotherapies for weight loss: Understanding the role of incretins to enable weight loss and improved health outcomes.
    Diabetes Obes Metab. 2025;27 Suppl 2:48-65.
    >> Share

    March 2025
  622. ZHU Y, Jun M, Fletcher RA, Arnott C, et al
    Variability in HbA1c and the risk of major clinical outcomes in type 2 diabetes with chronic kidney disease: Post hoc analysis from the CREDENCE trial.
    Diabetes Obes Metab. 2025 Mar 27. doi: 10.1111/dom.16363.
    >> Share

  623. DAI L, Wang Q
    Two-pronged approach: Therapeutic effect of biological scaffold combined with immune intervention and beta-cell replacement on type 1 diabetic mice.
    Diabetes Obes Metab. 2025 Mar 27. doi: 10.1111/dom.16373.
    >> Share

  624. MELIN EO, Thunander M, Wanby P, Holmberg S, et al
    Low levels of soluble neuropilin-1 were associated with depression in adults with newly diagnosed type 2 diabetes.
    Diabetes Obes Metab. 2025 Mar 27. doi: 10.1111/dom.16347.
    >> Share

  625. BONIFACIO E, Ziegler AG
    Type 1 diabetes risk factors, risk prediction and presymptomatic detection: Evidence and guidance for screening.
    Diabetes Obes Metab. 2025 Mar 25. doi: 10.1111/dom.16354.
    >> Share

  626. RAJAB AM, Pearson S, Ajjan RA
    Use of adjunctive glycaemic agents with vascular protective properties in individuals with type 1 diabetes: Potential benefits and risks.
    Diabetes Obes Metab. 2025 Mar 25. doi: 10.1111/dom.16332.
    >> Share

  627. RANJAN AG, Schmidt S, Norgaard K
    Faster-acting insulin aspart versus insulin aspart for adults with type 1 diabetes treated with non-automated insulin pump and continuous glucose monitoring-A double-blind randomized controlled crossover trial.
    Diabetes Obes Metab. 2025 Mar 24. doi: 10.1111/dom.16326.
    >> Share

  628. RATZKI-LEEWING A, Harris SB, Rabasa-Lhoret R, Poon Y, et al
    FRONTIER: FReeStyle Libre system use in Ontario among people with diabetes in the IC/ES database-Evidence from real-world practice: Patients on basal insulin, glucagon-like peptide 1 receptor agonist or oral therapies.
    Diabetes Obes Metab. 2025 Mar 21. doi: 10.1111/dom.16266.
    >> Share

  629. MELIS P, Lucijanic M, Kranjcec B, Cigrovski Berkovic M, et al
    The effect of semaglutide on intestinal iron absorption in patients with type 2 diabetes mellitus-A pilot study.
    Diabetes Obes Metab. 2025 Mar 21. doi: 10.1111/dom.16368.
    >> Share

  630. SUN J, Hu W, Ye S, Xu M, et al
    Global, regional and country-specific burden of chronic kidney disease due to type 1 diabetes mellitus: A systematic analysis of the 2021 global disease burden study.
    Diabetes Obes Metab. 2025 Mar 21. doi: 10.1111/dom.16358.
    >> Share

  631. KAKU K, Shimoda M, Osonoi T, Iwamoto M, et al
    Efficacy and safety of imeglimin add-on to DPP-4 inhibitor therapy in Japanese patients with type 2 diabetes mellitus: An interim analysis of the randomised, double-blind FAMILIAR trial.
    Diabetes Obes Metab. 2025 Mar 21. doi: 10.1111/dom.16336.
    >> Share

  632. GUAN J, Qiu J, Li L, Fu M, et al
    A meta-analysis of adverse offspring health outcomes in patients with gestational diabetes mellitus.
    Diabetes Obes Metab. 2025 Mar 21. doi: 10.1111/dom.16341.
    >> Share

  633. COON SA, White RT, Pagnozzi D, Cowart K, et al
    Real-world impact of tirzepatide on the risk of progression to type 2 diabetes and metabolic outcomes in people with obesity and pre-diabetes.
    Diabetes Obes Metab. 2025 Mar 19. doi: 10.1111/dom.16349.
    >> Share

  634. ASVOLD BO, Skaro M, Valle C, Grytli B, et al
    Long-term effects of continuous glucose monitoring on glycaemic control: Real-world evidence in a general adult population with type 1 diabetes in Norway.
    Diabetes Obes Metab. 2025 Mar 18. doi: 10.1111/dom.16334.
    >> Share

  635. DAVIDSEN L, Cichosz SL, Staehr PB, Vestergaard P, et al
    Efficacy and safety of continuous glucose monitoring on glycaemic control in patients with chronic pancreatitis and insulin-treated diabetes: A randomised, open-label, crossover trial.
    Diabetes Obes Metab. 2025 Mar 18. doi: 10.1111/dom.16356.
    >> Share

  636. VILSBOLL T, Fu A, Kellerer M, Kumar B, et al
    Efficacy and hypoglycaemia outcomes with once-weekly insulin icodec versus once-daily basal insulin in type 2 diabetes according to baseline glucagon-like peptide-1 receptor agonist and sodium-glucose co-transporter-2 inhibitor use: A post hoc analysi
    Diabetes Obes Metab. 2025 Mar 17. doi: 10.1111/dom.16328.
    >> Share

  637. HALUZIK M, Cypryk K, Alvarez A, Lauand F, et al
    Efficacy and safety of switching to iGlarLixi from premixed insulins in people with type 2 diabetes: The Soli-SWITCH study.
    Diabetes Obes Metab. 2025 Mar 17. doi: 10.1111/dom.16276.
    >> Share

  638. SOURIJ H, Azhar K, Aberer F, Sourij C, et al
    Impact of level 2 hypoglycaemia on neuroaxonal damage biomarker in individuals with type 2 diabetes: A stepwise hypoglycaemic clamp study.
    Diabetes Obes Metab. 2025 Mar 17. doi: 10.1111/dom.16340.
    >> Share

  639. TSUR A, Cahn A, Hanoch L, Pollack R, et al
    Kidney outcomes with SGLT2 inhibitors in patients with diabetes and an insulin-deficient phenotype: A real world analysis.
    Diabetes Obes Metab. 2025 Mar 14. doi: 10.1111/dom.16329.
    >> Share

  640. HUNTER GIBBLE T, Chinthammit C, Ward JM, Cappell K, et al
    Real-world use of tirzepatide among individuals without evidence of type 2 diabetes: Results from the Veradigm(R) database.
    Diabetes Obes Metab. 2025 Mar 14. doi: 10.1111/dom.16330.
    >> Share


  641. Correction to "The effect of HbA1c variability on the efficacy of intensive blood pressure control in patients with type 2 diabetes".
    Diabetes Obes Metab. 2025 Mar 13. doi: 10.1111/dom.16323.
    >> Share

  642. VERGANI M, Borella ND, Rizzo M, Conti M, et al
    Metabolic dysfunction-associated steatotic liver disease, insulin sensitivity and continuous glucose monitoring metrics in patients with type 1 diabetes: A multi-centre cross-sectional study.
    Diabetes Obes Metab. 2025 Mar 13. doi: 10.1111/dom.16333.
    >> Share

  643. PETERSEN MC, Jones KE, Markov AM, Salam M, et al
    Effect of dapagliflozin on blood and breath ketones during supervised insulin withdrawal in adults with type 1 diabetes: A randomized crossover trial.
    Diabetes Obes Metab. 2025 Mar 13. doi: 10.1111/dom.16324.
    >> Share

  644. XI JY, Wang YJ, Li XH, Sun NM, et al
    Impact of healthy lifestyles on the risk of metabolic dysfunction-associated steatotic liver disease among adults with comorbid hypertension and diabetes: Novel insight from a largely middle-aged and elderly cohort in South China.
    Diabetes Obes Metab. 2025 Mar 7. doi: 10.1111/dom.16289.
    >> Share

  645. COSTA S, Miranda C, Elefante A, Vallone V, et al
    Effectiveness and safety of daily oral semaglutide in people with type 2 diabetes mellitus switching from sulfonylureas: A real-world retrospective study.
    Diabetes Obes Metab. 2025 Mar 6. doi: 10.1111/dom.16314.
    >> Share

  646. CARIOU B, Thys A, Oliveira AR, Letertre MPM, et al
    Effect of alirocumab on postprandial hyperlipidaemia in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, cross-over trial.
    Diabetes Obes Metab. 2025 Mar 5. doi: 10.1111/dom.16305.
    >> Share

  647. RETNAKARAN R, Pu J, Emery A, Kramer CK, et al
    The coordinated changes in insulin sensitivity and insulin secretion associated with the remission of type 2 diabetes following short-term insulin therapy.
    Diabetes Obes Metab. 2025 Mar 5. doi: 10.1111/dom.16315.
    >> Share

  648. FABRICIUS TW, Verhulst C, Svensson CH, Wienberg M, et al
    Effects of insulin-induced hypoglycaemia on cardiac function in people with type 1 and type 2 diabetes and people without diabetes.
    Diabetes Obes Metab. 2025 Mar 5. doi: 10.1111/dom.16283.
    >> Share

  649. KO JH, Moon SJ, Ajjan RA, Lee MY, et al
    Workplace-based continuous glucose monitoring with structured education for pre-diabetes and type 2 diabetes: A prospective community cohort study.
    Diabetes Obes Metab. 2025 Mar 5. doi: 10.1111/dom.16304.
    >> Share

  650. EL GHANDOUR S, Akbarpoor F, Malik M, Kalsekar M, et al
    Effect of tirzepatide on weight and metabolism in a multiethnic cohort with and without diabetes.
    Diabetes Obes Metab. 2025 Mar 3. doi: 10.1111/dom.16287.
    >> Share

  651. BHATTACHARJEE A, Ali MR, Kloecker D, Ling S, et al
    Five-year trajectories of HbA1c by age, sex, ethnicity and deprivation in adults with newly diagnosed type 2 diabetes: Observational study in England.
    Diabetes Obes Metab. 2025 Mar 3. doi: 10.1111/dom.16288.
    >> Share

  652. XU Y, Echouffo Tcheugui JB, Coresh J, Grams ME, et al
    Trends in obesity and glucagon-like peptide-1 receptor agonist prescriptions in type 1 diabetes in the United States.
    Diabetes Obes Metab. 2025 Mar 3. doi: 10.1111/dom.16300.
    >> Share

  653. WYSHAM C, Bindal A, Levrat-Guillen F, Kostadinova D, et al
    A systematic literature review on the burden of diabetic ketoacidosis in type 2 diabetes mellitus.
    Diabetes Obes Metab. 2025 Mar 3. doi: 10.1111/dom.16282.
    >> Share

  654. MATHER KJ, Mari A, Weerakkody G, Heise T, et al
    Greater improvement in insulin sensitivity per unit weight loss associated with tirzepatide versus semaglutide: An exploratory analysis.
    Diabetes Obes Metab. 2025;27:1507-1514.
    >> Share

  655. MANTOVANI A, Lunardi G, Bonapace S, Molinero AE, et al
    Ceramide-based risk score CERT-1 improves risk prediction for overall mortality and adverse cardiovascular outcomes in patients with and without cardiovascular disease: A prospective cohort study.
    Diabetes Obes Metab. 2025;27:1488-1497.
    >> Share

  656. TANG H, Zhang B, Lu Y, Donahoo WT, et al
    Assessing the benefit-risk profile of newer glucose-lowering drugs: A systematic review and network meta-analysis of randomized outcome trials.
    Diabetes Obes Metab. 2025;27:1444-1455.
    >> Share

  657. JIA Q, Zuo A, Song H, Zhang C, et al
    Effects of sodium-glucose cotransporter-2 inhibitors in myocardial infarction patients: A systematic review and meta-analysis.
    Diabetes Obes Metab. 2025;27:1276-1286.
    >> Share

  658. WEN J, Razick A, How-Volkman C, Bernstein E, et al
    An exploratory analysis of glucagon-like peptide-1 (GLP-1) agonists and biosimilars: A literature review.
    Diabetes Obes Metab. 2025;27:1113-1122.
    >> Share

  659. OO TT
    Repurposing metformin: A potential off-label indication for ischaemic stroke?
    Diabetes Obes Metab. 2025;27:1065-1078.
    >> Share

  660. CAESAR R
    The impact of novel probiotics isolated from the human gut on the gut microbiota and health.
    Diabetes Obes Metab. 2025;27 Suppl 1.
    >> Share

    February 2025
  661. GROBMAN B, Mansur A, Lu CY
    Disparities in heart failure deaths among people with diabetes in the United States: 1999-2020.
    Diabetes Obes Metab. 2025 Feb 28. doi: 10.1111/dom.16301.
    >> Share

  662. TESFAYE H, Paik JM, Zakoul H, Schmedt N, et al
    Empagliflozin versus DPP4i or GLP-1RA for the risk of nephrolithiasis in patients with type 2 diabetes: Research letter from the EMPRISE cohort study.
    Diabetes Obes Metab. 2025 Feb 28. doi: 10.1111/dom.16303.
    >> Share

  663. OP DEN KAMP-BRULS YMH, Op den Kamp YJM, Veeraiah P, Zapata Perez R, et al
    Carnitine supplementation improves insulin sensitivity and skeletal muscle acetylcarnitine formation in patients with type 2 diabetes.
    Diabetes Obes Metab. 2025 Feb 28. doi: 10.1111/dom.16298.
    >> Share

  664. SONG L, Yuan X, Huang S, Zhang Y, et al
    iGlarLixi provides improved early glycaemic control after 12 weeks of treatment compared with basal insulin in Asian people with type 2 diabetes: A post hoc analysis of the LixiLan-O-AP and LixiLan-L-CN studies.
    Diabetes Obes Metab. 2025 Feb 27. doi: 10.1111/dom.16260.
    >> Share

  665. PANG X, Dan W, Lin L, Li H, et al
    Association of normal range of urinary albumin-to-creatinine ratio with all-cause mortality among diabetic adults with preserved kidney function: National Health and Nutrition Examination Survey (NHANES) 2003-2018.
    Diabetes Obes Metab. 2025 Feb 25. doi: 10.1111/dom.16269.
    >> Share

  666. OLSEN MT, Jensen SH, Rasmussen LM, Klarskov CK, et al
    Most hospitalised patients with type 2 diabetes benefit from continuous glucose monitoring compared to point-of-care glucose testing in a non-intensive care unit setting: A heterogeneity of treatment effect analysis.
    Diabetes Obes Metab. 2025 Feb 25. doi: 10.1111/dom.16297.
    >> Share

  667. GOSHRANI A, Lin R, O'Neal D, Ekinci EI, et al
    Time in range-A new gold standard in type 2 diabetes research?
    Diabetes Obes Metab. 2025 Feb 25. doi: 10.1111/dom.16279.
    >> Share

  668. HANKOSKY ER, Chinthammit C, Meeks A, Huang A, et al
    Real-world use and effectiveness of tirzepatide among individuals without type 2 diabetes: Results from the Optum Market Clarity database.
    Diabetes Obes Metab. 2025 Feb 25. doi: 10.1111/dom.16290.
    >> Share

  669. OKTAVIAN P, Kencono Wungu CD, Mudjanarko SW, Amin IM, et al
    A comparison of ultra-rapid and rapid insulin in automated insulin delivery for type 1 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Diabetes Obes Metab. 2025 Feb 25. doi: 10.1111/dom.16268.
    >> Share

  670. ROBERTS CGP, Athinarayanan SJ, Ratner RE, Umpierrez GE, et al
    Illnesses associated with ketosis including diabetic ketoacidosis during very low carbohydrate and ketogenic diets.
    Diabetes Obes Metab. 2025 Feb 25. doi: 10.1111/dom.16252.
    >> Share

  671. BERRY SA, Liarakos AL, Koutroukas V, Choudhary P, et al
    The challenge of assessing impaired awareness of hypoglycaemia in diabetes in the era of continuous glucose monitoring: A narrative review of evidence and translation into clinical practice.
    Diabetes Obes Metab. 2025 Feb 25. doi: 10.1111/dom.16284.
    >> Share

  672. TOSHIMITSU T, Irie J
    An update and overview of the various health-related benefits of probiotics: A focus on clinical trials demonstrating efficacy, tolerability and use in patients with impaired glucose tolerance and type 2 diabetes.
    Diabetes Obes Metab. 2025 Feb 24. doi: 10.1111/dom.16273.
    >> Share

  673. YANG X, Cao Y, Cao X, Wang L, et al
    Anti-VEGF monotherapy versus anti-VEGF therapy combined with laser or intravitreal glucocorticoid therapy for diabetic macular edema: A Bayesian network meta-analysis.
    Diabetes Obes Metab. 2025 Feb 20. doi: 10.1111/dom.16270.
    >> Share

  674. MONAMI M, Bordoni L, Ragghianti B, Silverii GA, et al
    Efficacy and safety of a bio-absorbable antibiotic delivery in calcium sulphate granules for the treatment of osteomyelitis in patients with diabetic foot: A randomized, double blinded, controlled clinical study The BIG D-FOOT study.
    Diabetes Obes Metab. 2025 Feb 19. doi: 10.1111/dom.16254.
    >> Share

  675. SOURIJ H, Bracken RM, Carstensen L, Pagliaro Rocha TM, et al
    No evidence of increased hypoglycaemia attributed to physical activity with once-weekly insulin icodec versus once-daily basal insulin degludec in type 1 diabetes: A post hoc analysis of ONWARDS 6.
    Diabetes Obes Metab. 2025 Feb 19. doi: 10.1111/dom.16265.
    >> Share

  676. LEWIS GA, Hughes DM, Irving G, Wilding J, et al
    Association between diabetes self-management education attendance, hospital admissions and mortality in type 2 diabetes: A cohort analysis protocol.
    Diabetes Obes Metab. 2025 Feb 19. doi: 10.1111/dom.16257.
    >> Share

  677. GIUGLIANO D, Longo M, Caruso P, Gicchino M, et al
    Effect of SGLT-2 Inhibitors Versus DPP-4 Inhibitors on Peripheral Artery Disease Risk Among People With Type 2 Diabetes: A 48-Month Prospective Study.
    Diabetes Obes Metab. 2025 Feb 19. doi: 10.1111/dom.16277.
    >> Share

  678. VIJAYAN A, Lanzinger S, Forestier N, Hess G, et al
    Analysis of patient characteristics and safety of insulin glargine U300 use in 21 359 patients with type-2 diabetes and chronic kidney disease: DPV registry study.
    Diabetes Obes Metab. 2025 Feb 19. doi: 10.1111/dom.16245.
    >> Share

  679. SHIKAMURA M, Takayama A, Yokogawa K, Kawakami K, et al
    Temporal risk patterns of severe hypovolemia associated with sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus: A self-controlled case series study.
    Diabetes Obes Metab. 2025 Feb 18. doi: 10.1111/dom.16259.
    >> Share

  680. SAHAY R, Gangwani D, Singh M, Gupta S, et al
    Fixed dose combination of dapagliflozin, glimepiride and extended-release metformin tablets in patients with type 2 diabetes poorly controlled by metformin and glimepiride: A phase III, open label, randomized clinical study in India.
    Diabetes Obes Metab. 2025 Feb 14. doi: 10.1111/dom.16218.
    >> Share

  681. SHAH VN, Dex T, Meneghini L, Rodrigues A, et al
    Treatment satisfaction and time in range after 16 weeks of treatment with iGlarLixi in insulin-naive adults with suboptimally controlled type 2 diabetes.
    Diabetes Obes Metab. 2025 Feb 14. doi: 10.1111/dom.16251.
    >> Share

  682. ZOU Y, Zhuo M, Chen W, Song W, et al
    Multiomics analysis of O-GlcNAcylation in podocytes of diabetic kidney disease.
    Diabetes Obes Metab. 2025 Feb 14. doi: 10.1111/dom.16274.
    >> Share

  683. O'DONNELL HK, Simmons KM, Gitelman SE, Dex T, et al
    Real-world experiences of adult individuals or caregivers of children who received teplizumab treatment in stage 2 type 1 diabetes.
    Diabetes Obes Metab. 2025 Feb 13. doi: 10.1111/dom.16246.
    >> Share

  684. ISHIBASHI R, Takatsuna Y, Koshizaka M, Tatsumi T, et al
    Ranibizumab with luseogliflozin in type 2 diabetes with diabetic macular oedema: A randomised clinical trial.
    Diabetes Obes Metab. 2025 Feb 11. doi: 10.1111/dom.16244.
    >> Share

  685. BELLEMARE M, Bourcier L, Iglesies-Grau J, Boulet J, et al
    Mechanisms of diabetic cardiomyopathy: Focus on inflammation.
    Diabetes Obes Metab. 2025 Feb 10. doi: 10.1111/dom.16242.
    >> Share

  686. ROSSING P, Benamar M, Cheng AYY, Kumar B, et al
    Efficacy and hypoglycaemia outcomes with once-weekly insulin icodec versus once-daily basal insulin in individuals with type 2 diabetes by kidney function: A post hoc participant-level analysis of the ONWARDS 1-5 trials.
    Diabetes Obes Metab. 2025 Feb 10. doi: 10.1111/dom.16231.
    >> Share

  687. HOWELL CR, Tanaka S, Zhang L, Carson AP, et al
    Adding social determinants of health to the equation: Development of a cardiometabolic disease staging model using clinical and social determinants of health to predict type 2 diabetes.
    Diabetes Obes Metab. 2025 Feb 10. doi: 10.1111/dom.16241.
    >> Share

  688. POON ET, Li HY, Kong APS, Little JP, et al
    Efficacy of high-intensity interval training in individuals with type 2 diabetes mellitus: An umbrella review of systematic reviews and meta-analyses.
    Diabetes Obes Metab. 2025 Feb 5. doi: 10.1111/dom.16220.
    >> Share

  689. HA KH, Jang Y, Kim DJ
    Effectiveness of gemigliptin on risk of major adverse kidney events in people with type 2 diabetes: A Korean cohort study.
    Diabetes Obes Metab. 2025 Feb 5. doi: 10.1111/dom.16230.
    >> Share

  690. SMANIOTTO V, Heller S, O'Neal D, Jendle J, et al
    MiniMed 780G system performance in older users with type 1 diabetes: Real-world evidence and the case for stricter glycaemic targets.
    Diabetes Obes Metab. 2025 Feb 4. doi: 10.1111/dom.16227.
    >> Share

  691. FRIAS JP, Ratzki-Leewing A, Dex T, Meneghini L, et al
    Effect of iGlarLixi on continuous glucose monitoring-measured time in range in insulin-naive adults with suboptimally controlled type 2 diabetes.
    Diabetes Obes Metab. 2025 Feb 4. doi: 10.1111/dom.16214.
    >> Share

  692. LIU D, Yu S, Zhang Y, Li Q, et al
    Fibroblast growth factor 23 predicts incident diabetic kidney disease: A 4.6-year prospective study.
    Diabetes Obes Metab. 2025 Feb 3. doi: 10.1111/dom.16224.
    >> Share

  693. IKEDA K, Mano-Usui F, Kishimoto Y, Yabe D, et al
    Concurrent SGLT2 inhibitor use in patients with type 2 diabetes hospitalised for high-dose corticosteroid therapy: Mitigated iatrogenic hyperglycaemia.
    Diabetes Obes Metab. 2025 Feb 3. doi: 10.1111/dom.16221.
    >> Share

  694. MATSUSHIRO M, Yamaguchi Y, Kuwata H, Hamamoto Y, et al
    Short-term outcomes of switching from GLP-1 receptor agonists to tirzepatide in type 2 diabetes: A retrospective, observational study in clinical practice.
    Diabetes Obes Metab. 2025 Feb 2. doi: 10.1111/dom.16237.
    >> Share

  695. COSENTINO F, Dagogo-Jack S, Frederich R, Cannon CP, et al
    Long-term weight loss and cardiorenal outcomes by baseline BMI in the VERTIS CV trial.
    Diabetes Obes Metab. 2025;27:583-594.
    >> Share

  696. HE Q, Cheng Z, Li Y, Xing X, et al
    A biweekly DPP-4 inhibitor cofrogliptin monotherapy in Chinese patients with impaired glucose tolerance: A phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial.
    Diabetes Obes Metab. 2025;27:965-975.
    >> Share

  697. MORENO-LOPEZ M, Louvet I, Delalleau N, Acosta-Montalvo A, et al
    The role of the glucagon-FGF21 axis in improving beta cell function during glucose intolerance and SGLT2 inhibition.
    Diabetes Obes Metab. 2025;27:885-898.
    >> Share

  698. CERSOSIMO E, YueJuan Q, Baskoy G, Chavez A, et al
    Effect of dapagliflozin on renal haemodynamics in hyperfiltering T2D patients.
    Diabetes Obes Metab. 2025;27:944-952.
    >> Share

  699. NEYER M, Vogel JB, Elsner P, Kuehrer H, et al
    Three decades of glucose-lowering therapy in patients at high cardiovascular risk - A real-world analysis.
    Diabetes Obes Metab. 2025;27:835-844.
    >> Share

  700. USUI R, Hamamoto Y, Imura M, Omori Y, et al
    Differential effects of imeglimin and metformin on insulin and incretin secretion-An exploratory randomized controlled trial.
    Diabetes Obes Metab. 2025;27:856-865.
    >> Share

  701. ZHANG M, Lin C, Cai X, Jiao R, et al
    One or two? Comparison of the cardiorenal effects between combination therapy and monotherapy with SGLT2i or GLP1RA.
    Diabetes Obes Metab. 2025;27:806-815.
    >> Share

  702. SONG ZQ, Chen YQ, Xuan CH, Ni TT, et al
    Effect of smoking behaviour and related blood DNA methylation on visceral adipose tissues.
    Diabetes Obes Metab. 2025;27:619-628.
    >> Share

  703. AO N, Du J, Jin S, Suo L, et al
    The cellular and molecular mechanisms mediating the protective effects of sodium-glucose linked transporter 2 inhibitors against metabolic dysfunction-associated fatty liver disease.
    Diabetes Obes Metab. 2025;27:457-467.
    >> Share

  704. HAGGAG AZ, Xu J, Butcher L, Pagnussat S, et al
    Non-clinical and first-in-human characterization of ECC5004/AZD5004, a novel once-daily, oral small-molecule GLP-1 receptor agonist.
    Diabetes Obes Metab. 2025;27:551-562.
    >> Share

    January 2025
  705. BOMBACI B, Passanisi S, Calderone M, Macri F, et al
    Long-term use of Minimed 780G in children and adolescents with type 1 diabetes under real-world conditions: The benefits of optimal settings.
    Diabetes Obes Metab. 2025 Jan 31. doi: 10.1111/dom.16226.
    >> Share

  706. XU Z, Fang J, Wang Y, Wu X, et al
    Targeted metabolomics reveals novel biomarkers for gestational diabetes mellitus.
    Diabetes Obes Metab. 2025 Jan 30. doi: 10.1111/dom.16213.
    >> Share

  707. STEENS ILM, Ji Y, Sedaghat S, Pankow J, et al
    Diabetes and incident stroke and mediation by microvascular dysfunction: Pooled analysis of three population-based studies.
    Diabetes Obes Metab. 2025 Jan 30. doi: 10.1111/dom.16217.
    >> Share

  708. NGUYEN TTD, Chen HM, Lin HW, Ou HT, et al
    Clinical effectiveness and cost-effectiveness of first-line early combination of dipeptidyl peptidase 4 inhibitors and metformin in patients with type 2 diabetes in Taiwan: A modelling study.
    Diabetes Obes Metab. 2025 Jan 30. doi: 10.1111/dom.16215.
    >> Share

  709. SHEN J, Sarwal A, Singh R, Hartsell SE, et al
    Comparative effectiveness of insulin glargine, glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in veterans with type 2 diabetes.
    Diabetes Obes Metab. 2025 Jan 30. doi: 10.1111/dom.16207.
    >> Share

  710. YAMAMOTO K, Ihana-Sugiyama N, Sugiyama T, Yamaoka T, et al
    Recognition of ophthalmology consultation and fundus examination among individuals with diabetes in Japan: A cross-sectional study using claims-questionnaire linked data.
    Diabetes Obes Metab. 2025 Jan 30. doi: 10.1111/dom.16164.
    >> Share

  711. CHENG AYY, Heine RJ, Del Prato S, Green JB, et al
    Striving for early effective glycaemic and weight management in type 2 diabetes: A narrative review.
    Diabetes Obes Metab. 2025 Jan 28. doi: 10.1111/dom.16206.
    >> Share

  712. CAI J, Liu J, Lu J, Ni J, et al
    Impact of time in tight range on all-cause and cardiovascular mortality in type 2 diabetes: A prospective cohort study.
    Diabetes Obes Metab. 2025 Jan 27. doi: 10.1111/dom.16212.
    >> Share

  713. DOVC K, Spanbauer C, Chiarle E, Bratina N, et al
    Postprandial time in tight range with faster insulin aspart compared with standard insulin aspart in youth with type 1 diabetes using automated insulin delivery.
    Diabetes Obes Metab. 2025 Jan 27. doi: 10.1111/dom.16211.
    >> Share

  714. GULATI K, Wijndaele K, Webb J, von Arx LB, et al
    Achievement of HbA1c and weight targets in adults with type 2 diabetes on once weekly injectable glucagon-like peptide-1 receptor agonist therapy in UK primary care: A retrospective, real-world study.
    Diabetes Obes Metab. 2025 Jan 22. doi: 10.1111/dom.16201.
    >> Share

  715. AKERKAR A, Ronn PF, Kosjerina V, Hansen CS, et al
    Cumulative risk of diabetic foot complications in risk groups of type 1 and type 2 diabetes: Real-world evidence from a 22-year follow-up study.
    Diabetes Obes Metab. 2025 Jan 22. doi: 10.1111/dom.16200.
    >> Share

  716. ZHOU Y, Boucsein A, Michaels VR, Gray MK, et al
    Predictors of glycaemic improvement in children and young adults with type 1 diabetes and very elevated HbA1c using the MiniMed 780G system.
    Diabetes Obes Metab. 2025 Jan 20. doi: 10.1111/dom.16210.
    >> Share

  717. MCEWAN P, Foos V, Roberts G, Jenkins RH, et al
    Beyond glycated haemoglobin: Modelling contemporary management of type 2 diabetes with the updated Cardiff model.
    Diabetes Obes Metab. 2025 Jan 19. doi: 10.1111/dom.16141.
    >> Share

  718. LEITE NC, Villela-Nogueira CA, Santos LV, Cardoso CRL, et al
    Prognostic value of changes in vibration-controlled transient elastography parameters for liver, cardiovascular and mortality outcomes in individuals with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease: The Rio de Janeiro
    Diabetes Obes Metab. 2025 Jan 16. doi: 10.1111/dom.16195.
    >> Share

  719. SUN M, Liu Q, Liu Y, Ning N, et al
    Baseline and cumulative Chinese visceral adiposity index and diabetic kidney disease: A prospective cohort study.
    Diabetes Obes Metab. 2025 Jan 15. doi: 10.1111/dom.16184.
    >> Share

  720. MATSUBAYASHI Y, Fujihara K, Khin L, Ferreira ED, et al
    Association of changes in the type 2 diabetes and MASLD/related SLD status with risk of developing cardiovascular disease.
    Diabetes Obes Metab. 2025 Jan 15. doi: 10.1111/dom.16196.
    >> Share

  721. SUZUKI R, Shoji S, Yoshinaga Y, Kosakai Y, et al
    Risk of insulin initiation with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: A real-world claims database study in Japan.
    Diabetes Obes Metab. 2025 Jan 13. doi: 10.1111/dom.16188.
    >> Share

  722. WU X, Huang Q, Ding Y, Cao Q, et al
    Effect of insulin sensitivity, insulin secretion, and beta cell function on the remission of type 2 diabetes: A post hoc analysis of the IDEATE trial.
    Diabetes Obes Metab. 2025 Jan 13. doi: 10.1111/dom.16180.
    >> Share

  723. LIN CM, Chen JC, Meyerowitz-Katz G, Huang YN, et al
    Unexpected cardiovascular risks of glucagon-like peptide-1 receptor agonist and aspirin co-administration in individuals with obesity, with and without type 2 diabetes: A propensity score matched cohort study.
    Diabetes Obes Metab. 2025 Jan 13. doi: 10.1111/dom.16191.
    >> Share

  724. LU W, Xie L, Zhang Y, Gao H, et al
    Long-term blood glucose control via glucose-activated transcriptional regulation of insulin analogue in type 1 diabetes mice.
    Diabetes Obes Metab. 2025 Jan 13. doi: 10.1111/dom.16197.
    >> Share

  725. WANG Y, Lin T, Lu J, He W, et al
    Trends and analysis of risk factor differences in the global burden of chronic kidney disease due to type 2 diabetes from 1990 to 2021: A population-based study.
    Diabetes Obes Metab. 2025 Jan 13. doi: 10.1111/dom.16183.
    >> Share


  726. Correction to "Long-term safety and efficacy of glucagon-like peptide-1 receptor agonists in individuals with obesity and without type 2 diabetes: A global retrospective cohort study".
    Diabetes Obes Metab. 2025 Jan 13. doi: 10.1111/dom.16204.
    >> Share

  727. FIORE V, Carbotta G, Barraco S, Falasca P, et al
    Real-world retrospective study in elderly patients aged 65 years and older with type 2 diabetes mellitus treated with daily oral semaglutide (SEMA-elderly).
    Diabetes Obes Metab. 2025 Jan 10. doi: 10.1111/dom.16174.
    >> Share

  728. RUBINO DM, Pedersen SD, Connery L, Cao D, et al
    Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trials.
    Diabetes Obes Metab. 2025 Jan 9. doi: 10.1111/dom.16176.
    >> Share

  729. TANG C, Hao J, Tao F, Feng Q, et al
    Association of Metformin use with risk of dementia in patients with type 2 diabetes: A systematic review and meta-analysis.
    Diabetes Obes Metab. 2025 Jan 8. doi: 10.1111/dom.16192.
    >> Share

  730. HANSEN AL, Andersen MK, Engelhard LM, Brons C, et al
    Impact of TCF7L2 rs7903146 on clinical presentation and risk of complications in patients with type 2 diabetes.
    Diabetes Obes Metab. 2025 Jan 8. doi: 10.1111/dom.16193.
    >> Share

  731. ALKHUZAM K, Li P, Abuloha S, Xue Q, et al
    Long-term health benefit and economic return of time in range (TIR) improvement in individuals with type 2 diabetes.
    Diabetes Obes Metab. 2025 Jan 8. doi: 10.1111/dom.16168.
    >> Share

  732. STICE E, Rohde P, Desjardins CD, Gee K, et al
    A preliminary randomized trial of a brief dissonance-based type 2 diabetes prevention programme for adults with pre-diabetes.
    Diabetes Obes Metab. 2025 Jan 7. doi: 10.1111/dom.16170.
    >> Share

  733. ZHAO J, Sun Z, Li Z, Xu M, et al
    MicroRNA-mediated Ets1 repression in retinal endothelial cells: A novel anti-angiogenic mechanism in nonproliferative diabetic retinopathy.
    Diabetes Obes Metab. 2025 Jan 7. doi: 10.1111/dom.16182.
    >> Share

  734. SON H, Sohn SH, Kim HA, Choe HJ, et al
    Real-time continuous glucose monitoring improves postoperative glucose control in people with type 2 diabetes mellitus undergoing coronary artery bypass grafting: A randomized clinical trial.
    Diabetes Obes Metab. 2025 Jan 7. doi: 10.1111/dom.16177.
    >> Share

  735. VERMILLAC G, Lafont C, Godot C, Kerbourc'h S, et al
    Paediatric-to-adult transition in type 1 diabetes: A two-centre experience of a structured program, 2014 to 2022.
    Diabetes Obes Metab. 2025 Jan 7. doi: 10.1111/dom.16140.
    >> Share

  736. CHEN M, Dou C, Ye C, Kong L, et al
    Socioeconomic and mental health inequalities in global burden of type 2 diabetes: Evidence from the Global Burden of Disease Study 2021.
    Diabetes Obes Metab. 2025 Jan 6. doi: 10.1111/dom.16173.
    >> Share

  737. HOPKINS R, Young KG, Thomas NJ, Jones AG, et al
    Treatment outcomes with oral anti-hyperglycaemic therapies in people with diabetes secondary to a pancreatic condition (type 3c diabetes): A population-based cohort study.
    Diabetes Obes Metab. 2025 Jan 6. doi: 10.1111/dom.16163.
    >> Share

  738. SEUFERT J, Wiesner T, Pegelow K, Kenzler J, et al
    Effectiveness and safety of iGlarLixi in people with type 2 diabetes not at target on basal insulin and oral antidiabetic therapy in a prospective observational trial.
    Diabetes Obes Metab. 2025 Jan 6. doi: 10.1111/dom.16161.
    >> Share

  739. PODOBNIK J, Prentice KJ
    Metabolic interventions as adjunctive therapies to insulin in type 1 diabetes: Current clinical landscape and perspectives.
    Diabetes Obes Metab. 2025 Jan 6. doi: 10.1111/dom.16154.
    >> Share

  740. KIM MK, Kim J, Park SJ, Song YJ, et al
    Impact of caloric restriction on diabetes remission in Korean adults with obesity (CREDO-K study).
    Diabetes Obes Metab. 2025 Jan 3. doi: 10.1111/dom.16166.
    >> Share

  741. HALLIG SJ, Aalders J, Christensen MH, Andersen MS, et al
    The cardio-metabolic protein profile is associated with development of type 2 diabetes at long term follow-up after gestational diabetes mellitus: Results from the OGFUS study.
    Diabetes Obes Metab. 2025 Jan 2. doi: 10.1111/dom.16148.
    >> Share

  742. AZHAR K, Ramirez-Obermayer A, Sourij C, Knoll L, et al
    Sustained weight reduction following 12 weeks of intermittent fasting intervention in people with insulin-treated type 2 diabetes-Two-year follow-up of the randomised controlled InterFast-2 trial.
    Diabetes Obes Metab. 2025 Jan 2. doi: 10.1111/dom.16158.
    >> Share

  743. LEE DY, Moon JS, Jung I, Chung SM, et al
    Risk acceleration by gout on major adverse cardiovascular events and all-cause death in patients with diabetes and chronic kidney disease.
    Diabetes Obes Metab. 2025 Jan 2. doi: 10.1111/dom.16165.
    >> Share

  744. SANTOS-BAEZ LS, Diaz-Rizzolo DA, Borhan R, Popp CJ, et al
    Predictive models of post-prandial glucose response in persons with prediabetes and early onset type 2 diabetes: A pilot study.
    Diabetes Obes Metab. 2025 Jan 2. doi: 10.1111/dom.16160.
    >> Share

  745. GROSICKI GJ, Thomas JG, Dhurandhar NV, Lofton H, et al
    Glucagon-like peptide-1 receptor agonists discontinuation is higher in individuals with overweight and obesity without type 2 diabetes.
    Diabetes Obes Metab. 2025 Jan 2. doi: 10.1111/dom.16151.
    >> Share

  746. LOU Y, Xie Y, Jiang Q, Huang S, et al
    The effect of sarcopenic obesity on glycaemic status based on fasting plasma glucose and glycated haemoglobin: A prospective cohort study.
    Diabetes Obes Metab. 2025;27:291-299.
    >> Share

  747. JIAO R, Lin C, Cai X, Wang J, et al
    Characterizing body composition modifying effects of a glucagon-like peptide 1 receptor-based agonist: A meta-analysis.
    Diabetes Obes Metab. 2025;27:259-267.
    >> Share

    December 2024
  748. XIE C, Iroga P, Bound MJ, Grivell J, et al
    Impact of the timing of metformin administration on the plasma lactate response to intraduodenal glucose infusion in type 2 diabetes.
    Diabetes Obes Metab. 2024 Dec 27. doi: 10.1111/dom.16169.
    >> Share

  749. BAECHLE C, Rosenbauer J, Stahl-Pehe A, Seufert J, et al
    Effectiveness of add-on therapy with SGLT2 inhibitors or GLP-1 receptor agonists in adults with type 1 diabetes: A prospective DPV registry study.
    Diabetes Obes Metab. 2024 Dec 27. doi: 10.1111/dom.16149.
    >> Share

  750. WONG HJ, Lin NHY, Teo YH, Yeo BSY, et al
    Anti-diabetic effects of GLP-1 receptor agonists on obese and overweight patients across diabetes status, administration routes, treatment duration and baseline characteristics: A systematic review.
    Diabetes Obes Metab. 2024 Dec 26. doi: 10.1111/dom.16136.
    >> Share

  751. FUKUNAGA K, Morishita A, Imachi H, Oura K, et al
    Efficacy of imeglimin in patients with type 2 diabetes mellitus complicated by metabolic dysfunction-associated steatotic liver disease: A multicentre study.
    Diabetes Obes Metab. 2024 Dec 26. doi: 10.1111/dom.16157.
    >> Share

  752. TAKAHASHI A, Nomoto H, Yokoyama H, Yokozeki K, et al
    Efficacy of imeglimin treatment versus metformin dose escalation on glycemic control in subjects with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor plus low-dose metformin: A multicenter, prospective, randomized, open-label, parallel
    Diabetes Obes Metab. 2024 Dec 26. doi: 10.1111/dom.16150.
    >> Share

  753. BORYSOWSKI J, Klosowska D, Paczek L, Ordak M, et al
    Exclusion of older persons from randomized controlled trials in type 2 diabetes: A cross-sectional study.
    Diabetes Obes Metab. 2024 Dec 26. doi: 10.1111/dom.16137.
    >> Share

  754. XU Z, Wen S, Dong M, Zhou L, et al
    Targeting central pathway of Glucose-Dependent Insulinotropic Polypeptide, Glucagon and Glucagon-like Peptide-1 for metabolic regulation in obesity and type 2 diabetes.
    Diabetes Obes Metab. 2024 Dec 26. doi: 10.1111/dom.16146.
    >> Share

  755. ZHAO X, Xu X, Wang S, Zhang X, et al
    Heterogeneous blood pressure treatment effects on cognitive decline in type 2 diabetes: A machine learning analysis of a randomized clinical trial.
    Diabetes Obes Metab. 2024 Dec 26. doi: 10.1111/dom.16145.
    >> Share

  756. GUO L, Chen L, Zhao F, Liu X, et al
    Improved glycaemic control in people with type 2 diabetes initiating or switching to IDegAsp in a real-world setting in China.
    Diabetes Obes Metab. 2024 Dec 20. doi: 10.1111/dom.16139.
    >> Share

  757. SOHN M, Park YH, Lim S
    Effects of choline alfoscerate on cognitive function and quality of life in type 2 diabetes: A double-blind, randomized, placebo-controlled trial.
    Diabetes Obes Metab. 2024 Dec 20. doi: 10.1111/dom.16131.
    >> Share

  758. WANG Y, Lu J, Yu J, Ni J, et al
    Association between time in tight range and incident diabetic retinopathy in adults with type 2 diabetes.
    Diabetes Obes Metab. 2024 Dec 18. doi: 10.1111/dom.16143.
    >> Share

  759. MOURA FA, Kamanu FK, Wiviott SD, Giugliano RP, et al
    Type 2 diabetes genetic risk and incident diabetes across diabetes risk enhancers.
    Diabetes Obes Metab. 2024 Dec 18. doi: 10.1111/dom.16123.
    >> Share

  760. HERMAN WH, Kuo S, Zhang P
    A comment on "Metformin in the Diabetes Prevention Program 3-year trial: The cost-effectiveness that never was".
    Diabetes Obes Metab. 2024 Dec 18. doi: 10.1111/dom.16124.
    >> Share

  761. CHEN L, Wan H, Han J, Yang C, et al
    Efficacy and safety of switching to insulin glargine 300 U/mL in people with type 2 diabetes uncontrolled on basal insulin in China: A post hoc subpopulation analysis of the INITIATION study.
    Diabetes Obes Metab. 2024 Dec 18. doi: 10.1111/dom.16144.
    >> Share

  762. GARGOURI I, Charfi H, Belabed W, Outenah C, et al
    Precision medicine in type 1 diabetes: comparing metabolic outcomes of Control-IQ and MiniMed 780G according to patient characteristics.
    Diabetes Obes Metab. 2024 Dec 17. doi: 10.1111/dom.16118.
    >> Share

  763. YANG S, Yuan Y, Zhang B, Wu T, et al
    Identification of adipose tissue-derived exosomal microRNA as a novel causal biomarker for cognitive impairment in type 2 diabetes mellitus: Triangulating evidence from Mendelian randomization and multicentre population studies.
    Diabetes Obes Metab. 2024 Dec 17. doi: 10.1111/dom.16121.
    >> Share

  764. HUANG CC, Hsu RF, Chen WM, Shia BC, et al
    Metformin lowers risk of hearing loss and mortality in type 2 diabetes.
    Diabetes Obes Metab. 2024 Dec 17. doi: 10.1111/dom.16128.
    >> Share

  765. ERWIN AP, Patrie JT, Horton WB
    Heart failure phenotypes in people with type 1 diabetes.
    Diabetes Obes Metab. 2024 Dec 17. doi: 10.1111/dom.16133.
    >> Share

  766. MOURA FS, Amaral MJM, Lima LCV, Souza M, et al
    Prevalence of MASLD in children and adolescents with type 1 diabetes: A meta-analysis.
    Diabetes Obes Metab. 2024 Dec 17. doi: 10.1111/dom.16125.
    >> Share

  767. YU YH, Platt RW, Reynier P, Yu OHY, et al
    Metformin and risk of adverse pregnancy outcomes among pregnant women with gestational diabetes in the United Kingdom: A population-based cohort study.
    Diabetes Obes Metab. 2024 Dec 16. doi: 10.1111/dom.16115.
    >> Share

  768. SSEMMONDO E, Shah N, Newham M, Rigby A, et al
    Effect of introduction of intermittently scanned continuous glucose monitoring on glycaemic control in individuals living with type 2 diabetes mellitus treated with non-insulin therapies-A randomised controlled trial.
    Diabetes Obes Metab. 2024 Dec 11. doi: 10.1111/dom.16116.
    >> Share

  769. WANG Y, Wen Q, Lu Y, Yang J, et al
    Identifying subgroups benefiting from intensive glycaemic treatment to improve renal outcomes in type 2 diabetes: Insights from the ACCORD trial.
    Diabetes Obes Metab. 2024 Dec 9. doi: 10.1111/dom.16111.
    >> Share

  770. BAEK S, Park J, Chung JY, Kwak SH, et al
    Short-term efficacy and safety of metformin in individuals with type 2 diabetes and mild hepatic impairment: A propensity score-matched real-world study.
    Diabetes Obes Metab. 2024 Dec 6. doi: 10.1111/dom.16108.
    >> Share

  771. WANG G, Fu J, Li X, Wang J, et al
    Comparative efficacy and safety of dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes mellitus: A network meta-analysis.
    Diabetes Obes Metab. 2024 Dec 6. doi: 10.1111/dom.16114.
    >> Share

  772. BAO Y, Hu Y, Shi M, Zhao Z, et al
    SGLT2 inhibitors reduce epicardial adipose tissue more than GLP-1 agonists or exercise interventions in patients with type 2 diabetes mellitus and/or obesity: A systematic review and network meta-analysis.
    Diabetes Obes Metab. 2024 Dec 6. doi: 10.1111/dom.16107.
    >> Share

  773. LI M, Yu H, Wan S, Hu F, et al
    The fibrosis investigating navigator in diabetes (FIND): A tool to predict liver fibrosis risk in subjects with diabetes.
    Diabetes Obes Metab. 2024 Dec 5. doi: 10.1111/dom.16109.
    >> Share

  774. FINKELSTEIN EA, Gardner DS, Tham KW, Gandhi M, et al
    Effectiveness and cost-effectiveness of an app and rewards-based intervention in type 2 diabetes: A randomised controlled trial.
    Diabetes Obes Metab. 2024 Dec 5. doi: 10.1111/dom.16067.
    >> Share

  775. WANG X, Pei J, Zheng K, Liu M, et al
    The effect of HbA1c variability on the efficacy of intensive blood pressure control in patients with type 2 diabetes.
    Diabetes Obes Metab. 2024 Dec 3. doi: 10.1111/dom.16112.
    >> Share

  776. MEULMEESTER FL, van Dijk KW, van Heemst D, Noordam R, et al
    Association of a composite trait for anthropometrics, adiposity and energy expenditure with cardiometabolic diseases: An age-stratified cohort and genetic risk score analysis.
    Diabetes Obes Metab. 2024;26:5922-5930.
    >> Share

  777. DUBIN RL, Heymsfield SB, Ravussin E, Greenway FL, et al
    Glucagon-like peptide-1 receptor agonist-based agents and weight loss composition: Filling the gaps.
    Diabetes Obes Metab. 2024;26:5503-5518.
    >> Share

  778. CHEN C, Liu X, Zhang J, Hu S, et al
    Changes in insulin utilization in China from 2020 to 2022.
    Diabetes Obes Metab. 2024;26:5681-5689.
    >> Share

  779. GABE MBN, Fuhr R, Sinn A, Eliasen A, et al
    Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants.
    Diabetes Obes Metab. 2024;26:5805-5811.
    >> Share

  780. ZOU Y, Jiang F, Sun C, Zhao C, et al
    Safety, pharmacokinetics and pharmacodynamics of multiple-dose noiiglutide (SHR20004), a novel GLP-1 receptor agonist, in Chinese obese subjects without diabetes mellitus.
    Diabetes Obes Metab. 2024 Dec 1. doi: 10.1111/dom.16080.
    >> Share

  781. LIU R, Zhang J, Chen S, Xiao Y, et al
    Intestinal mucosal immunity and type 1 diabetes: Non-negligible communication between gut and pancreas.
    Diabetes Obes Metab. 2024 Dec 1. doi: 10.1111/dom.16101.
    >> Share

  782. AJJAN RA
    The clinical importance of measuring glycaemic variability: Utilising new metrics to optimise glycaemic control.
    Diabetes Obes Metab. 2024;26 Suppl 7.
    >> Share

  783. BENHALIMA K, Yamamoto JM
    Use of continuous glucose monitoring and hybrid closed-loop therapy in pregnancy.
    Diabetes Obes Metab. 2024;26 Suppl 7:74-91.
    >> Share

  784. KONG YW, Morrison D, Lu JC, Lee MH, et al
    Continuous ketone monitoring: Exciting implications for clinical practice.
    Diabetes Obes Metab. 2024;26 Suppl 7.
    >> Share

  785. ANANDHAKRISHNAN A, Hussain S
    Automating insulin delivery through pump and continuous glucose monitoring connectivity: Maximizing opportunities to improve outcomes.
    Diabetes Obes Metab. 2024;26 Suppl 7:27-46.
    >> Share

    November 2024
  786. KRISTENSEN DK, Mose FH, Buus NH, Duus CL, et al
    SGLT2 inhibition improves endothelium-independent vasodilatory function in type 2 diabetes: A double-blind, randomized, placebo-controlled crossover trial.
    Diabetes Obes Metab. 2024 Nov 29. doi: 10.1111/dom.16097.
    >> Share

  787. WU A, Pu J, Emery A, Harris SB, et al
    Role of the liver in the sustained normalisation of A1c over 2 years following short-term insulin therapy in early type 2 diabetes.
    Diabetes Obes Metab. 2024 Nov 28. doi: 10.1111/dom.16099.
    >> Share

  788. WANG W, Han Y, Jiang X, Shao J, et al
    Development of a predictive model for gastrointestinal side effects of metformin treatment in Chinese individuals with type 2 diabetes based on four randomised clinical trials.
    Diabetes Obes Metab. 2024 Nov 28. doi: 10.1111/dom.16095.
    >> Share

  789. ARMSTRONG MJ, Okanoue T, Sundby Palle M, Sejling AS, et al
    Similar weight loss with semaglutide regardless of diabetes and cardiometabolic risk parameters in individuals with metabolic dysfunction-associated steatotic liver disease: Post hoc analysis of three randomised controlled trials.
    Diabetes Obes Metab. 2024 Nov 28. doi: 10.1111/dom.16065.
    >> Share

  790. VALE C, Lourenco IM, Jordan G, Golovaty I, et al
    Early combination therapy with SGLT2i and GLP-1 RA or dual GIP/GLP-1 RA in type 2 diabetes.
    Diabetes Obes Metab. 2024 Nov 27. doi: 10.1111/dom.16077.
    >> Share

  791. ADDALA A, Ritter V, Schneider-Utaka AK, Alamarie SA, et al
    Psychosocial outcomes in a diverse sample of youth and their families who initiated continuous glucose monitoring within the first year of type 1 diabetes diagnosis.
    Diabetes Obes Metab. 2024 Nov 27. doi: 10.1111/dom.16093.
    >> Share

  792. ENG PC, Lee SH, Der Teo AE, Lim DST, et al
    Postnatal glycaemic outcomes in women with high-risk gestational diabetes: Identifying key predictors for early intervention.
    Diabetes Obes Metab. 2024 Nov 27. doi: 10.1111/dom.16085.
    >> Share

  793. LUNDEMOSE SB, McCarthy OM, Christensen MB, Laugesen C, et al
    Is low-dose glucagon needed and effective in preventing fasted exercise-induced hypoglycaemia in type 1 diabetes treated with the MiniMed 780G, an automated insulin delivery system?
    Diabetes Obes Metab. 2024 Nov 27. doi: 10.1111/dom.16103.
    >> Share

  794. WHELEHAN G, Dirks ML, West S, Abdelrahman DR, et al
    High-protein vegan and omnivorous diets improve peripheral insulin sensitivity to a similar extent in people with type 2 diabetes.
    Diabetes Obes Metab. 2024 Nov 27. doi: 10.1111/dom.16100.
    >> Share

  795. UMPIERREZ G, Gill J, Hood D, Li X, et al
    Treatment persistence, adherence and healthcare resource utilisation for iGlarLixi versus basal-bolus insulin or premixed insulin in older adult ethnic minorities with type 2 diabetes: SoliEthnicity study.
    Diabetes Obes Metab. 2024 Nov 27. doi: 10.1111/dom.16075.
    >> Share

  796. KASTRATI L, Alvarez-Martinez M, Thomas A, Thevis M, et al
    Effect of exercise on plasma insulin levels in individuals with type 1 diabetes: A systematic review and meta-analysis.
    Diabetes Obes Metab. 2024 Nov 26. doi: 10.1111/dom.16088.
    >> Share

  797. JIANG Y, Zhu H, Gong F
    Why does GLP-1 agonist combined with GIP and/or GCG agonist have greater weight loss effect than GLP-1 agonist alone in obese adults without type 2 diabetes?
    Diabetes Obes Metab. 2024 Nov 26. doi: 10.1111/dom.16106.
    >> Share

  798. GENG J, Ruan X, Wu X, Chen X, et al
    Network Mendelian randomisation analysis deciphers protein pathways linking type 2 diabetes and gastrointestinal disease.
    Diabetes Obes Metab. 2024 Nov 26. doi: 10.1111/dom.16087.
    >> Share

  799. SINGH J, Adel FW, Scott CG, Chen HH, et al
    Natriuretic peptide levels and predicting risk of developing new diabetes mellitus and metabolic syndrome.
    Diabetes Obes Metab. 2024 Nov 25. doi: 10.1111/dom.16073.
    >> Share

  800. DICEMBRINI I, Cavallo G, Ranaldi F, Scoccimarro D, et al
    Glycaemic response to pasta from three different wheat varieties in individuals with type 2 diabetes.
    Diabetes Obes Metab. 2024 Nov 25. doi: 10.1111/dom.16082.
    >> Share

  801. LIU W, Hu X, Fang Y, Hong S, et al
    Development and external validation of an algorithm for self-identification of risk for microvascular complications in patients with type 1 diabetes.
    Diabetes Obes Metab. 2024 Nov 25. doi: 10.1111/dom.16068.
    >> Share

  802. SHAH R, Finlay AY, Ali FM, Otwombe K, et al
    Comparison of the impact of type 1 and type 2 diabetes on quality of life of families of patients: A UK cross-sectional study.
    Diabetes Obes Metab. 2024 Nov 24. doi: 10.1111/dom.16058.
    >> Share

  803. ZOU Y, Yang Q, Lang Y, Liu K, et al
    The prognostic impact of the Stress Hyperglycemia Ratio on End-Stage Renal Disease among patients with Diabetic Kidney Disease.
    Diabetes Obes Metab. 2024 Nov 21. doi: 10.1111/dom.16056.
    >> Share

  804. TYRER F, Gharibzadeh S, Gillies C, Lawson C, et al
    Incidence of diabetes mellitus following hospitalisation for COVID-19 in the United Kingdom: A prospective observational study.
    Diabetes Obes Metab. 2024 Nov 20. doi: 10.1111/dom.16071.
    >> Share

  805. SRIDHAR VS, Davies MJ, Banks P, Girard M, et al
    Effects of sotagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease stages 3 and 4.
    Diabetes Obes Metab. 2024 Nov 20. doi: 10.1111/dom.16079.
    >> Share

  806. FU X, Zhao Y, Wu Y, Wen L, et al
    Relationship between trajectory of Chinese visceral adiposity index and risk of type 2 diabetes mellitus: Evidence from the China-PAR project.
    Diabetes Obes Metab. 2024 Nov 19. doi: 10.1111/dom.16074.
    >> Share

  807. VAN HECK JIP, Ajie M, Joosten LAB, Tack CJ, et al
    Circulating inflammatory proteins are elevated in type 1 and type 2 diabetes and associated to complications.
    Diabetes Obes Metab. 2024 Nov 19. doi: 10.1111/dom.16066.
    >> Share

  808. ZHENG T, Yang R, Li X, Dai Z, et al
    Integrative transcriptome analysis reveals Serpine2 promotes glomerular mesangial cell proliferation and extracellular matrix accumulation via activating ERK1/2 signalling pathway in diabetic nephropathy.
    Diabetes Obes Metab. 2024 Nov 18. doi: 10.1111/dom.16069.
    >> Share


  809. Correction to "Real-world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus".
    Diabetes Obes Metab. 2024 Nov 18. doi: 10.1111/dom.16083.
    >> Share

  810. SARABHAI T, Kostev K
    Incidence and risk factors of new-onset diabetes mellitus: A five-year follow-up study in solid organ transplant recipients in Germany.
    Diabetes Obes Metab. 2024 Nov 18. doi: 10.1111/dom.16072.
    >> Share

  811. GOLUBIC R, Car J, Nicolaides K
    Enhancing postpartum cardiometabolic health for women with previous gestational diabetes: Next steps and unanswered questions for pharmacological and lifestyle strategies.
    Diabetes Obes Metab. 2024 Nov 18. doi: 10.1111/dom.16070.
    >> Share

  812. GETHER IM, Andersen ES, Foghsgaard S, Ellegaard AM, et al
    Increased gallbladder emptying and reduced GLP-1 response in pregnancy with and without gestational diabetes mellitus.
    Diabetes Obes Metab. 2024 Nov 14. doi: 10.1111/dom.16064.
    >> Share

  813. RODRIGUEZ P, Breslaw N, Xiao H, Bena J, et al
    De-intensification of basal-bolus therapy by replacing prandial insulin with once-weekly subcutaneous semaglutide in individuals with well-controlled type 2 diabetes: A single-centre, open-label randomised trial (TRANSITION-T2D).
    Diabetes Obes Metab. 2024 Nov 12. doi: 10.1111/dom.16057.
    >> Share

  814. RILEY DR, Henney A, Anson M, Hernadez G, et al
    The cumulative impact of type 2 diabetes and obstructive sleep apnoea on cardiovascular, liver, diabetes-related and cancer outcomes.
    Diabetes Obes Metab. 2024 Nov 11. doi: 10.1111/dom.16059.
    >> Share

  815. ZHANG Z, Wang Y, Lu J, Zhou J, et al
    Time in tight range: A key metric for optimal glucose control in the era of advanced diabetes technologies and therapeutics.
    Diabetes Obes Metab. 2024 Nov 11. doi: 10.1111/dom.16033.
    >> Share

  816. MAGAGNOLI J, Cummings TH, Hardin JW, Ambati J, et al
    Targeting the cholinergic anti-inflammatory pathway for type 2 diabetes prevention: A retrospective cohort study.
    Diabetes Obes Metab. 2024 Nov 11. doi: 10.1111/dom.16060.
    >> Share

  817. GOLOMB RC, Tittel SR, Welters A, Karges W, et al
    Increased cardiovascular risk in people with LADA in comparison to type 1 diabetes and type 2 diabetes: Findings from the DPV registry in Germany and Austria.
    Diabetes Obes Metab. 2024 Nov 11. doi: 10.1111/dom.16048.
    >> Share

  818. MILDER TY, Lin J, Pearson SA, de Oliveira Costa J, et al
    Discontinuation of SGLT2i in people with type 2 diabetes following hospitalisation for heart failure: A cause for concern?
    Diabetes Obes Metab. 2024 Nov 7. doi: 10.1111/dom.16061.
    >> Share

  819. GREGORIC N, Sikonja J, Janez A, Jensterle M, et al
    Semaglutide improved sperm morphology in obese men with type 2 diabetes mellitus and functional hypogonadism.
    Diabetes Obes Metab. 2024 Nov 7. doi: 10.1111/dom.16042.
    >> Share

  820. SMEIJER JD, Gomez MF, Rossing P, Heerspink HJL, et al
    The effect of the endothelin receptor antagonist atrasentan on insulin resistance in phenotypic clusters of patients with type 2 diabetes and chronic kidney disease.
    Diabetes Obes Metab. 2024 Nov 6. doi: 10.1111/dom.16041.
    >> Share

  821. HE B, Lam HS, Qiu X, Shen S, et al
    Association and mediation pathways of maternal hyperglycaemia and liability to gestational diabetes with neonatal outcomes: A two-sample Mendelian randomization study.
    Diabetes Obes Metab. 2024 Nov 6. doi: 10.1111/dom.16045.
    >> Share

  822. LEE CH, Lui DT, Mak LY, Fong CH, et al
    Benefits of combining SGLT2 inhibitors and pioglitazone on risk of MASH in type 2 diabetes-A real-world study.
    Diabetes Obes Metab. 2024 Nov 5. doi: 10.1111/dom.16049.
    >> Share

  823. WONDIMKUN YA, Caughey GE, Inacio MC, Air T, et al
    Glucose-lowering medicines use before and after entry into long-term care facilities.
    Diabetes Obes Metab. 2024;26:4966-4975.
    >> Share

  824. LIU Q, Celis-Morales C, Sattar N, Welsh P, et al
    Association of glycaemic control with intraocular pressure in a large general population: Results from the UK Biobank.
    Diabetes Obes Metab. 2024;26:5192-5201.
    >> Share

  825. GENG L, Sun B, Chen Y
    A meta-analysis of randomized controlled studies examining the effects of sodium-glucose co-transporter-2 inhibitors on peripheral artery disease and risk of amputations.
    Diabetes Obes Metab. 2024;26:5376-5389.
    >> Share

  826. ELHENAWY YI, Abdel Kader MS, Thabet RA
    Performance of the MiniMed 780G system on mitigating menstrual cycle-dependent glycaemic variability.
    Diabetes Obes Metab. 2024;26:4916-4923.
    >> Share

  827. FESTA A, Saely CH, Drexel H
    Sodium-glucose co-transporter-2 inhibitors: Writing the next chapter of a unique success story.
    Diabetes Obes Metab. 2024;26:4816-4819.
    >> Share

  828. HAMBLIN PS, Earnest A, Russell AW, Talic S, et al
    Utilization and cost of non-insulin glucose-lowering drugs in Australia from 2013 to 2023.
    Diabetes Obes Metab. 2024;26:4924-4932.
    >> Share

  829. FUJIHARA K, Matsubayashi Y, Kitazawa M, Sato T, et al
    Achieving normoglycaemia with tirzepatide: Post hoc exploratory analysis of the SURPASS J-mono and J-combo studies.
    Diabetes Obes Metab. 2024;26:5304-5311.
    >> Share

  830. KNOP FK, Urva S, Rettiganti M, Benson CT, et al
    A long-acting glucose-dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon-like peptide-1 receptor agonist therapy.
    Diabetes Obes Metab. 2024;26:5474-5478.
    >> Share

  831. GOEAU-BRISSONNIERE M, Rives-Lange C, Phan A, Kourti E, et al
    Real-life use of liraglutide 3 mg in obesity management: The SAX-RL study.
    Diabetes Obes Metab. 2024;26:5488-5491.
    >> Share

  832. KIM TH, Lee K, Park S, Cho H, et al
    Association between glucagon-like peptide-1 receptor agonists and risk of suicidality: A comprehensive analysis of the global pharmacovigilance database.
    Diabetes Obes Metab. 2024;26:5183-5191.
    >> Share

  833. WHELEHAN G, Bello O, Hakim O, Ladwa M, et al
    Ethnic differences in the relationship between ectopic fat deposition and insulin sensitivity in Black African and White European men across a spectrum of glucose tolerance.
    Diabetes Obes Metab. 2024;26:5211-5221.
    >> Share

  834. SHEN TH, Aby ES, Vock D, Farley JF, et al
    Sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors on major liver outcomes in metabolic dysfunction-associated steatotic liver disease.
    Diabetes Obes Metab. 2024;26:5116-5125.
    >> Share

  835. SELBY NM, Taal MW
    What every clinician needs to know about chronic kidney disease: Detection, classification and epidemiology.
    Diabetes Obes Metab. 2024;26 Suppl 6:3-12.
    >> Share

  836. BAKRIS G
    Mineralocorticoid receptor antagonists and reno-protection: What's the evidence & where do they fit? A guide for non-specialists.
    Diabetes Obes Metab. 2024;26 Suppl 6:33-42.
    >> Share

  837. MAYNE KJ, Hanlon P, Lees JS
    Detecting and managing the patient with chronic kidney disease in primary care: A review of the latest guidelines.
    Diabetes Obes Metab. 2024;26 Suppl 6:43-54.
    >> Share

    October 2024
  838. MA J, Dong Y, Liu J, Gao S, et al
    The role of GRB2 in diabetes, diabetes complications and related disorders.
    Diabetes Obes Metab. 2024 Oct 30. doi: 10.1111/dom.16015.
    >> Share

  839. DAI N, Su X, Wang Y
    Cost-utility analysis of once-weekly insulin icodec and once-daily insulin glargine in patients with type 2 diabetes receiving basal-bolus insulin therapy in China.
    Diabetes Obes Metab. 2024 Oct 30. doi: 10.1111/dom.16031.
    >> Share

  840. YU XF, Lim CED, Chen H
    The role of vitamin D in glycaemic control in patients with type 2 diabetes-A pilot D4D trial.
    Diabetes Obes Metab. 2024 Oct 28. doi: 10.1111/dom.16023.
    >> Share

  841. PRATTICHIZZO F, Veronesi V, Rigoni M, La Grotta R, et al
    Body weight variability as a predictor of cardiovascular outcomes in type 1 diabetes: A nationwide cohort study.
    Diabetes Obes Metab. 2024 Oct 28. doi: 10.1111/dom.16038.
    >> Share

  842. HTUN HL, Lian W, Phua HP, Lim MY, et al
    Visit-to-visit HbA1c variability and risk of potentially avoidable hospitalisations in adults with type 2 diabetes receiving outpatient care at a tertiary hospital.
    Diabetes Obes Metab. 2024 Oct 28. doi: 10.1111/dom.16026.
    >> Share

  843. WASEHUUS V, Rotbain Curovic V, Tofte N, Lindhardt M, et al
    Effect of spironolactone wash-out on albuminuria after long-term treatment in individuals with type 2 diabetes and high risk of kidney disease-An observational follow-up of the PRIORITY study.
    Diabetes Obes Metab. 2024 Oct 28. doi: 10.1111/dom.16037.
    >> Share

  844. ISMAIL HM, Liu J, Netherland M Jr, Hasan NA, et al
    Safety and effects of acetylated and butyrylated high-amylose maize starch on youths recently diagnosed with type 1 diabetes: A pilot study.
    Diabetes Obes Metab. 2024 Oct 28. doi: 10.1111/dom.16039.
    >> Share

  845. DONG Q, Xi Y, Brandmaier S, Fuchs M, et al
    Subphenotypes of adult-onset diabetes: Data-driven clustering in the population-based KORA cohort.
    Diabetes Obes Metab. 2024 Oct 28. doi: 10.1111/dom.16022.
    >> Share

  846. HORIKAWA C, Takahara M, Katakami N, Takeda Y, et al
    Dietary potassium intake and its interaction with sodium intake on risk of developing cardiovascular disease in persons with type 2 diabetes: The Japan Diabetes Complication and its Prevention Prospective study (JDCP study 12).
    Diabetes Obes Metab. 2024 Oct 28. doi: 10.1111/dom.16035.
    >> Share

  847. ANDERSEN LL, Calatayud J, Nunez-Cortes R, Polo-Lopez A, et al
    Graded association of muscle strength with all-cause and cause-specific mortality in older adults with diabetes: Prospective cohort study across 28 countries.
    Diabetes Obes Metab. 2024 Oct 23. doi: 10.1111/dom.16019.
    >> Share

  848. QIAN XX
    BreathSpec holds potential suitability for real-time detection of halitosis-associated volatile organic compounds in diabetes and other diseases.
    Diabetes Obes Metab. 2024 Oct 22. doi: 10.1111/dom.16032.
    >> Share

  849. DAI J, Chang J, Choi JM, Bullock A, et al
    Trends in anti-diabetic medication use, severe hyperglycaemia and severe hypoglycaemia among American Indian and Alaska Native Peoples, 2009-2013.
    Diabetes Obes Metab. 2024 Oct 21. doi: 10.1111/dom.16021.
    >> Share

  850. FAN X, Liu Y, Chen X, Xu Y, et al
    Synergies between diabetes and hyperhomocysteinaemia: New insights to predict and prevent adverse cardiovascular effects.
    Diabetes Obes Metab. 2024 Oct 21. doi: 10.1111/dom.15947.
    >> Share

  851. FRIIS BRYDE NIELSEN C, Moller Thysen S, Bach Kampmann F, Hansen TW, et al
    The associations between functional vitamin K status and all-cause mortality, cardiovascular disease and end-stage kidney disease in persons with type 1 diabetes.
    Diabetes Obes Metab. 2024 Oct 21. doi: 10.1111/dom.16025.
    >> Share

  852. CARLSSON LMS, Carlsson B, Jacobson P, Andersson-Assarsson JC, et al
    Association between delay in diabetes development and mortality in people with obesity: Up to 33 years follow-up of the prospective Swedish Obese Subjects study.
    Diabetes Obes Metab. 2024 Oct 21. doi: 10.1111/dom.16010.
    >> Share

  853. GAO L, Bian F, Pan T, Jiang H, et al
    Efficacy and safety of cofrogliptin once every 2 weeks in Chinese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, phase 3 trial.
    Diabetes Obes Metab. 2024 Oct 21. doi: 10.1111/dom.16014.
    >> Share

  854. ZHANG L, Shen Y, Liu H, Li W, et al
    Body mass index trajectories and time in target range after delivery and long-term type 2 diabetes risk in women with a history of gestational diabetes mellitus.
    Diabetes Obes Metab. 2024 Oct 21. doi: 10.1111/dom.16020.
    >> Share

  855. CHENG YW, Chan YH, Chuang C, Chen SW, et al
    Association of initial serum sodium change and clinical outcome in patients with diabetes receiving sodium-glucose cotransporter-2 inhibitor therapy: A multicentre database analysis in Taiwan.
    Diabetes Obes Metab. 2024 Oct 21. doi: 10.1111/dom.16011.
    >> Share

  856. CHEN HL, Wang IT, Tsai YW, Lee YH, et al
    Superior benefits of sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors for diabetic kidney disease: A cohort study.
    Diabetes Obes Metab. 2024 Oct 18. doi: 10.1111/dom.15998.
    >> Share

  857. GOURDY P, Bonadonna RC, Mauricio D, Muller-Wieland D, et al
    Effectiveness and safety of insulin glargine 300 U/mL in insulin-naive individuals according to diabetes duration: Results from the REALI European pooled data analysis.
    Diabetes Obes Metab. 2024 Oct 17. doi: 10.1111/dom.16008.
    >> Share

  858. RODRIGO-CARBO C, Madinaveitia-Nisarre L, Perez-Calahorra S, Gracia-Rubio I, et al
    Low-calorie, high-protein diets, regardless of protein source, improve glucose metabolism and cardiometabolic profiles in subjects with prediabetes or type 2 diabetes and overweight or obesity.
    Diabetes Obes Metab. 2024 Oct 17. doi: 10.1111/dom.16013.
    >> Share

  859. AMIN NB, Frederich R, Tsamandouras N, Haggag AZ, et al
    Evaluation of an oral small-molecule glucagon-like peptide-1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: A dose-ranging, phase 2, randomized, placebo-controlled study.
    Diabetes Obes Metab. 2024 Oct 16. doi: 10.1111/dom.16005.
    >> Share

  860. LIU M, Pei J, Zeng C, Xin Y, et al
    Association of non-high-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio with cardiovascular outcomes in patients with type 2 diabetes mellitus: Evidence from the ACCORD cohort.
    Diabetes Obes Metab. 2024 Oct 16. doi: 10.1111/dom.16018.
    >> Share

  861. ROTBAIN CUROVIC V, Stougaard EB, Hansen TW
    Slowing the progression of diabetic and non-diabetic kidney disease: A summary of the current evidence base for sodium-glucose co-transporter-2 inhibitors.
    Diabetes Obes Metab. 2024 Oct 15. doi: 10.1111/dom.16007.
    >> Share

  862. OSTROMINSKI JW, Cho SMJ, Vaduganathan M, Honigberg MC, et al
    Cause-specific death in adults with type 1 diabetes and type 2 diabetes: Insights from the UK Biobank.
    Diabetes Obes Metab. 2024 Oct 14. doi: 10.1111/dom.16009.
    >> Share

  863. DOVER AR, Wright RJ, Forbes S, Strachan MWJ, et al
    Change in glycated haemoglobin in adults with type 2 diabetes on basal-bolus insulin regimens following commencement of Freestyle Libre use.
    Diabetes Obes Metab. 2024 Oct 10. doi: 10.1111/dom.16003.
    >> Share

  864. DICKER D, Pinto D, Reges O
    Metformin continuation post-metabolic bariatric surgery and relapse of diabetes.
    Diabetes Obes Metab. 2024 Oct 9. doi: 10.1111/dom.15962.
    >> Share

  865. BELL DSH, Jerkins T
    Diabetic Charcot neuroarthropathy: A threat to both limb and life.
    Diabetes Obes Metab. 2024 Oct 9. doi: 10.1111/dom.15994.
    >> Share

  866. DAVIS GM, Peters AL, Bode BW, Carlson AL, et al
    Glycaemic outcomes in adults with type 2 diabetes over 34 weeks with the Omnipod(R) 5 automated insulin delivery system.
    Diabetes Obes Metab. 2024 Oct 9. doi: 10.1111/dom.15993.
    >> Share

  867. ZHENG C, Wu J, Li N, Wei X, et al
    Cost-effectiveness of finerenone added to standard of care for patients with type 2 diabetes-related chronic kidney disease in the United States.
    Diabetes Obes Metab. 2024 Oct 8. doi: 10.1111/dom.15997.
    >> Share

  868. HONG JH, Kim MJ, Min KW, Won JC, et al
    Efficacy and safety of a fixed-dose combination of dapagliflozin and linagliptin (AJU-A51) in patients with type 2 diabetes mellitus: A multicentre, randomized, double-blind, parallel-group, placebo-controlled phase III study.
    Diabetes Obes Metab. 2024 Oct 7. doi: 10.1111/dom.15985.
    >> Share

  869. KONG X, Wang W
    Prevalence of individuals with diabetes and chronic kidney disease indicated for finerenone treatment in the United States: A National Health and Nutrition Examination Survey-based estimation.
    Diabetes Obes Metab. 2024 Oct 7. doi: 10.1111/dom.16006.
    >> Share

  870. HERMANNS N, Ehrmann D, Kulzer B, Klinker L, et al
    Somatic and mental symptoms associated with dysglycaemia, diabetes-related complications and mental conditions in people with diabetes: Assessments in daily life using continuous glucose monitoring and ecological momentary assessment.
    Diabetes Obes Metab. 2024 Oct 7. doi: 10.1111/dom.15983.
    >> Share

  871. KARAKUS KE, Mason E, Akturk HK
    Long-term glycaemic improvement with the initiation of an automated insulin delivery system in insulin pump-naive older adults with type 1 diabetes.
    Diabetes Obes Metab. 2024 Oct 7. doi: 10.1111/dom.15996.
    >> Share

  872. ZHU Y, Liu J, Wang B
    Integrated approach of machine learning, Mendelian randomization and experimental validation for biomarker discovery in diabetic nephropathy.
    Diabetes Obes Metab. 2024 Oct 6. doi: 10.1111/dom.15933.
    >> Share

  873. WONG BWX, Tan DYZ, Li LJ, Yong EL, et al
    Individual and combined effects of muscle strength and visceral adiposity on incident prediabetes and type 2 diabetes in a longitudinal cohort of midlife Asian women.
    Diabetes Obes Metab. 2024 Oct 4. doi: 10.1111/dom.15995.
    >> Share

  874. YUAN X, Li D, Wang K, Lauand F, et al
    iGlarLixi effectively reduces residual hyperglycaemia in Chinese people with type 2 diabetes on basal insulin: A post hoc analysis of the LixiLan-L-CN study.
    Diabetes Obes Metab. 2024 Oct 3. doi: 10.1111/dom.15968.
    >> Share

  875. SOURIJ H, Azhar K, Aziz F, Kojzar H, et al
    Metabolic risk factor targets in relation to clinical characteristics and comorbidities among individuals with type 2 diabetes treated in primary care - The countrywide cross-sectional AUSTRO-PROFIT study.
    Diabetes Obes Metab. 2024 Oct 3. doi: 10.1111/dom.15988.
    >> Share

  876. CHEN W, Liu L, Hu F
    Efficacy of vitamin D supplementation on glycaemic control in type 2 diabetes: An updated systematic review and meta-analysis of randomized controlled trials.
    Diabetes Obes Metab. 2024 Oct 2. doi: 10.1111/dom.15941.
    >> Share

  877. LE TN, Bright R, Truong VK, Li J, et al
    Key biomarkers in type 2 diabetes patients: A systematic review.
    Diabetes Obes Metab. 2024 Oct 2. doi: 10.1111/dom.15991.
    >> Share

  878. BANO A, Kunzler J, Wehrli F, Kastrati L, et al
    Clinical evidence for high-risk CE-marked medical devices for glucose management: A systematic review and meta-analysis.
    Diabetes Obes Metab. 2024;26:4753-4766.
    >> Share

  879. CZUPRYNIAK L, Mosenzon O, Rychlik I, Clodi M, et al
    Barriers to early diagnosis of chronic kidney disease and use of sodium-glucose cotransporter-2 inhibitors for renal protection: A comprehensive review and call to action.
    Diabetes Obes Metab. 2024;26:4165-4177.
    >> Share

  880. LI T, Sang M, Wang J, Sun Z, et al
    Dark tea consumption is associated with a reduced risk of dysglycaemia and increased urinary glucose and sodium excretion in Chinese adults.
    Diabetes Obes Metab. 2024;26:4705-4712.
    >> Share

  881. KASSEM S, Khalaila B, Stein N, Saliba W, et al
    Efficacy, adherence and persistence of various glucagon-like peptide-1 agonists: nationwide real-life data.
    Diabetes Obes Metab. 2024;26:4646-4652.
    >> Share

  882. HASHIMOTO H, Satoh M, Nakayama S, Toyama M, et al
    Comparison of renal prognosis between dipeptidyl peptidase-4 inhibitor users and non-users.
    Diabetes Obes Metab. 2024;26:4460-4467.
    >> Share

  883. LU Y, Tang H, Kotecha P, Cho H, et al
    Newer glucose-lowering drugs and risk of suicidal ideation and behaviours: A network meta-analysis of randomized outcome trials.
    Diabetes Obes Metab. 2024;26:4783-4786.
    >> Share

  884. JIMBA T, Kaneko H, Azegami T, Suzuki Y, et al
    Body weight change associated kidney outcomes of sodium-glucose cotransporter new users.
    Diabetes Obes Metab. 2024;26:4535-4543.
    >> Share

  885. FORST T, De Block C, Del Prato S, Armani S, et al
    The role of incretin receptor agonists in the treatment of obesity.
    Diabetes Obes Metab. 2024;26:4178-4196.
    >> Share

  886. HUANG P, Zhu Y, Qin J
    Research advances in understanding crosstalk between organs and pancreatic beta-cell dysfunction.
    Diabetes Obes Metab. 2024;26:4147-4164.
    >> Share

  887. JOHNSON CE, Sussman WB, Weeda ER
    Medication adherence to sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists: A meta-analysis.
    Diabetes Obes Metab. 2024;26:4544-4550.
    >> Share

  888. PATEL PM, Thomas D, Liu Z, Aldrich-Renner S, et al
    Systematic review of disparities in continuous glucose monitoring and insulin pump utilization in the United States: Key themes and evidentiary gaps.
    Diabetes Obes Metab. 2024;26:4293-4301.
    >> Share

  889. TKAC I, Kozarova M, Stancakova Yaluri A, Javorsky M, et al
    Treatment with sodium-glucose cotransporter 2 inhibitors and risk of lower-limb amputations.
    Diabetes Obes Metab. 2024;26:4803-4805.
    >> Share

  890. NAGENDRA L, Dutta D, Kamrul-Hasan ABM
    Bariatric surgery and tirzepatide-Friends, not foes!
    Diabetes Obes Metab. 2024;26:4806.
    >> Share

  891. MATTHEWS DR
    Sodium-glucose co-transporter-2 inhibitors: A paradigm shift in treatment for type 2 diabetes.
    Diabetes Obes Metab. 2024;26 Suppl 5:3-4.
    >> Share

  892. NYSTROM T
    Key results from observational studies and real-world evidence of sodium-glucose cotransporter-2 inhibitor effectiveness and safety in reducing cardio-renal risk.
    Diabetes Obes Metab. 2024;26 Suppl 5:35-57.
    >> Share

  893. LI S, Yang B, Shang S, Jiang W, et al
    Association of hypertension and long-term blood pressure changes with new-onset diabetes in the elderly: A 10-year cohort study.
    Diabetes Obes Metab. 2024 Oct 1. doi: 10.1111/dom.15986.
    >> Share

    September 2024
  894. KHIAR H, Leveque E, Lopez AG, Moreau-Grange L, et al
    Serum levels of the incretin-like peptide 26RFa are diminished in women living with obesity and diabetes and restored after sleeve gastrectomy: Results from the prospective pilot RFa-Ba-S study.
    Diabetes Obes Metab. 2024 Sep 30. doi: 10.1111/dom.15871.
    >> Share

  895. IWAMOTO Y, Kimura T, Dan K, Iwamoto H, et al
    Tirzepatide, a dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 receptor agonist, exhibits favourable effects on pancreatic beta-cells and hepatic steatosis in obese type 2 diabetic db/db mice.
    Diabetes Obes Metab. 2024 Sep 30. doi: 10.1111/dom.15972.
    >> Share

  896. HANNAH K, Nemlekar P, Bushman JS, Norman GJ, et al
    Risk of hypoglycaemia among people with type 2 diabetes not treated with insulin: A retrospective analysis of Medicare Advantage beneficiaries.
    Diabetes Obes Metab. 2024 Sep 30. doi: 10.1111/dom.15982.
    >> Share

  897. LI H, Su W, Zheng Z, Li J, et al
    The coexistence of low muscle mass and obesity evaluated by dual energy X-ray absorptiometry, rather than low muscle mass or obesity alone, is associated with macrovascular but not microvascular complications in patients with type 2 diabetes mellitus.
    Diabetes Obes Metab. 2024 Sep 30. doi: 10.1111/dom.15978.
    >> Share

  898. DYER BP, Burton C, Rathod-Mistry T, Blagojevic-Bucknall M, et al
    Are patients with newly diagnosed frozen shoulder more likely to be diagnosed with type 2 diabetes? A cohort study in UK electronic health records.
    Diabetes Obes Metab. 2024 Sep 30. doi: 10.1111/dom.15965.
    >> Share

  899. SADEGHI S, Hosseinpanah F, Khalaj A, Ebadinejad A, et al
    Remission and relapse of diabetes after sleeve gastrectomy and one-anastomosis gastric bypass: The Tehran Obesity Treatment Study.
    Diabetes Obes Metab. 2024 Sep 30. doi: 10.1111/dom.15974.
    >> Share

  900. HU S, Wang S, Gu S, Qi C, et al
    Cost-utility analysis and drug pricing of once-weekly insulin icodec versus once-daily insulin degludec for type 2 diabetes patients treated with basal insulin in China.
    Diabetes Obes Metab. 2024 Sep 30. doi: 10.1111/dom.15973.
    >> Share

  901. SHAN S, Luo Z, Yao L, Zhou J, et al
    Cross-country inequalities in disease burden and care quality of chronic kidney disease due to type 2 diabetes mellitus, 1990-2021: Findings from the global burden of disease study 2021.
    Diabetes Obes Metab. 2024 Sep 30. doi: 10.1111/dom.15969.
    >> Share

  902. KARAKASIS P, Koufakis T, Patoulias D, Barkas F, et al
    Effects of glucagon-like peptide-1 receptor agonists on glycated haemoglobin and continuous glucose monitoring metrics as adjunctive therapy to insulin in adults with type 1 diabetes: A meta-analysis of randomized controlled trials.
    Diabetes Obes Metab. 2024 Sep 30. doi: 10.1111/dom.15979.
    >> Share

  903. LI P, Spector E, Alkhuzam K, Patel R, et al
    Developing an automated algorithm for identification of children and adolescents with diabetes using electronic health records from the OneFlorida+ clinical research network.
    Diabetes Obes Metab. 2024 Sep 30. doi: 10.1111/dom.15987.
    >> Share

  904. MAFFEIS C, Piona C, Morandi A, Marigliano M, et al
    Glycaemic control metrics and metabolic dysfunction-associated steatotic liver disease in children and adolescents with type 1 diabetes.
    Diabetes Obes Metab. 2024 Sep 30. doi: 10.1111/dom.15961.
    >> Share

  905. GROBMAN B, Mansur A, Lu CY
    Disparities in suicide rates among patients with diabetes in the United States.
    Diabetes Obes Metab. 2024 Sep 30. doi: 10.1111/dom.15989.
    >> Share

  906. JIANG H, Zhang K, Zhang X
    Mendelian randomization analysis of the association between childhood overweight or obesity and gestational diabetes mellitus.
    Diabetes Obes Metab. 2024 Sep 30. doi: 10.1111/dom.15975.
    >> Share

  907. WATADA H, Asbjornsdottir B, Nishida T, Nishimura R, et al
    Efficacy and safety of once-weekly insulin icodec versus once-daily basal insulin in Japanese individuals with type 2 diabetes: A subgroup analysis of the ONWARDS 1, 2 and 4 trials.
    Diabetes Obes Metab. 2024 Sep 30. doi: 10.1111/dom.15960.
    >> Share

  908. MARUYAMA-SAKURAI K, Tachimori H, Saito E, Kohsaka S, et al
    Cost-effectiveness of sodium-glucose cotransporter-2 inhibitors in the treatment of diabetic nephropathy in Japan.
    Diabetes Obes Metab. 2024 Sep 30. doi: 10.1111/dom.15832.
    >> Share

  909. KIILAVUORI M, Varimo T, Tuomaala AK, Pulkkinen MA, et al
    Children and adolescent with suboptimal control of type 1 diabetes improve during the first 2 years on automated insulin delivery system.
    Diabetes Obes Metab. 2024 Sep 30. doi: 10.1111/dom.15992.
    >> Share

  910. LI J, Cui HL, Xie DD, Wang QY, et al
    Global and regional estimates of hip fracture burden associated with type 1 diabetes from 1990 to 2021.
    Diabetes Obes Metab. 2024 Sep 26. doi: 10.1111/dom.15970.
    >> Share

  911. CASTANEDA J, de Galan BE, van Kuijk SMJ, Arrieta A, et al
    The interdependence of targets for continuous glucose monitoring outcomes in type 1 diabetes with automated insulin delivery.
    Diabetes Obes Metab. 2024 Sep 26. doi: 10.1111/dom.15955.
    >> Share

  912. ELKABBANY ZA, Ismail EAR, Hamed ET, Elbarbary NS, et al
    The impact of vildagliptin as an add-on therapy on matrix metalloproteinase-14 levels, liver stiffness and subclinical atherosclerosis in adolescents with type 1 diabetes and non-alcoholic steatohepatitis: A randomized controlled trial.
    Diabetes Obes Metab. 2024 Sep 24. doi: 10.1111/dom.15958.
    >> Share

  913. REN Q, Li L, Su X, Hu X, et al
    Cofrogliptin once every 2 weeks as add-on therapy to metformin versus daily linagliptin in patients with type 2 diabetes in China: A randomized, double-blind, non-inferiority trial.
    Diabetes Obes Metab. 2024 Sep 23. doi: 10.1111/dom.15915.
    >> Share

  914. REIS-BARBOSA PH, Aguila MB, Mandarim-de-Lacerda CA
    Tirzepatide, a dual receptor agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1, enhances beta-cell survival and maintenance markers in obese diabetic ovariectomized mice.
    Diabetes Obes Metab. 2024 Sep 22. doi: 10.1111/dom.15937.
    >> Share

  915. RAZAGHIZAD A, Ni J, Marques P, Mavrakanas TA, et al
    Cardiovascular phenotypes in type 2 diabetes: Latent class analysis of the CANVAS Program and CREDENCE trial.
    Diabetes Obes Metab. 2024 Sep 20. doi: 10.1111/dom.15768.
    >> Share

  916. MACLEISH SA, Hood KK, Polonsky WH, Wood JR, et al
    Psychosocial outcomes with the Omnipod(R) 5 Automated Insulin Delivery System in caregivers of very young children with type 1 diabetes.
    Diabetes Obes Metab. 2024 Sep 20. doi: 10.1111/dom.15906.
    >> Share

  917. LIU Y, Chen Y, Lam SHM, Huang B, et al
    Diabetes mellitus and adverse clinical events in patients with atrial fibrillation: A report from the GLORIA-AF registry phase III.
    Diabetes Obes Metab. 2024 Sep 20. doi: 10.1111/dom.15950.
    >> Share

  918. HENNIES N, Gorgens SW, Killer J, Otto T, et al
    Prevalence of obesity and cardiovascular disease in adults with type 2 diabetes and use of diabetes medication in Germany: A claims data study.
    Diabetes Obes Metab. 2024 Sep 19. doi: 10.1111/dom.15931.
    >> Share

  919. STENBERG E, Cao Y, Ottosson J, Hedberg S, et al
    Glycaemic and weight effects of metabolic surgery or semaglutide in diabetes dosage for patients with type 2 diabetes.
    Diabetes Obes Metab. 2024 Sep 18. doi: 10.1111/dom.15952.
    >> Share

  920. WIEGAND S, Becker M, Schmid S, Weghuber D, et al
    Trends in pharmacological management of paediatric patients with type 2 diabetes from 2000 to 2023 in German-speaking countries: Analysis based on the Diabetes Prospective Follow-up Registry.
    Diabetes Obes Metab. 2024 Sep 18. doi: 10.1111/dom.15930.
    >> Share

  921. ZHANG TY, Zhang ZM, Wang XN, Kuang HY, et al
    Relationship between weight-adjusted-waist index and all-cause and cardiovascular mortality in individuals with type 2 diabetes.
    Diabetes Obes Metab. 2024 Sep 18. doi: 10.1111/dom.15929.
    >> Share

  922. NICOLIER C, Kunzler J, Lizoain A, Kerber D, et al
    Detection of hypoglycaemia in type 1 diabetes through breath volatile organic compound profiling using gas chromatography-ion mobility spectrometry.
    Diabetes Obes Metab. 2024 Sep 16. doi: 10.1111/dom.15944.
    >> Share

  923. POTTEGARD A, Andersen JH, Sondergaard J, Rasmussen L, et al
    Treatment trajectories for Danish individuals with type 2 diabetes in the era of emerging glucose-lowering therapies.
    Diabetes Obes Metab. 2024 Sep 16. doi: 10.1111/dom.15912.
    >> Share

  924. JI L, Lu Y, Shen Z, Hu P, et al
    Impact of baseline characteristics on the efficacy of once-weekly subcutaneous semaglutide among participants with type 2 diabetes: A post hoc analysis of SUSTAIN China.
    Diabetes Obes Metab. 2024 Sep 16. doi: 10.1111/dom.15888.
    >> Share

  925. TABESH M, Sacre JW, Mehta K, Chen L, et al
    The association of glycaemic risk factors and diabetes duration with risk of heart failure in people with type 2 diabetes: A systematic review and meta-analysis.
    Diabetes Obes Metab. 2024 Sep 13. doi: 10.1111/dom.15938.
    >> Share

  926. GARG SK, Hirsch IB, Repetto E, Snell-Bergeon J, et al
    Impact of continuous glucose monitoring on hospitalizations and glucose control in people with type 2 diabetes: real-world analysis.
    Diabetes Obes Metab. 2024 Sep 12. doi: 10.1111/dom.15866.
    >> Share

  927. LUNDHOLM MD, Kirschling S, Hu B, Aminian A, et al
    Long-term outcomes of metabolic surgery versus medical/lifestyle therapy on metabolic dysfunction-associated fatty liver disease in adults with obesity and type 2 diabetes.
    Diabetes Obes Metab. 2024 Sep 12. doi: 10.1111/dom.15932.
    >> Share

  928. GUO J, Tang H, Shao H, Lu Y, et al
    Sodium-glucose cotransporter 2 inhibitors and the risk of Parkinson disease in real-world patients with type 2 diabetes.
    Diabetes Obes Metab. 2024 Sep 10. doi: 10.1111/dom.15943.
    >> Share

  929. PIKKEMAAT M, Woodward M, Af Geijerstam P, Harrap S, et al
    Lipids and apolipoproteins and the risk of vascular disease and mortality outcomes in women and men with type 2 diabetes in the ADVANCE study.
    Diabetes Obes Metab. 2024 Sep 10. doi: 10.1111/dom.15935.
    >> Share

  930. LONG W, Light PE, Simpson SH
    Glyburide use is associated with a greater likelihood of mortality or rehospitalization after acute coronary syndrome compared to gliclazide use in adults with type 2 diabetes: A cohort study.
    Diabetes Obes Metab. 2024 Sep 9. doi: 10.1111/dom.15917.
    >> Share

  931. KELLY MS, Scopelliti EM, Goodson KE, Lo CMA, et al
    Real-world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus.
    Diabetes Obes Metab. 2024 Sep 9. doi: 10.1111/dom.15934.
    >> Share

  932. PAI YW, Chen IC, Lin JF, Chen XH, et al
    Association of sodium-glucose cotransporter 2 inhibitors with risk of incident dementia and all-cause mortality in older patients with type 2 diabetes: A retrospective cohort study using the TriNetX US collaborative networks.
    Diabetes Obes Metab. 2024 Sep 9. doi: 10.1111/dom.15918.
    >> Share

  933. MAYER CS, Fontelo P
    Semaglutide use in people with obesity and type 2 diabetes from real-world utilization data: An analysis of the All of US Program.
    Diabetes Obes Metab. 2024 Sep 9. doi: 10.1111/dom.15911.
    >> Share

  934. HALUZIK M, Al-Sofiani ME, Cheng AYY, Lauand F, et al
    Time-in-range derived from self-measured blood glucose in people with type 2 diabetes advancing to iGlarLixi: A participant-level pooled analysis of three phase 3 LixiLan randomized controlled trials.
    Diabetes Obes Metab. 2024 Sep 8. doi: 10.1111/dom.15811.
    >> Share

  935. PUNTHAKEE Z, Hall S, McInnes N, Sherifali D, et al
    Evaluating remission of type 2 diabetes using a metabolic intervention including fixed-ratio insulin degludec and liraglutide: A randomized controlled trial.
    Diabetes Obes Metab. 2024 Sep 6. doi: 10.1111/dom.15926.
    >> Share

  936. WANG S, Song S, Gao J, Duo Y, et al
    Glycated haemoglobin variability and risk of renal function decline in type 2 diabetes mellitus: An updated systematic review and meta-analysis.
    Diabetes Obes Metab. 2024 Sep 4. doi: 10.1111/dom.15861.
    >> Share

  937. VAN DEN HEUVEL T, Castaneda J, Arrieta A, Voelker B, et al
    Generating real-world evidence on diabetes technology using the CareLink Personal data management system.
    Diabetes Obes Metab. 2024 Sep 4. doi: 10.1111/dom.15868.
    >> Share

  938. CHEN MD, Deng CF, Chen PF, Li A, et al
    Non-invasive metabolic biomarkers in initial cognitive impairment in patients with diabetes: A systematic review and meta-analysis.
    Diabetes Obes Metab. 2024 Sep 4. doi: 10.1111/dom.15916.
    >> Share

  939. VAN HULTEN V, Driessen JHM, Andersen S, Kvist A, et al
    Fracture risk revisited: Bone mineral density T-score and fracture risk in type 2 diabetes.
    Diabetes Obes Metab. 2024 Sep 4. doi: 10.1111/dom.15890.
    >> Share

  940. FU L, Cheng H, Xiong J, Xiao P, et al
    Mediating role of inflammatory biomarkers in the causal effect of body composition on glycaemic traits and type 2 diabetes.
    Diabetes Obes Metab. 2024 Sep 4. doi: 10.1111/dom.15923.
    >> Share

  941. MEHROTRA-VARMA S, Lu JY, Boparai MS, Henry S, et al
    Patients with type 1 diabetes are at elevated risk of developing new hypertension, chronic kidney disease and diabetic ketoacidosis after COVID-19: Up to 40 months' follow-up.
    Diabetes Obes Metab. 2024 Sep 2. doi: 10.1111/dom.15900.
    >> Share

  942. ARAI T, Atsukawa M, Tsubota A, Oikawa T, et al
    Beneficial effect of oral semaglutide for type 2 diabetes mellitus in patients with metabolic dysfunction-associated steatotic liver disease: A prospective, multicentre, observational study.
    Diabetes Obes Metab. 2024 Sep 2. doi: 10.1111/dom.15898.
    >> Share

  943. VAN HULTEN V, Souverein PC, Starup-Linde J, Viggers R, et al
    The association of type 2 diabetes-related characteristics with fracture risk at different sites.
    Diabetes Obes Metab. 2024 Sep 2. doi: 10.1111/dom.15884.
    >> Share

  944. JEONG IK, Choi KM, Han KA, Kim KA, et al
    Efficacy and safety of dapagliflozin add-on to evogliptin plus metformin therapy in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled study.
    Diabetes Obes Metab. 2024 Sep 2. doi: 10.1111/dom.15838.
    >> Share

  945. KAFAI YAHYAVI S, Kristensen PL, Hjorthoj C, Hansen KB, et al
    The use of composite endpoints in cardiovascular outcome trials for diabetes: A review of 22 randomized clinical trials published since 2008.
    Diabetes Obes Metab. 2024 Sep 2. doi: 10.1111/dom.15907.
    >> Share

  946. BASU A, Montano-Campos F, Huang ES, Laiteerapong N, et al
    Updating and calibrating the Real-World Progression In Diabetes (RAPIDS) model in a non-Veterans Affairs population.
    Diabetes Obes Metab. 2024 Sep 2. doi: 10.1111/dom.15878.
    >> Share

  947. GIUGLIANO D, Esposito K, De Nicola L
    Diabetic kidney disease: The fourth pharmacological pillar may be semaglutide.
    Diabetes Obes Metab. 2024 Sep 2. doi: 10.1111/dom.15892.
    >> Share

  948. SRIDHAR VS, Cosentino F, Dagogo-Jack S, McGuire DK, et al
    Effects of ertugliflozin on uric acid and gout-related outcomes in persons with type 2 diabetes and cardiovascular disease: Post hoc analyses from VERTIS CV.
    Diabetes Obes Metab. 2024 Sep 2. doi: 10.1111/dom.15895.
    >> Share

  949. LIANG G, Lai M, Wang Y, Li N, et al
    Decreased complexity of glucose time series index associated with adverse pregnancy outcomes in gestational diabetes mellitus.
    Diabetes Obes Metab. 2024;26:3587-3596.
    >> Share

  950. RASMUSSEN DGK, Hansen MK, Frederiksen P, Luo Y, et al
    Association of type III collagen turnover with cardiovascular outcomes and impact with canagliflozin in the CANVAS Program: A post hoc analysis.
    Diabetes Obes Metab. 2024;26:4060-4068.
    >> Share

  951. PALMIOTTI A, Berk KA, Koehorst M, Hovingh MV, et al
    Reversal of insulin resistance in people with obesity by lifestyle-induced weight loss does not impact the proportion of circulating 12alpha-hydroxylated bile acids.
    Diabetes Obes Metab. 2024;26:4019-4029.
    >> Share

  952. CARDOZA K, Kang A, Smyth B, Yi TW, et al
    Geographic and racial variability in kidney, cardiovascular and safety outcomes with canagliflozin: A secondary analysis of the CREDENCE randomized trial.
    Diabetes Obes Metab. 2024;26:3530-3540.
    >> Share

  953. PELEKANOU C, Anastasiou CA, Mavrogianni C, Cardon G, et al
    Physical activity in relation to metabolic health and obesity: The Feel4Diabetes study.
    Diabetes Obes Metab. 2024;26:3705-3714.
    >> Share

  954. XUAN X, Zhang Y, Song Y, Zhang B, et al
    Role of protein arginine methyltransferase 1 in obesity-related metabolic disorders: Research progress and implications.
    Diabetes Obes Metab. 2024;26:3491-3500.
    >> Share

  955. DASH S
    Opportunities to optimize lifestyle interventions in combination with glucagon-like peptide-1-based therapy.
    Diabetes Obes Metab. 2024;26 Suppl 4:3-15.
    >> Share

  956. NEELAND IJ, Linge J, Birkenfeld AL
    Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies.
    Diabetes Obes Metab. 2024;26 Suppl 4:16-27.
    >> Share

    August 2024
  957. LIARAKOS AL, Crabtree TSJ, Wilmot EG
    Patient-reported outcomes in studies of diabetes technology: What matters.
    Diabetes Obes Metab. 2024 Aug 31. doi: 10.1111/dom.15858.
    >> Share

  958. LASSEN MCH, Johansen ND, Modin D, Catarig AM, et al
    Adherence to glucagon-like peptide-1 receptor agonist treatment in type 2 diabetes mellitus: A nationwide registry study.
    Diabetes Obes Metab. 2024 Aug 31. doi: 10.1111/dom.15872.
    >> Share

  959. YEN YH, Yen FS, Ko FS, Wei JC, et al
    Microvascular disease and its association with dementia in patients with type 2 diabetes: A nationwide cohort study in Taiwan.
    Diabetes Obes Metab. 2024 Aug 29. doi: 10.1111/dom.15908.
    >> Share

  960. XU W, Wang Y, Tanuseputro P, Lam CLK, et al
    Optimizing physician-encounter frequency for type 2 diabetes patients in primary care based on cardiovascular risk assessment: A target trial emulation study.
    Diabetes Obes Metab. 2024 Aug 29. doi: 10.1111/dom.15899.
    >> Share

  961. DAVIDSON MB
    Glycaemic treatment of newly diagnosed type 2 diabetes.
    Diabetes Obes Metab. 2024 Aug 29. doi: 10.1111/dom.15904.
    >> Share

  962. HIRSCH IB, Parkin CG, Cavaiola TS, Bergenstal RM, et al
    Use of continuous glucose monitoring when initiating glucagon-like peptide-1 receptor agonist therapy in insulin-treated diabetes.
    Diabetes Obes Metab. 2024 Aug 28. doi: 10.1111/dom.15883.
    >> Share

  963. STEENACKERS N, Sparso T, Charleer S, De Block C, et al
    Health-related quality of life of people with type 1 diabetes: An IMI2 SOPHIA post hoc analysis of FUTURE and ADJUNCT-ONE.
    Diabetes Obes Metab. 2024 Aug 27. doi: 10.1111/dom.15886.
    >> Share

  964. SHARMA A, Mariam A, Zacherle E, Milinovich A, et al
    Elucidating the role of weight loss and glycaemic control in patients with type 2 diabetes.
    Diabetes Obes Metab. 2024 Aug 27. doi: 10.1111/dom.15896.
    >> Share

  965. JIANG L, Lai J, Xu X, Lu Y, et al
    Reduced insulin clearance in paediatric metabolic (dysfunction)-associated fatty liver disease and its dual role in beta-cell offload and diabetes risk.
    Diabetes Obes Metab. 2024 Aug 27. doi: 10.1111/dom.15902.
    >> Share

  966. AO Y, Ye H, Liu X, Li Y, et al
    Fish oil supplementation in relation to the risk of chronic kidney disease among patients with diabetes.
    Diabetes Obes Metab. 2024 Aug 27. doi: 10.1111/dom.15880.
    >> Share

  967. DEJGAARD TF, Frandsen CS, Kielgast U, Storling J, et al
    Liraglutide enhances insulin secretion and prolongs the remission period in adults with newly diagnosed type 1 diabetes (the NewLira study): A randomized, double-blind, placebo-controlled trial.
    Diabetes Obes Metab. 2024 Aug 27. doi: 10.1111/dom.15889.
    >> Share

  968. TANDAY N, Zhu W, Tarasov AI, Flatt PR, et al
    [P(3)]PP, a stable, long-acting pancreatic polypeptide analogue, evokes weight lowering and pancreatic beta-cell-protective effects in obesity-associated diabetes.
    Diabetes Obes Metab. 2024 Aug 27. doi: 10.1111/dom.15897.
    >> Share

  969. WANG J, Yang J, Jiang W, Liu W, et al
    Effect of semaglutide on primary prevention of diabetic kidney disease in people with type 2 diabetes: A post hoc analysis of the SUSTAIN 6 randomized controlled trial.
    Diabetes Obes Metab. 2024 Aug 27. doi: 10.1111/dom.15860.
    >> Share

  970. HUANG YN, Liao WL, Huang JY, Lin YJ, et al
    Long-term safety and efficacy of glucagon-like peptide-1 receptor agonists in individuals with obesity and without type 2 diabetes: A global retrospective cohort study.
    Diabetes Obes Metab. 2024 Aug 22. doi: 10.1111/dom.15869.
    >> Share

  971. THABIT H, Rubio J, Karuppan M, Mubita W, et al
    Use of real-time continuous glucose monitoring in non-critical care insulin-treated inpatients under non-diabetes speciality teams in hospital: A pilot randomized controlled study.
    Diabetes Obes Metab. 2024 Aug 21. doi: 10.1111/dom.15885.
    >> Share

  972. ZHOU Y, Liu S, Zhang Q, Zhang S, et al
    Bidirectional association between type 2 diabetes and irritable bowel syndrome: A large-scale prospective cohort study.
    Diabetes Obes Metab. 2024 Aug 20. doi: 10.1111/dom.15852.
    >> Share

  973. RASMUSSEN L, Andersen JH, Karlstad O, Giunta DH, et al
    Early uptake of semaglutide for type 2 diabetes in Scandinavia and characteristics of initiators in Denmark: A register-based drug utilization study.
    Diabetes Obes Metab. 2024 Aug 20. doi: 10.1111/dom.15876.
    >> Share

  974. SAETANG T, Greeviroj P, Thavaraputta S, Santisitthanon P, et al
    The effectiveness of telemonitoring and integrated personalized diabetes management in people with insulin-treated type 2 diabetes mellitus.
    Diabetes Obes Metab. 2024 Aug 19. doi: 10.1111/dom.15870.
    >> Share

  975. GAN X, Ye Z, Zhang Y, He P, et al
    Sweetened beverages and atrial fibrillation in people with prediabetes or diabetes.
    Diabetes Obes Metab. 2024 Aug 19. doi: 10.1111/dom.15859.
    >> Share

  976. HORTON WB, Dart ME, Kavuru VS, Girton MR, et al
    Using natriuretic peptides to screen for, identify and treat stage B heart failure in people with type 2 diabetes: An initial cost-effectiveness analysis.
    Diabetes Obes Metab. 2024 Aug 19. doi: 10.1111/dom.15873.
    >> Share

  977. WANG Y, Chin WY, Lam CLK, Wan EYF, et al
    Trajectory of haemoglobin A1c and incidence of cardiovascular disease in patients with type 2 diabetes mellitus.
    Diabetes Obes Metab. 2024 Aug 19. doi: 10.1111/dom.15856.
    >> Share

  978. FARZANBAKHSH S, Amini MR, Madani H, Sadri B, et al
    Safety evaluation of bi-layered allogenic keratinocyte and fibroblast skin substitute for diabetic foot ulcers-SAFESKIN-DFU: A Phase 1 clinical trial.
    Diabetes Obes Metab. 2024 Aug 19. doi: 10.1111/dom.15843.
    >> Share

  979. ASTBURY NM
    Interventions to improve glycaemic control in people living with, and at risk of developing type 2 diabetes.
    Diabetes Obes Metab. 2024 Aug 19. doi: 10.1111/dom.15855.
    >> Share

  980. JI L, Gao L, Feng Z, Chen G, et al
    The efficacy and safety of ISIS 449884 injection as monotherapy in patients with type 2 diabetes: A randomized phase II study.
    Diabetes Obes Metab. 2024 Aug 19. doi: 10.1111/dom.15862.
    >> Share

  981. MU Y
    The efficacy and safety of insulin glargine 100 U/mL + lixisenatide versus insulin degludec + insulin aspart in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli-D randomized controlled trial.
    Diabetes Obes Metab. 2024 Aug 19. doi: 10.1111/dom.15857.
    >> Share

  982. INOUE M, Sakanaka A, Katakami N, Furuno M, et al
    Periodontal tissue susceptibility to glycaemic control in type 2 diabetes.
    Diabetes Obes Metab. 2024 Aug 14. doi: 10.1111/dom.15835.
    >> Share

  983. RITTENHOUSE BE, Alolayan S, Eguale T, Segal AR, et al
    Metformin in the Diabetes Prevention Program 3-year trial: The cost-effectiveness that never was.
    Diabetes Obes Metab. 2024 Aug 14. doi: 10.1111/dom.15851.
    >> Share

  984. CHEN TY, Lee HF, Chan YH, Chuang C, et al
    Comparing clinical outcomes in patients with type 2 diabetes mellitus after ischaemic stroke: Sodium-glucose cotransporter 2 inhibitors users versus non-users. A propensity score matching National Cohort Study.
    Diabetes Obes Metab. 2024 Aug 12. doi: 10.1111/dom.15804.
    >> Share

  985. KOTECHA P, Chen W, Donahoo WT, Jaffee M, et al
    Continuous glucose monitoring and all-cause mortality in insulin-using population with diabetes and cognitive impairment.
    Diabetes Obes Metab. 2024 Aug 12. doi: 10.1111/dom.15842.
    >> Share

  986. TSABAN G, Aharon-Hananel G, Shalem S, Zelicha H, et al
    The effect of Mankai plant consumption on postprandial glycaemic response among patients with type 2 diabetes: A randomized crossover trial.
    Diabetes Obes Metab. 2024 Aug 12. doi: 10.1111/dom.15840.
    >> Share

  987. BOLDUC ME, Potter KJ, Olmos M, Bonhoure A, et al
    Cystic fibrosis-related diabetes develops from a combination of insulin secretion defects and insulin resistance.
    Diabetes Obes Metab. 2024 Aug 9. doi: 10.1111/dom.15844.
    >> Share

  988. YALE JF, Major-Pedersen A, Catarig AM, Jain R, et al
    Real-world safety profile of once-weekly semaglutide in people with type 2 diabetes: Analysis of pooled data from the SemaglUtide Real-world Evidence (SURE) programme.
    Diabetes Obes Metab. 2024 Aug 8. doi: 10.1111/dom.15794.
    >> Share

  989. GOLL N, Moszka N, Kantartzis K, Preissl H, et al
    Oxytocin does not acutely improve glucose tolerance in men with type 2 diabetes.
    Diabetes Obes Metab. 2024 Aug 8. doi: 10.1111/dom.15812.
    >> Share

  990. REIS-BARBOSA PH, Marcondes-de-Castro I, Marinho TS, Aguila MB, et al
    The dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist tirzepatide effects on body weight evolution, adiponectin, insulin and leptin levels in the combination of obesity, type 2 diabetes and menopause in mice.
    Diabetes Obes Metab. 2024 Aug 7. doi: 10.1111/dom.15820.
    >> Share

  991. CHU L, Bradley RM, Auerbach P, Abitbol A, et al
    Real-world impact of adding a glucagon-like peptide-1 receptor agonist compared with basal insulin on metabolic targets in adults living with type 2 diabetes and chronic kidney disease already treated with a sodium-glucose co-transporter-2 inhibitor:
    Diabetes Obes Metab. 2024 Aug 7. doi: 10.1111/dom.15834.
    >> Share

  992. WANG Z, Lu J
    Adapting study designs of Mendelian randomization for disease complications: Insights from type 1 diabetes complications research.
    Diabetes Obes Metab. 2024 Aug 7. doi: 10.1111/dom.15813.
    >> Share

  993. ANDERSEN G, Eloy R, Heise T, Gaudier M, et al
    ADO09, a co-formulation of pramlintide and insulin A21G, lowers body weight versus insulin lispro in type 1 diabetes.
    Diabetes Obes Metab. 2024 Aug 7. doi: 10.1111/dom.15827.
    >> Share

  994. WAN EYF, Wong ZCT, Yan VKC, Chui CSL, et al
    Comparing the effectiveness of molnupiravir and nirmatrelvir-ritonavir in non-hospitalized and hospitalized COVID-19 patients with type 2 diabetes: A target trial emulation study.
    Diabetes Obes Metab. 2024 Aug 7. doi: 10.1111/dom.15830.
    >> Share

  995. HENNEY AE, Riley DR, Heague M, Hydes TJ, et al
    Sodium-glucose cotransporter 2 inhibitors reduce the risk of incident type 2 diabetes in people with heart failure without diabetes: An analysis of real-world, cohort data.
    Diabetes Obes Metab. 2024 Aug 7. doi: 10.1111/dom.15833.
    >> Share

  996. HOLMAN N, Young B, Gregg EW, Wareham N, et al
    Trends in hospitalization for cardio-renal disease and mortality in people with type 1 diabetes in England, 2009-2019.
    Diabetes Obes Metab. 2024 Aug 5. doi: 10.1111/dom.15783.
    >> Share

  997. MAJIC TENGG A, Cigrovski Berkovic M
    Immune checkpoint inhibitor-induced diabetes: Twists and turns of diabetology.
    Diabetes Obes Metab. 2024 Aug 2. doi: 10.1111/dom.15848.
    >> Share

  998. BABA Y, Watanabe S, Hayashi S, Sakai T, et al
    Semaglutide improves treatment satisfaction and eating behaviour in Japanese patients with type 2 diabetes mellitus.
    Diabetes Obes Metab. 2024 Aug 2. doi: 10.1111/dom.15823.
    >> Share

  999. DAVIDSON MB, Davidson SJ
    Real-world evidence for computerized insulin dose-adjustment algorithms in the effective use of continuous glucose monitoring by primary care clinicians.
    Diabetes Obes Metab. 2024;26:3475-3477.
    >> Share

  1000. XIE P, Abildlund MT, Baekdal TA, He X, et al
    A phase 1, randomized, double-blind, placebo-controlled trial investigating the pharmacokinetics, pharmacodynamics, safety and tolerability of oral semaglutide in healthy Chinese subjects.
    Diabetes Obes Metab. 2024;26:3068-3077.
    >> Share

  1001. TANGRI N, Ferguson TW, Bamforth RJ, Leon SJ, et al
    Machine learning for prediction of chronic kidney disease progression: Validation of the Klinrisk model in the CANVAS Program and CREDENCE trial.
    Diabetes Obes Metab. 2024;26:3371-3380.
    >> Share

  1002. CHEUNG JTK, Yang A, Wu H, Lau ESH, et al
    Association of dipeptidyl peptidase-4 inhibitor initiation at glycated haemoglobin <7.5% with reduced major clinical events mediated by low glycated haemoglobin variability.
    Diabetes Obes Metab. 2024;26:3339-3351.
    >> Share

  1003. RIESTER MR, Zullo AR, Joshi R, Daiello LA, et al
    Comparative safety and cardiovascular effectiveness of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in nursing homes.
    Diabetes Obes Metab. 2024;26:3403-3417.
    >> Share

  1004. MOHAMMEDI K, Hess S, McQueen M, Pigeyre M, et al
    Determinants of serious health outcome-free status in middle-aged and older people with dysglycaemia: Exploratory analysis of the ORIGIN trial.
    Diabetes Obes Metab. 2024;26:3272-3280.
    >> Share

  1005. HAKARIYA H, Ohnishi M, Tanimoto T
    Japan initiates market authorization of weight-loss drug semaglutide under universal health coverage, but with stringent prescription restrictions.
    Diabetes Obes Metab. 2024;26:3006-3008.
    >> Share

  1006. KLONOFF DC, Kim SH, Galindo RJ, Joseph JI, et al
    Risks of peri- and postoperative complications with glucagon-like peptide-1 receptor agonists.
    Diabetes Obes Metab. 2024;26:3128-3136.
    >> Share

  1007. CEFALO CMA, Riccio A, Succurro E, Marini MA, et al
    Frequency of prediabetes in individuals with increased adiposity and metabolically healthy or unhealthy phenotypes.
    Diabetes Obes Metab. 2024;26:3191-3199.
    >> Share

  1008. JONES KL, Marathe CS, Wu T, Rayner CK, et al
    Getting the measure of the pressure: Optimal assessment of the effects of glucagon-like peptide-1 receptor agonists on blood pressure.
    Diabetes Obes Metab. 2024;26:3003-3005.
    >> Share

  1009. ASLAM A, Chapman A, Urwin A, Ohol S, et al
    Real-world data from first UK Omnipod 5 users: A single-centre observational study.
    Diabetes Obes Metab. 2024;26:3462-3465.
    >> Share

  1010. DIMAKOS J, Cui Y, Platt RW, Renoux C, et al
    Fluoroquinolones and the risk of severe hypoglycaemia among sulphonylurea users: Population-based cohort study.
    Diabetes Obes Metab. 2024;26:3088-3098.
    >> Share

  1011. BERGENSTAL RM, Philis-Tsimikas A, Wysham C, Carr MC, et al
    Once-weekly insulin efsitora alfa: Design and rationale for the QWINT phase 3 clinical development programme.
    Diabetes Obes Metab. 2024;26:3020-3030.
    >> Share

  1012. SILVERII GA
    Optimizing metformin therapy in practice: Tailoring therapy in specific patient groups to improve tolerability, efficacy and outcomes.
    Diabetes Obes Metab. 2024;26 Suppl 3:42-54.
    >> Share

  1013. SOLINI A, Trico D
    Clinical efficacy and cost-effectiveness of metformin in different patient populations: A narrative review of real-world evidence.
    Diabetes Obes Metab. 2024;26 Suppl 3:20-30.
    >> Share

    July 2024
  1014. OULHAJ A, Aziz F, Suliman A, Eller K, et al
    Estimated glomerular filtration rate slope and risk of primary and secondary major adverse cardiovascular events and heart failure hospitalization in people with type 2 diabetes: An analysis of the EXSCEL trial.
    Diabetes Obes Metab. 2024 Jul 31. doi: 10.1111/dom.15817.
    >> Share

  1015. CHEN L, Wen B, Liu H, Wu H, et al
    Efficacy and safety of insulin glargine 300 U/mL in people with type 2 diabetes in China: The INITIATION study.
    Diabetes Obes Metab. 2024 Jul 29. doi: 10.1111/dom.15814.
    >> Share

  1016. BAK JCG, de Vries SAG, Serne EH, Groenwold RHH, et al
    Mortality patterns in Dutch diabetes outpatients.
    Diabetes Obes Metab. 2024 Jul 29. doi: 10.1111/dom.15750.
    >> Share

  1017. MOURA FA, Bellavia A, Berg DD, Melloni GEM, et al
    Risk of new-onset diabetes and efficacy of pharmacological weight loss therapy.
    Diabetes Obes Metab. 2024 Jul 26. doi: 10.1111/dom.15798.
    >> Share

  1018. SOLIMAN Y, Everett K, Shulman R, Austin PC, et al
    Persistent disparities in insulin pump uptake despite a universal pump programme for type 1 diabetes in Ontario, Canada.
    Diabetes Obes Metab. 2024 Jul 26. doi: 10.1111/dom.15799.
    >> Share

  1019. ZHENG K, Azhie A, You X, Naghibzadeh M, et al
    Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors for the treatment of diabetes mellitus in liver transplant recipients.
    Diabetes Obes Metab. 2024 Jul 26. doi: 10.1111/dom.15769.
    >> Share

  1020. PARK S, Ballreich J, Ward T, Shi L, et al
    Cost-effectiveness analysis of a digital diabetes-prevention programme versus an in-person diabetes-prevention programme in people with prediabetes in the United States.
    Diabetes Obes Metab. 2024 Jul 26. doi: 10.1111/dom.15807.
    >> Share

  1021. CHERUBINI V, Mozzillo E, Iafusco D, Bonfanti R, et al
    Follow-up and monitoring programme in children identified in early-stage type 1 diabetes during screening in the general population of Italy.
    Diabetes Obes Metab. 2024 Jul 26. doi: 10.1111/dom.15779.
    >> Share

  1022. KWAK SH, Han KA, Kim ES, Choi SH, et al
    Long-term efficacy and safety of enavogliflozin in Korean people with type 2 diabetes: A 52-week extension of a Phase 3 randomized controlled trial.
    Diabetes Obes Metab. 2024 Jul 26. doi: 10.1111/dom.15738.
    >> Share

  1023. CHAUDHRY K, Karalliedde J
    Chronic kidney disease in type 2 diabetes: The size of the problem, addressing residual renal risk and what we have learned from the CREDENCE trial.
    Diabetes Obes Metab. 2024 Jul 23. doi: 10.1111/dom.15765.
    >> Share

  1024. SHAMIM MA, Patil AN, Amin U, Roy T, et al
    Glucagon-like peptide-1 receptor agonists in adolescents with overweight or obesity with or without type 2 diabetes multimorbidity-a systematic review and network meta-analysis.
    Diabetes Obes Metab. 2024 Jul 23. doi: 10.1111/dom.15777.
    >> Share

  1025. IWAMOTO H, Kimura T, Fushimi Y, Iwamoto M, et al
    Effectiveness of switching from dipeptidyl peptidase-4 inhibitor to oral glucagon-like peptide-1 receptor agonist in Japanese participants with type 2 diabetes mellitus: Prospective observational study using propensity score matching.
    Diabetes Obes Metab. 2024 Jul 22. doi: 10.1111/dom.15784.
    >> Share

  1026. REZENDE LFM, de Almeida-Pittito B, Wahrhaftig J, Matos B, et al
    Time trends in hypertension and diabetes prevalence by body mass index categories in Brazilian adults from 2006 to 2023.
    Diabetes Obes Metab. 2024 Jul 22. doi: 10.1111/dom.15780.
    >> Share

  1027. SIRIYOTHA S, Lukkunaprasit T, Looareesuwan P, Kunakorntham P, et al
    Individual treatment effects of sodium-glucose co-transporter-2 inhibitors on the risk of chronic kidney disease in patients with type 2 diabetes: A counterfactual prediction model based on real-world data.
    Diabetes Obes Metab. 2024 Jul 22. doi: 10.1111/dom.15793.
    >> Share

  1028. CHEN AX, Fletcher R, Neuen BL, Neal B, et al
    An overview of the CANVAS Program and CREDENCE trial: The primary outcomes and key clinical implications for those managing patients with type 2 diabetes.
    Diabetes Obes Metab. 2024 Jul 22. doi: 10.1111/dom.15751.
    >> Share

  1029. LIN DS, Lo HY, Huang KC, Lin TT, et al
    Incidence and progression of diabetic retinopathy in patients treated with glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: A population-based cohort study.
    Diabetes Obes Metab. 2024 Jul 19. doi: 10.1111/dom.15788.
    >> Share

  1030. NEUPANE S, Florkowski WJ, Dhakal U, Dhakal C, et al
    Regional disparities in type 2 diabetes prevalence and associated risk factors in the United States.
    Diabetes Obes Metab. 2024 Jul 18. doi: 10.1111/dom.15797.
    >> Share

  1031. ESCOBAR VASCO MA, Fantaye SH, Raghunathan S, Solis-Herrera C, et al
    The potential role of finerenone in patients with type 1 diabetes and chronic kidney disease.
    Diabetes Obes Metab. 2024 Jul 18. doi: 10.1111/dom.15773.
    >> Share

  1032. ZHANG YY, Chen BX, Yang Q, Wan Q, et al
    The causal relationship between plasma protein-to-protein ratios and type 2 diabetes and its complications: Proteomics mendelian randomization study.
    Diabetes Obes Metab. 2024 Jul 18. doi: 10.1111/dom.15792.
    >> Share

  1033. PIONA C, Passanisi S, Bombaci B, Marigliano M, et al
    Time in tight range in automated insulin delivery system users: Real-world data from children and adolescents with type 1 diabetes.
    Diabetes Obes Metab. 2024 Jul 18. doi: 10.1111/dom.15791.
    >> Share

  1034. ZHAO L, Zeng Q, Zhou X, Tang L, et al
    Impact of non-alcoholic fatty liver disease and fibrosis on mortality and kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A multi-cohort longitudinal study.
    Diabetes Obes Metab. 2024 Jul 18. doi: 10.1111/dom.15758.
    >> Share

  1035. WANG W, Qiao J, Zhang L, Zhang J, et al
    Prevalence of very high cardiovascular disease risk in patients with type 2 diabetes mellitus: A population-based cross-sectional screening study.
    Diabetes Obes Metab. 2024 Jul 17. doi: 10.1111/dom.15763.
    >> Share

  1036. LI J, Zhang R, Zhang C, Liu G, et al
    Effects of intensive treatment of Chinese women with gestational diabetes on the risk of offspring being overweight from 3 to 8 years of age.
    Diabetes Obes Metab. 2024 Jul 15. doi: 10.1111/dom.15770.
    >> Share

  1037. LI J, Sun Y, Yu B, Cai L, et al
    Association patterns of ketone bodies with the risk of adverse outcomes according to diabetes status.
    Diabetes Obes Metab. 2024 Jul 15. doi: 10.1111/dom.15782.
    >> Share

  1038. RIZZI A, Tartaglione L, Lucaccini Paoli L, Leo ML, et al
    Evaluation of time in tight range and the glycaemia risk index in adults with type 1 diabetes using an advanced hybrid closed loop system: A 1-year real-world assessment.
    Diabetes Obes Metab. 2024 Jul 15. doi: 10.1111/dom.15766.
    >> Share

  1039. DONG W, Wan EYF, Fong DYT, Tan KC, et al
    Development and validation of 10-year risk prediction models of cardiovascular disease in Chinese type 2 diabetes mellitus patients in primary care using interpretable machine learning-based methods.
    Diabetes Obes Metab. 2024 Jul 15. doi: 10.1111/dom.15745.
    >> Share

  1040. SCHAEFER E, Lang A, Kupriyanova Y, Bodis KB, et al
    Adherence to the Dietary Approaches to Stop Hypertension (DASH) diet is associated with lower visceral and hepatic lipid content in recent-onset type 1 diabetes and type 2 diabetes.
    Diabetes Obes Metab. 2024 Jul 15. doi: 10.1111/dom.15772.
    >> Share

  1041. CHAN JCN, Yang A, Chu N, Chow E, et al
    Current type 2 diabetes guidelines: Individualized treatment and how to make the most of metformin.
    Diabetes Obes Metab. 2024 Jul 11. doi: 10.1111/dom.15700.
    >> Share

  1042. LI W, Qin R, Tang Z, Wang C, et al
    Inhibition of inflammation and apoptosis through the cyclic GMP-AMP synthase-stimulator of interferon genes pathway by stress granules after ALKBH5 demethylase activation during diabetic myocardial ischaemia-reperfusion injury.
    Diabetes Obes Metab. 2024 Jul 11. doi: 10.1111/dom.15743.
    >> Share

  1043. WEIR MR
    Cardiovascular risk reduction in type 2 diabetes: What the non-specialist needs to know about current guidelines.
    Diabetes Obes Metab. 2024 Jul 10. doi: 10.1111/dom.15764.
    >> Share

  1044. KAZIBWE R, Singleton M, Bancks MP, Namutebi J, et al
    Efficacy of Aspirin for primary prevention among adults with high-risk type 2 diabetes in the ACCORD trial.
    Diabetes Obes Metab. 2024 Jul 10. doi: 10.1111/dom.15753.
    >> Share

  1045. AL-OZAIRI E, Irshad M, AlKandari J, Mashankar A, et al
    Liver fibrosis and liver stiffness in patients with obesity and type 1 diabetes.
    Diabetes Obes Metab. 2024 Jul 10. doi: 10.1111/dom.15760.
    >> Share

  1046. ABBASI M, Heath B, McGinness L
    Advances in metformin-delivery systems for diabetes and obesity management.
    Diabetes Obes Metab. 2024 Jul 10. doi: 10.1111/dom.15759.
    >> Share

  1047. DE KLERK JA, Beulens JWJ, Bijkerk R, van Zonneveld AJ, et al
    Circulating small non-coding RNAs are associated with the insulin-resistant and obesity-related type 2 diabetes clusters.
    Diabetes Obes Metab. 2024 Jul 10. doi: 10.1111/dom.15786.
    >> Share

  1048. AUZANNEAU M, Seufert J, Zimny S, Haak T, et al
    Regional socioeconomic deprivation associated with the use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in adults with type 2 diabetes in Germany.
    Diabetes Obes Metab. 2024 Jul 9. doi: 10.1111/dom.15741.
    >> Share

  1049. BRIEDITIS E, Li X, Sundquist K, Jansaker F, et al
    Vulvovaginal candidiasis and type 2 diabetes: A nationwide retrospective cohort study.
    Diabetes Obes Metab. 2024 Jul 8. doi: 10.1111/dom.15757.
    >> Share

  1050. HOU T, Li Y, Yan Q, Zhou Y, et al
    The interaction effect between BMI, diabetes and age at diabetes onset on the risk of thyroid cancer: A population-based cohort study in Shanghai, China.
    Diabetes Obes Metab. 2024 Jul 8. doi: 10.1111/dom.15746.
    >> Share


  1051. Correction to "Cardiovascular health metrics defined by Life's Essential 8 scores and subsequent macrovascular and microvascular complications in individuals with type 2 diabetes: A prospective cohort study".
    Diabetes Obes Metab. 2024 Jul 8. doi: 10.1111/dom.15806.
    >> Share

  1052. HAN KA, Hwang YC, Moon SJ, Cho HC, et al
    Dual add-on therapy of gemigliptin and dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin alone: The SOLUTION 2 study.
    Diabetes Obes Metab. 2024 Jul 8. doi: 10.1111/dom.15717.
    >> Share

  1053. PETRIE JR
    Metformin beyond type 2 diabetes: Emerging and potential new indications.
    Diabetes Obes Metab. 2024 Jul 4. doi: 10.1111/dom.15756.
    >> Share

  1054. LI P, Kianmehr H, Guan D, Kulshreshtha A, et al
    Renal function as an effect modifier of intensive glucose control in delaying cognitive function decline among individuals with type 2 diabetes: A revisit to the ACCORD MIND trial.
    Diabetes Obes Metab. 2024 Jul 4. doi: 10.1111/dom.15744.
    >> Share

  1055. ZHANG D, Zhu J, Wewer Albrechtsen NJ, Rayner CK, et al
    Impairments of insulin and glucagon sensitivity in Chinese women with gestational diabetes mellitus.
    Diabetes Obes Metab. 2024 Jul 3. doi: 10.1111/dom.15740.
    >> Share

  1056. KHALAFI M, Habibi Maleki A, Symonds ME, Rosenkranz SK, et al
    The effects of intermittent fasting on body composition and cardiometabolic health in adults with prediabetes or type 2 diabetes: A systematic review and meta-analysis.
    Diabetes Obes Metab. 2024 Jul 2. doi: 10.1111/dom.15730.
    >> Share

  1057. SUN M, Lu Z, Chen WM, Lv S, et al
    Metformin monotherapy versus predominantly older non-metformin antidiabetic medications for cerebrovascular risk in early type 2 diabetes management.
    Diabetes Obes Metab. 2024 Jul 2. doi: 10.1111/dom.15739.
    >> Share

  1058. CHANG ML, Tai J, Cheng JS, Chen WT, et al
    Factors associated with treatment responses to pioglitazone in patients with steatotic liver disease: A 3-year prospective cohort study.
    Diabetes Obes Metab. 2024;26:2969-2978.
    >> Share

  1059. ALMEIDA OP, Fong Z, Hill Almeida LM, Sanfilippo FM, et al
    Cross-sectional, case-control and longitudinal associations between exposure to glucagon-like peptide-1 receptor agonists and the dispensing of antidepressants.
    Diabetes Obes Metab. 2024;26:2925-2932.
    >> Share

  1060. WHITE T, Selvarajah V, Wolfhagen-Sand F, Svangard N, et al
    Prediction of cardiovascular risk factors from retinal fundus photographs: Validation of a deep learning algorithm in a prospective non-interventional study in Kenya.
    Diabetes Obes Metab. 2024;26:2722-2731.
    >> Share

  1061. ZHANG J, Xu S, Liu X, Zhang J, et al
    Time trends and regional variation in utilization of antidiabetic medicines in China, 2015-2022.
    Diabetes Obes Metab. 2024;26:2752-2760.
    >> Share

  1062. BUTTICE L, Ghani M, Suthakar J, Gnanalingham S, et al
    The effect of sodium-glucose cotransporter-2 inhibitors on inflammatory biomarkers: A meta-analysis of randomized controlled trials.
    Diabetes Obes Metab. 2024;26:2706-2721.
    >> Share

  1063. GOLDENBERG RM
    A comment on 'Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: A systematic review and meta-analysis of randomized controlled trials'.
    Diabetes Obes Metab. 2024;26:2997-2999.
    >> Share

  1064. BAJAJ HS, Asbjornsdottir B, Bari TJ, Begtrup K, et al
    Once-weekly insulin icodec compared with daily basal insulin analogues in type 2 diabetes: Participant-level meta-analysis of the ONWARDS 1-5 trials.
    Diabetes Obes Metab. 2024 Jul 1. doi: 10.1111/dom.15726.
    >> Share

  1065. QUAST DR, Lancaster D, Xie C, Bound MJ, et al
    Randomised comparison of intravenous and subcutaneous routes of glucagon-like peptide-1 administration for lowering plasma glucose in hyperglycaemic subjects with type 2 diabetes.
    Diabetes Obes Metab. 2024 Jul 1. doi: 10.1111/dom.15736.
    >> Share

  1066. WERKMAN NCC, Driessen JHM, Klungel OH, Schaper NS, et al
    Incretin-based therapy and the risk of diabetic foot ulcers and related events.
    Diabetes Obes Metab. 2024 Jul 1. doi: 10.1111/dom.15721.
    >> Share

  1067. ZHANG X, Su Y, Zhu X
    The association of diabetes with progression of sleep-disordered breathing based on a prospective cohort.
    Diabetes Obes Metab. 2024 Jul 1. doi: 10.1111/dom.15742.
    >> Share

  1068. KAO YW, Yen KC, Chen SW, Chao TF, et al
    Early reduction in albuminuria is associated with a steeper 'dip' in initial estimated glomerular filtration rate but favourable long-term kidney outcomes in people with diabetes receiving sodium-glucose cotransporter-2 inhibitors.
    Diabetes Obes Metab. 2024 Jul 1. doi: 10.1111/dom.15734.
    >> Share

    June 2024
  1069. LUO M, Sun M, Wang T, Wei J, et al
    Type 2 diabetes, glycaemic traits, structural brain capacity and cognitive function: A Mendelian randomization analysis.
    Diabetes Obes Metab. 2024 Jun 25. doi: 10.1111/dom.15702.
    >> Share

  1070. HAGI K, Kochi K, Watada H, Kaku K, et al
    Differences in imeglimin response in subgroups of patients with type 2 diabetes stratified by data-driven cluster analysis: A post-hoc analysis of imeglimin clinical trial data.
    Diabetes Obes Metab. 2024 Jun 25. doi: 10.1111/dom.15716.
    >> Share

  1071. ABERER F, Haberl HC, Elsayed H, Pottler T, et al
    Accuracy of the professional flash glucose monitoring system FreeStyle Libre Pro in hospitalized individuals with type 2 diabetes mellitus receiving standardized basal-bolus insulin therapy.
    Diabetes Obes Metab. 2024 Jun 25. doi: 10.1111/dom.15719.
    >> Share

  1072. AERNOUTS C, Belde SPW, Lambrechts J, Mertens J, et al
    Metabolic dysfunction-associated steatotic liver disease is associated with worse time in ranges in type 1 diabetes.
    Diabetes Obes Metab. 2024 Jun 25. doi: 10.1111/dom.15723.
    >> Share

  1073. AYESH H, Suhail S, Ayesh S, Niswender K, et al
    Comparative efficacy and safety of weekly tirzepatide versus weekly insulin in type 2 diabetes: A network meta-analysis of randomized clinical trials.
    Diabetes Obes Metab. 2024 Jun 25. doi: 10.1111/dom.15725.
    >> Share

  1074. LIU M, Gu W, Chen L, Li Y, et al
    The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli-D randomized controlled trial.
    Diabetes Obes Metab. 2024 Jun 22. doi: 10.1111/dom.15724.
    >> Share

  1075. AJIE M, van Heck JIP, Verhulst CEM, Fabricius TW, et al
    Real-life hypoglycaemia partially blunts the inflammatory response to experimental hypoglycaemia in people with type 1 diabetes.
    Diabetes Obes Metab. 2024 Jun 20. doi: 10.1111/dom.15712.
    >> Share

  1076. HENNEY AE, Riley DR, O'Connor B, Hydes TJ, et al
    Denosumab, for osteoporosis, reduces the incidence of type 2 diabetes, risk of foot ulceration and all-cause mortality in adults, compared with bisphosphonates: An analysis of real-world, cohort data, with a systematic review and meta-analysis.
    Diabetes Obes Metab. 2024 Jun 20. doi: 10.1111/dom.15708.
    >> Share

  1077. LI P, Alkhuzam K, Brown J, Zhang Y, et al
    Association between low cognitive performance and diabetes-related health indicators across racial and ethnic groups in adults with diabetes.
    Diabetes Obes Metab. 2024 Jun 20. doi: 10.1111/dom.15715.
    >> Share

  1078. BONNET F, Cooper ME, Kopp L, Fouque D, et al
    A review of the latest real-world evidence studies in diabetic kidney disease: What have we learned about clinical practice and the clinical effectiveness of interventions?
    Diabetes Obes Metab. 2024 Jun 20. doi: 10.1111/dom.15710.
    >> Share

  1079. RYBA-STANISLAWOWSKA M, Slominski B, Mysliwiec M
    Association of KLF14 rs4731702 gene polymorphism with metabolic phenotype in young patients with type 1 diabetes.
    Diabetes Obes Metab. 2024 Jun 18. doi: 10.1111/dom.15707.
    >> Share

  1080. YANG Q, Zeng B, Hao J, Yang Q, et al
    Real-world glycaemic outcomes of automated insulin delivery in type 1 diabetes: A meta-analysis.
    Diabetes Obes Metab. 2024 Jun 18. doi: 10.1111/dom.15718.
    >> Share

  1081. GUPTA Y, Goyal A, Tandon N
    Implications of antenatal 1-hour postload plasma glucose (>/= 11.6 mmol/L) for postpartum diabetes and cardiometabolic risk assessment in women with gestational diabetes: Post hoc analysis from the CHIP-F study.
    Diabetes Obes Metab. 2024 Jun 18. doi: 10.1111/dom.15722.
    >> Share

  1082. ZHOU Y, Xu M, Yin X, Gong Y, et al
    Association between new-onset atrial fibrillation and dementia among individuals with type 2 diabetes.
    Diabetes Obes Metab. 2024 Jun 14. doi: 10.1111/dom.15714.
    >> Share

  1083. AL-ABDULLAH L, Ahern A, Welsh P, Logue J, et al
    A predictive model for medium-term weight loss response in people with type 2 diabetes engaging in behavioural weight management interventions.
    Diabetes Obes Metab. 2024 Jun 14. doi: 10.1111/dom.15706.
    >> Share

  1084. WELK B, McClure JA, Carter B, Clarke C, et al
    No association between semaglutide and postoperative pneumonia in people with diabetes undergoing elective surgery.
    Diabetes Obes Metab. 2024 Jun 11. doi: 10.1111/dom.15711.
    >> Share

  1085. TINTI D, Nobili C, Baretta I, Rosso A, et al
    Paediatric type 1 diabetes mellitus: A comparison between multi-injection therapy and advanced hybrid closed-loop pump in the first year after diabetes onset.
    Diabetes Obes Metab. 2024 Jun 11. doi: 10.1111/dom.15704.
    >> Share

  1086. KIM NH, Moon JS, Lee YH, Cho HC, et al
    Efficacy and tolerability of initial triple combination therapy with metformin, dapagliflozin and saxagliptin compared with stepwise add-on therapy in drug-naive patients with type 2 diabetes (TRIPLE-AXEL study): A multicentre, randomized, 104-week, o
    Diabetes Obes Metab. 2024 Jun 10. doi: 10.1111/dom.15705.
    >> Share

  1087. DEL PRATO S, Giorgino F, Szafranski K, Poon Y, et al
    Cost-utility analysis of a flash continuous glucose monitoring system in the management of people with type 2 diabetes mellitus on basal insulin therapy-An Italian healthcare system perspective.
    Diabetes Obes Metab. 2024 Jun 10. doi: 10.1111/dom.15703.
    >> Share

  1088. ZU C, Liu M, Wang G, Meng Q, et al
    Association between longitudinal changes in body composition and the risk of kidney outcomes in participants with overweight/obesity and type 2 diabetes mellitus.
    Diabetes Obes Metab. 2024 Jun 10. doi: 10.1111/dom.15699.
    >> Share

  1089. NAPOLI R, Nicolucci A, Larosa M, Rossi MC, et al
    Treatment intensification following glucagon-like peptide-1 receptor agonists in type 2 diabetes: Comparative effectiveness analyses between different basal insulins. RESTORE-G real-world study.
    Diabetes Obes Metab. 2024 Jun 10. doi: 10.1111/dom.15697.
    >> Share

  1090. TANG F, Wang W, Wang Y, Lee Y, et al
    Moderate resistance training reduces intermuscular adipose tissue and risk factors of atherosclerotic cardiovascular disease for elderly patients with type 2 diabetes.
    Diabetes Obes Metab. 2024 Jun 9. doi: 10.1111/dom.15684.
    >> Share

  1091. WINTHER JB, Holst JJ
    Glucagon agonism in the treatment of metabolic diseases including type 2 diabetes mellitus and obesity.
    Diabetes Obes Metab. 2024 Jun 9. doi: 10.1111/dom.15693.
    >> Share

  1092. ODUTAYO A, Cosentino F, Pratley RE, Dagogo-Jack S, et al
    Hypoglycaemia and kidney events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTIS CV trial.
    Diabetes Obes Metab. 2024 Jun 5. doi: 10.1111/dom.15687.
    >> Share

  1093. SUN CJ, Nguyen E, Prentki M, Rabasa-Lhoret R, et al
    The daunting task of recruiting insulin-treated patients living with type 2 diabetes mellitus for intensive lifestyle interventions.
    Diabetes Obes Metab. 2024 Jun 5. doi: 10.1111/dom.15688.
    >> Share

  1094. YOSHIDA Y, Zu Y, Fan B, Li S, et al
    Cumulative effect of metabolic risk factors on left ventricular geometry in those with versus without early-onset type 2 diabetes or prediabetes: The Coronary Artery Risk Development in Young Adults (CARDIA) study.
    Diabetes Obes Metab. 2024 Jun 4. doi: 10.1111/dom.15681.
    >> Share

  1095. MARQUES P, Mavrakanas TA, Guida J, Gedeon T, et al
    Utilizing synchronous care to improve cardiovascular and renal health among patients with type 2 diabetes: Proof-of-concept results from the DECIDE-CV clinical programme.
    Diabetes Obes Metab. 2024 Jun 3. doi: 10.1111/dom.15691.
    >> Share

  1096. LONG J, Fang Q, Shi Z, Miao Z, et al
    Integrated biomarker profiling for predicting the response of type 2 diabetes to metformin.
    Diabetes Obes Metab. 2024 Jun 3. doi: 10.1111/dom.15689.
    >> Share

  1097. GONZALEZ-VIDAL T, Rivas-Otero D, Ramos-Ruiz G, Agueria-Cabal P, et al
    Impact of the basal/bolus ratio on continuous glucose monitoring parameters in patients with type 1 diabetes.
    Diabetes Obes Metab. 2024 Jun 3. doi: 10.1111/dom.15690.
    >> Share

  1098. HE Y, Kunutsor SK, Kingsnorth AP, Gillies C, et al
    Differential associations of risk factors with severe and non-severe hypoglycaemia: the Hypoglycaemia Assessment Tool prospective observational study in people with insulin-treated type 1 diabetes and type 2 diabetes.
    Diabetes Obes Metab. 2024 Jun 3. doi: 10.1111/dom.15677.
    >> Share

  1099. THOMAS L, Martel E, Rist W, Uphues I, et al
    The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection.
    Diabetes Obes Metab. 2024;26:2368-2378.
    >> Share

  1100. MILANOVIC S, Dedic N, Lew R, Burton D, et al
    TAAR1 agonist ulotaront delays gastric emptying of solids in patients with schizophrenia and concurrent metabolic syndrome with prediabetes.
    Diabetes Obes Metab. 2024;26:2466-2475.
    >> Share

  1101. LIU Y, Kimita W, Shamaitijiang X, Skudder-Hill L, et al
    Intra-pancreatic fat is associated with continuous glucose monitoring metrics.
    Diabetes Obes Metab. 2024;26:2359-2367.
    >> Share

  1102. STRATMANN B, Eggers B, Mattern Y, de Carvalho TS, et al
    Maladaptive response following glucose overload in GLUT4-overexpressing H9C2 cardiomyoblasts.
    Diabetes Obes Metab. 2024;26:2379-2389.
    >> Share

  1103. LUIZ MM, Maximo RO, de Oliveira DC, Ramirez PC, et al
    Could poor glycaemic control be a predictor of walking speed decline in older adults? Evidence from the English Longitudinal Study of Ageing.
    Diabetes Obes Metab. 2024;26:2349-2358.
    >> Share

  1104. PULKKINEN MA, Varimo TJ, Hakonen ET, Hero MT, et al
    During an 18-month course of automated insulin delivery treatment, children aged 2 to 6 years achieve and maintain a higher time in tight range.
    Diabetes Obes Metab. 2024;26:2431-2438.
    >> Share

  1105. ABDELMALEK MF, Harrison SA, Sanyal AJ
    The role of glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatohepatitis.
    Diabetes Obes Metab. 2024;26:2001-2016.
    >> Share

  1106. HASHEMY H, Nguyen A, Khafagy R, Roshandel D, et al
    Analyses of potential causal contributors to increased waist/hip ratio-associated cardiometabolic disease: A combined and sex-stratified Mendelian randomization study.
    Diabetes Obes Metab. 2024;26:2284-2291.
    >> Share

  1107. TOSHIMITSU T, Gotou A, Sashihara T, Hojo K, et al
    Ingesting probiotic yogurt containing Lactiplantibacillus plantarum OLL2712 improves glycaemic control in adults with prediabetes in a randomized, double-blind, placebo-controlled trial.
    Diabetes Obes Metab. 2024;26:2239-2247.
    >> Share

  1108. SILVERII GA, Marinelli C, Mannucci E, Rotella F, et al
    Glucagon-like peptide-1 receptor agonists and mental health: A meta-analysis of randomized controlled trials.
    Diabetes Obes Metab. 2024;26:2505-2508.
    >> Share

  1109. PETERMANN-ROCHA F, Apolinar E, Nazar G, Diaz-Toro F, et al
    Associations of diabesity with all-cause and cardiovascular disease mortality: Findings from the Mexico City Prospective Study.
    Diabetes Obes Metab. 2024;26:2199-2208.
    >> Share

    May 2024
  1110. KHAWAGI WY, Al-Kuraishy HM, Hussein NR, Al-Gareeb AI, et al
    Depression and type 2 diabetes: A causal relationship and mechanistic pathway.
    Diabetes Obes Metab. 2024 May 27. doi: 10.1111/dom.15630.
    >> Share

  1111. BAILEY CJ
    Metformin: Therapeutic profile in the treatment of type 2 diabetes.
    Diabetes Obes Metab. 2024 May 24. doi: 10.1111/dom.15663.
    >> Share

  1112. BUCKLEY A, Suliman S, Allum M, Mohammed N, et al
    Real world use of tirzepatide in the treatment of type 2 diabetes in an Arab population.
    Diabetes Obes Metab. 2024 May 24. doi: 10.1111/dom.15680.
    >> Share

  1113. WANG D, Chen Z, Wu Y, Ren J, et al
    Association between two novel anthropometric measures and type 2 diabetes in a Chinese population.
    Diabetes Obes Metab. 2024 May 24. doi: 10.1111/dom.15651.
    >> Share

  1114. SUN Y, Li W, Zhou Y, Wang B, et al
    Long-term changes in frailty and incident type 2 diabetes: A prospective cohort study based on the UK Biobank.
    Diabetes Obes Metab. 2024 May 24. doi: 10.1111/dom.15676.
    >> Share

  1115. SVENSSON CH, Fabricius TW, Verhulst CEM, Kristensen PL, et al
    Association between recent exposure to continuous glucose monitoring-recorded hypoglycaemia and counterregulatory and symptom responses to subsequent controlled hypoglycaemia in people with type 1 diabetes.
    Diabetes Obes Metab. 2024 May 22. doi: 10.1111/dom.15649.
    >> Share

  1116. SUGIMOTO T, Saji N, Omura T, Tokuda H, et al
    Cross-sectional association of continuous glucose monitoring-derived metrics with cerebral small vessel disease in older adults with type 2 diabetes.
    Diabetes Obes Metab. 2024 May 19. doi: 10.1111/dom.15659.
    >> Share

  1117. TSUKAMOTO S, Kobayashi K, Toyoda M, Tone A, et al
    Effect of preceding drug therapy on the renal and cardiovascular outcomes of combined sodium-glucose cotransporter-2 inhibitor and glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes and chronic kidney disease.
    Diabetes Obes Metab. 2024 May 19. doi: 10.1111/dom.15652.
    >> Share

  1118. LEITER LA, Raal FJ, Schwartz GG, Koenig W, et al
    Inclisiran in individuals with diabetes or obesity: Post hoc pooled analyses of the ORION-9, ORION-10 and ORION-11 Phase 3 randomized trials.
    Diabetes Obes Metab. 2024 May 17. doi: 10.1111/dom.15650.
    >> Share

  1119. SEGEV O, Raz I, Gerstein HC, Aviezer H, et al
    Development and first-stage validation of a digital version of the Digit Symbol Substitution test for use in assessing cognitive function in older people with diabetes.
    Diabetes Obes Metab. 2024 May 17. doi: 10.1111/dom.15657.
    >> Share

  1120. BUCKERIDGE C, Tsamandouras N, Carvajal-Gonzalez S, Brown LS, et al
    Once-daily oral small-molecule glucagon-like peptide-1 receptor agonist lotiglipron (PF-07081532) for type 2 diabetes and obesity: Two randomized, placebo-controlled, multiple-ascending-dose Phase 1 studies.
    Diabetes Obes Metab. 2024 May 16. doi: 10.1111/dom.15643.
    >> Share

  1121. GUO K, Ye J, Li J, Huang J, et al
    Effects of gut microbiome on type 1 diabetes susceptibility and complications: A large-scale bidirectional Mendelian randomization and external validation study.
    Diabetes Obes Metab. 2024 May 16. doi: 10.1111/dom.15658.
    >> Share

  1122. BOURRON O, Mohammedi K, De Keizer J, Schneider F, et al
    A prospective observational study to evaluate a possible relationship between vitamin K antagonist therapy and risk of peripheral arterial disease in patients with type 2 diabetes.
    Diabetes Obes Metab. 2024 May 15. doi: 10.1111/dom.15656.
    >> Share

  1123. GREENE E, Green CL, Hurst J, MacIver NJ, et al
    Metformin use associated with lower rate of hospitalization for influenza in individuals with diabetes.
    Diabetes Obes Metab. 2024 May 14. doi: 10.1111/dom.15655.
    >> Share

  1124. HU S, Shi C, Ma Y, Wang S, et al
    Cost-utility analysis and drug pricing for tirzepatide for type 2 diabetes in the Chinese market compared with semaglutide.
    Diabetes Obes Metab. 2024 May 13. doi: 10.1111/dom.15645.
    >> Share

  1125. ALMUALLEM S, Ali AK, Vourtzoumis P, Demyttenaere S, et al
    Validation of the Individualized Metabolic Surgery score in predicting long-term remission of diabetes after duodenal switch-type procedures.
    Diabetes Obes Metab. 2024 May 9. doi: 10.1111/dom.15647.
    >> Share

  1126. KANAOKA T, Wakui H, Yano Y, Nagasu H, et al
    Factors affecting the sodium-glucose cotransporter 2 inhibitors-related initial decline in glomerular filtration rate and its possible effect on kidney outcome in chronic kidney disease with type 2 diabetes: The Japan Chronic Kidney Disease Database.
    Diabetes Obes Metab. 2024 May 8. doi: 10.1111/dom.15611.
    >> Share

  1127. MORIOKA T, Takeuchi M, Ozeki A, Emoto M, et al
    A randomized, double-blind trial assessing the efficacy and safety of two doses of dulaglutide in Japanese participants with type 2 diabetes (AWARD-JPN).
    Diabetes Obes Metab. 2024 May 7. doi: 10.1111/dom.15644.
    >> Share

  1128. SHIKAMURA M, Takayama A, Takeuchi M, Kawakami K, et al
    Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in improvement of fatty liver index in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease: A
    Diabetes Obes Metab. 2024 May 6. doi: 10.1111/dom.15632.
    >> Share

  1129. TAKAHASHI A, Nomoto H, Onishi K, Manda S, et al
    A comparative study of the effects of imeglimin add-on or metformin dose escalation on glycaemic variability in subjects with type 2 diabetes treated with low-dose metformin (MEGMI-CGM study).
    Diabetes Obes Metab. 2024 May 3. doi: 10.1111/dom.15639.
    >> Share

  1130. YANG M, Yue H, Xu Q, Shao S, et al
    Pioglitazone reduces serum ketone bodies in sodium-glucose cotransporter-2 inhibitor-treated non-obese type 2 diabetes: A single-centre, randomized, crossover trial.
    Diabetes Obes Metab. 2024 May 3. doi: 10.1111/dom.15641.
    >> Share

  1131. SMATI S, Sotin T, Deniel P, Ducheix S, et al
    Empagliflozin mitigates metabolic dysfunction-associated steatotic liver disease by reducing de novo lipogenesis in a mouse model of lipoatrophic diabetes.
    Diabetes Obes Metab. 2024 May 3. doi: 10.1111/dom.15634.
    >> Share

  1132. TIRADO-AGUILAR OA, Martinez-Cruz N, Arce-Sanchez L, Borboa-Olivares H, et al
    Earlier detection of gestational diabetes impacts on medication requirements, neonatal and maternal outcomes.
    Diabetes Obes Metab. 2024 May 3. doi: 10.1111/dom.15633.
    >> Share

  1133. XIANG C, Sun Y, Luo Y, Xie C, et al
    Gastric emptying is slower in women than men with type 2 diabetes and impacts on postprandial glycaemia.
    Diabetes Obes Metab. 2024 May 2. doi: 10.1111/dom.15635.
    >> Share

  1134. SUN Y, Luo Y, Xiang C, Xie C, et al
    Gastric emptying in newly diagnosed, treatment-naive Han Chinese with type 2 diabetes and the impact of 4-week insulin pump therapy.
    Diabetes Obes Metab. 2024 May 2. doi: 10.1111/dom.15626.
    >> Share

  1135. CHEN J, Li YT, Niu Z, He Z, et al
    Investigating the causal association of generalized and abdominal obesity with microvascular complications in patients with type 2 diabetes: A community-based prospective study.
    Diabetes Obes Metab. 2024 May 2. doi: 10.1111/dom.15598.
    >> Share

  1136. LI S, Pan S, Jiang S, Shin JI, et al
    Prescription medication use among patients with type 2 diabetes in the United States: 1999-2020.
    Diabetes Obes Metab. 2024 May 2. doi: 10.1111/dom.15619.
    >> Share

  1137. LASSEN MCH, Johansen ND, Modin D, Nealon J, et al
    Effects of high-dose versus standard-dose quadrivalent influenza vaccine among patients with diabetes: A post-hoc analysis of the DANFLU-1 trial.
    Diabetes Obes Metab. 2024;26:1821-1829.
    >> Share

  1138. THIRUMALAI A, Chao JH, Kaleru T, Dong X, et al
    Bridging dose of U-100 glargine with first dose of insulin degludec improves glycaemia in the 48 h after transition in twice-daily glargine users.
    Diabetes Obes Metab. 2024;26:1868-1876.
    >> Share

  1139. TAN YH, Tan WL, Eichinger V, Ruch B, et al
    Blood glucose control using a mobile health application in Singapore, Philippines and Hong Kong: a retrospective real-world data analysis.
    Diabetes Obes Metab. 2024;26:1990-1992.
    >> Share

  1140. WU Y, Zhang C, Duan S, Li Y, et al
    TEAD1, MYO7A and NDUFC2 are novel functional genes associated with glucose metabolism in BXD recombinant inbred population.
    Diabetes Obes Metab. 2024;26:1775-1788.
    >> Share

  1141. SALERNO PRVO, Qian A, Dong W, Deo S, et al
    County-level socio-environmental factors and obesity prevalence in the United States.
    Diabetes Obes Metab. 2024;26:1766-1774.
    >> Share

  1142. YEW MJ, Heywood SE, Ng J, West OM, et al
    ACAD10 is not required for metformin's metabolic actions or for maintenance of whole-body metabolism in C57BL/6J mice.
    Diabetes Obes Metab. 2024;26:1731-1745.
    >> Share

  1143. GILBERT MP, Skelly J, Hernandez AF, Green JB, et al
    Effect of albiglutide on cardiovascular outcomes in older adults: A post hoc analysis of a randomized controlled trial.
    Diabetes Obes Metab. 2024;26:1714-1722.
    >> Share

  1144. DIALLO A, Diallo MF, Carlos-Bolumbu M, Galtier F, et al
    Uric acid-lowering effects of sodium-glucose cotransporter 2 inhibitors for preventing cardiovascular events and mortality: A systematic review and meta-analysis.
    Diabetes Obes Metab. 2024;26:1980-1985.
    >> Share

  1145. CHAN SY, Zhang H, Wong JT, Chang HF, et al
    Higher early pregnancy plasma myo-inositol associates with increased postprandial glycaemia later in pregnancy: Secondary analyses of the NiPPeR randomized controlled trial.
    Diabetes Obes Metab. 2024;26:1658-1669.
    >> Share

  1146. DE GERMAY S, Pambrun E, Pariente A, Grenet G, et al
    Use of sodium-glucose cotransporter-2 inhibitors in France: Analysis of French nationwide health insurance database.
    Diabetes Obes Metab. 2024;26:1678-1686.
    >> Share

  1147. SOURIJ C, Oulhaj A, Aziz F, Tripolt NJ, et al
    Impact of glycaemic status on the cardiac effects of empagliflozin when initiated immediately after myocardial infarction: A post-hoc analysis of the EMMY trial.
    Diabetes Obes Metab. 2024;26:1971-1975.
    >> Share

  1148. VERNSTROM L, Gullaksen S, Sorensen SS, Funck KL, et al
    Separate and combined effects of empagliflozin and semaglutide on vascular function: A 32-week randomized trial.
    Diabetes Obes Metab. 2024;26:1624-1635.
    >> Share

    April 2024
  1149. SU J, Fan X, Li M, Yu H, et al
    Association of lifestyle with reduced stroke risk in 41 314 individuals with diabetes: Two prospective cohort studies in China.
    Diabetes Obes Metab. 2024 Apr 29. doi: 10.1111/dom.15606.
    >> Share

  1150. SEUFERT J, Freemantle N, Guja C, Haluzik M, et al
    Real-life effectiveness of iGlarLixi (insulin glargine 100 U/mL and lixisenatide) in people with type 2 diabetes according to prior insulin use.
    Diabetes Obes Metab. 2024 Apr 29. doi: 10.1111/dom.15609.
    >> Share

  1151. NAKHLEH A, Abdul-Ghani M, Gazit S, Gross A, et al
    Real-world effectiveness of sodium-glucose cotransporter-2 inhibitors on the progression of chronic kidney disease in patients without diabetes, with and without albuminuria.
    Diabetes Obes Metab. 2024 Apr 28. doi: 10.1111/dom.15623.
    >> Share

  1152. MICHALOPOULOU M, Piernas C, Jebb SA, Gao M, et al
    Association of gestational diabetes with long-term risk of premature mortality, and cardiovascular outcomes and risk factors: A retrospective cohort analysis in the UK Biobank.
    Diabetes Obes Metab. 2024 Apr 28. doi: 10.1111/dom.15612.
    >> Share

  1153. REED J, Dong T, Eaton E, Friswold J, et al
    Continuous glucose monitoring for glycaemic control and cardiovascular risk reduction in patients with type 2 diabetes not on insulin therapy: A clinical trial.
    Diabetes Obes Metab. 2024 Apr 28. doi: 10.1111/dom.15608.
    >> Share

  1154. IWAMOTO Y, Kimura T, Shimoda M, Morimoto Y, et al
    C-peptide index at 2 h post-meal is a useful predictor of endogenous insulin secretory capacity and withdrawal from insulin therapy in subjects with type 2 diabetes.
    Diabetes Obes Metab. 2024 Apr 22. doi: 10.1111/dom.15595.
    >> Share

  1155. BIAN YC, Meng J, Hu T, Ma S, et al
    Biotransformation and disposition characteristics of HSK7653, a novel long-acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
    Diabetes Obes Metab. 2024 Apr 22. doi: 10.1111/dom.15605.
    >> Share

  1156. KIM JH, Lyu YS, Kim B, Kim MK, et al
    Cardiorenal outcomes and mortality after sodium-glucose cotransporter-2 inhibitor initiation in type 2 diabetes patients with percutaneous coronary intervention history.
    Diabetes Obes Metab. 2024 Apr 21. doi: 10.1111/dom.15565.
    >> Share


  1157. Correction to "Defining diabetes status using medication groups in Medicare data: Trends in prescribing diabetes medications to patients without a diabetes diagnosis over time".
    Diabetes Obes Metab. 2024 Apr 19. doi: 10.1111/dom.15618.
    >> Share

  1158. MALIK RA, Hwu CM, Jammah AA, Arteaga-Diaz JM, et al
    Real-world effectiveness and safety of insulin glargine 100 U/mL plus lixisenatide in adults with type 2 diabetes: An international, multicentre, 12-month, prospective observational study.
    Diabetes Obes Metab. 2024 Apr 18. doi: 10.1111/dom.15599.
    >> Share

  1159. WILSON M, Al-Hamid A, Abbas I, Birkett J, et al
    Identification of diagnostic biomarkers used in the diagnosis of cardiovascular diseases and diabetes mellitus: A systematic review of quantitative studies.
    Diabetes Obes Metab. 2024 Apr 18. doi: 10.1111/dom.15593.
    >> Share

  1160. HU Y, Li X, Wang X, Ma H, et al
    Smoking timing, genetic susceptibility and the risk of incident type 2 diabetes: A cohort study from the UK Biobank.
    Diabetes Obes Metab. 2024 Apr 15. doi: 10.1111/dom.15603.
    >> Share

  1161. DE OLIVEIRA COSTA J, Lin J, Milder TY, Greenfield JR, et al
    Geographic variation in sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist use in people with type 2 diabetes in New South Wales, Australia.
    Diabetes Obes Metab. 2024 Apr 15. doi: 10.1111/dom.15597.
    >> Share

  1162. JEONG SI, Ban MS, Hwang JG, Park MK, et al
    The effect of renal function on the pharmacokinetics and pharmacodynamics of enavogliflozin, a potent and selective sodium-glucose cotransporter-2 inhibitor, in type 2 diabetes.
    Diabetes Obes Metab. 2024 Apr 15. doi: 10.1111/dom.15573.
    >> Share

  1163. WANG Y, Jiang C, Dong X, Chen M, et al
    Combination of retagliptin and henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, active-controlled, phase 3 trial.
    Diabetes Obes Metab. 2024 Apr 15. doi: 10.1111/dom.15596.
    >> Share

  1164. DENG S, Hu X, Zhang X
    Association of single-point insulin sensitivity estimator index (SPISE) with future cardiovascular outcomes in patients with type 2 diabetes.
    Diabetes Obes Metab. 2024 Apr 15. doi: 10.1111/dom.15600.
    >> Share

  1165. IRLIK K, Aldosari H, Hendel M, Kwiendacz H, et al
    Artificial intelligence-enhanced electrocardiogram analysis for identifying cardiac autonomic neuropathy in patients with diabetes.
    Diabetes Obes Metab. 2024 Apr 11. doi: 10.1111/dom.15578.
    >> Share

  1166. GRANDO ALVES G, Cunha L, Henkes Machado R, Lins de Menezes V, et al
    Safety and efficacy of teplizumab in the treatment of type 1 diabetes mellitus: An updated systematic review and meta-analysis of randomized controlled trials.
    Diabetes Obes Metab. 2024 Apr 11. doi: 10.1111/dom.15581.
    >> Share

  1167. GUO L, Tian F, Liu L, Chen M, et al
    Retagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial.
    Diabetes Obes Metab. 2024 Apr 11. doi: 10.1111/dom.15601.
    >> Share

  1168. GUO L, Xi Y, Li L, Guo K, et al
    Real-world treatment satisfaction with dulaglutide, and its influencing factors, in a Chinese population with type 2 diabetes mellitus.
    Diabetes Obes Metab. 2024 Apr 10. doi: 10.1111/dom.15590.
    >> Share

  1169. SAID F, Arnott C, Voors AA, Heerspink HJL, et al
    Prediction of new-onset heart failure in patients with type 2 diabetes derived from ALTITUDE and CANVAS.
    Diabetes Obes Metab. 2024 Apr 8. doi: 10.1111/dom.15592.
    >> Share

  1170. SIMON SL, Snell-Bergeon JK, Schafer M, Barker AJ, et al
    Sleep duration and association with cardiometabolic health in adolescents and adults with type 1 diabetes: Results from the BCQR-T1D study.
    Diabetes Obes Metab. 2024 Apr 8. doi: 10.1111/dom.15582.
    >> Share

  1171. VIVIAN EM, Chewning BA, Voils CI, Brown RL, et al
    Healthy Outcomes through Peer Educators: Feasibility of a peer support diabetes prevention programme for African-American grandmother caregivers.
    Diabetes Obes Metab. 2024 Apr 3. doi: 10.1111/dom.15574.
    >> Share

  1172. CHEN GL, Liu Y, Gao XF, Wu KQ, et al
    Safety, tolerability, pharmacokinetic, pharmacodynamic and immunogenicity profiles of Exendin-4-IgG4-Fc in healthy subjects: A phase 1, single-centre, randomized, double-blind, dose escalation study.
    Diabetes Obes Metab. 2024;26:1395-1406.
    >> Share

  1173. GUY A, Azab AN, Liberty IF, Afawi Z, et al
    Adherence to liraglutide among individuals with overweight and obesity: Patient characteristics and clinical measures.
    Diabetes Obes Metab. 2024;26:1346-1354.
    >> Share

  1174. LAU D, Gamble JM
    Suicidality among users of glucagon-like peptide-1 receptor agonists: An emerging signal?
    Diabetes Obes Metab. 2024;26:1150-1156.
    >> Share

  1175. HOPE DCD, Ansari S, Choudhury S, Alexiadou K, et al
    Adaptive infusion of a glucagon-like peptide-1/glucagon receptor co-agonist G3215, in adults with overweight or obesity: Results from a phase 1 randomized clinical trial.
    Diabetes Obes Metab. 2024;26:1479-1491.
    >> Share

  1176. BAZYDLO-GUZENDA K, Jarus-Dziedzic K, Gierczak-Pachulska A, Buda P, et al
    First-in-human study of CPL207280, a novel G-protein-coupled receptor 40/free fatty acid receptor 1 agonist, in healthy volunteers after single and multiple administration.
    Diabetes Obes Metab. 2024;26:1376-1385.
    >> Share

  1177. CUKIERMAN-YAFFE T, Ramasundarahettige C, Bosch J, Gerstein HC, et al
    Effect of basal insulin and omega 3 fatty acids on cognitive impairment in dysglycaemia: An exploratory analysis of the ORIGIN trial.
    Diabetes Obes Metab. 2024;26:1180-1187.
    >> Share

  1178. NERILD HH, Bronden A, Haddouchi AE, Ellegaard AM, et al
    Elucidating the glucose-lowering effect of the bile acid sequestrant sevelamer.
    Diabetes Obes Metab. 2024;26:1252-1263.
    >> Share

  1179. TOMLINSON JW
    Bardet-Biedl syndrome: A focus on genetics, mechanisms and metabolic dysfunction.
    Diabetes Obes Metab. 2024;26 Suppl 2:13-24.
    >> Share

  1180. GOLUBIC R, Kennet J, Parker V, Robertson D, et al
    Dual glucagon-like peptide-1 and glucagon receptor agonism reduces energy intake in type 2 diabetes with obesity.
    Diabetes Obes Metab. 2024 Apr 1. doi: 10.1111/dom.15579.
    >> Share

  1181. LUO J, Zhao X, Li Q, Zou B, et al
    Evaluating the global impact of low physical activity on type 2 diabetes: Insights from the global burden of disease 2019 study.
    Diabetes Obes Metab. 2024 Apr 1. doi: 10.1111/dom.15568.
    >> Share

  1182. SAFDAR NZ, Alobaid AM, Hopkins M, Dempsey PC, et al
    Short, frequent, light-intensity walking activity improves postprandial vascular-inflammatory biomarkers in people with type 1 diabetes: The SIT-LESS randomized controlled trial.
    Diabetes Obes Metab. 2024 Apr 1. doi: 10.1111/dom.15564.
    >> Share

  1183. KUHNE T, Wallace E, Herzig D, Helleputte S, et al
    Combined intake of caffeine and low-dose glucose to reduce exercise-related hypoglycaemia in individuals with type 1 diabetes on ultra-long-acting insulin degludec: A randomized, controlled, double-blind, cross-over trial.
    Diabetes Obes Metab. 2024 Apr 1. doi: 10.1111/dom.15580.
    >> Share

  1184. DARSALIA V, Vercalsteren E, Karampatsi D, Romanitan MO, et al
    The need for registry-based studies in diabetes and stroke: A unique opportunity to understand whether diabetic treatments improve post-stroke outcome.
    Diabetes Obes Metab. 2024 Apr 1. doi: 10.1111/dom.15577.
    >> Share

  1185. CHRISTOFIDES EA, Puente O, Norwood P, Denham D, et al
    Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus(R)) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label study.
    Diabetes Obes Metab. 2024 Apr 1. doi: 10.1111/dom.15560.
    >> Share

  1186. HUANG ZG, Gao JW, Zhang HF, You S, et al
    Cardiovascular health metrics defined by Life's Essential 8 scores and subsequent macrovascular and microvascular complications in individuals with type 2 diabetes: A prospective cohort study.
    Diabetes Obes Metab. 2024 Apr 1. doi: 10.1111/dom.15583.
    >> Share

  1187. TALHA KM, Green J, Filippatos G, Pocock S, et al
    Impact of empagliflozin on insulin needs in patients with heart failure and diabetes: An EMPEROR-Pooled analysis.
    Diabetes Obes Metab. 2024 Apr 1. doi: 10.1111/dom.15572.
    >> Share

  1188. MAHMOUD F, Mueller T, Mullen A, Sainsbury C, et al
    Patterns of initial and first-intensifying antidiabetic drug utilization among patients with type 2 diabetes mellitus in Scotland, 2010-2020: A retrospective population-based cohort study.
    Diabetes Obes Metab. 2024 Apr 1. doi: 10.1111/dom.15584.
    >> Share

  1189. ANSON M, Henney AE, Zhao SS, Ibarburu GH, et al
    Effect of combination pioglitazone with sodium-glucose cotransporter-2 inhibitors or glucagon-like peptide-1 receptor agonists on outcomes in type 2 diabetes: A systematic review, meta-analysis, and real-world study from an international federated dat
    Diabetes Obes Metab. 2024 Apr 1. doi: 10.1111/dom.15576.
    >> Share

  1190. KANBAY M, Copur S, Topcu AU, Guldan M, et al
    An update review of post-transplant diabetes mellitus: Concept, risk factors, clinical implications and management.
    Diabetes Obes Metab. 2024 Apr 1. doi: 10.1111/dom.15575.
    >> Share

  1191. HODGSON A, Gillies CL, Highton P, Haddon L, et al
    Risk of lower extremity amputation in patients with type 2 diabetes mellitus and peripheral arterial disease receiving sodium-glucose cotransporter-2 inhibitors versus other medications: A systematic review and meta-analysis of observational cohort st
    Diabetes Obes Metab. 2024 Apr 1. doi: 10.1111/dom.15571.
    >> Share

    March 2024

  1192. Correction to 'In people with type 2 diabetes, sarcopenia is associated with the incidence of cardiovascular disease: A prospective cohort study from the UK Biobank'.
    Diabetes Obes Metab. 2024 Mar 27. doi: 10.1111/dom.15591.
    >> Share

  1193. SUZUKI Y, Kaneko H, Nagasawa H, Okada A, et al
    Comparison of estimated glomerular filtration rate change with sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists among people with diabetes: A propensity-score matching study.
    Diabetes Obes Metab. 2024 Mar 26. doi: 10.1111/dom.15561.
    >> Share

  1194. CARIOU B, Linge J, Neeland IJ, Dahlqvist Leinhard O, et al
    Effect of tirzepatide on body fat distribution pattern in people with type 2 diabetes.
    Diabetes Obes Metab. 2024 Mar 26. doi: 10.1111/dom.15566.
    >> Share

  1195. ZHANG Y, Yang D, Jia Q, Yan J, et al
    The effect of glucagon-like peptide-1 receptor agonists on cardiac function and structure in patients with or without type 2 diabetes mellitus: An updated systematic review and meta-analysis.
    Diabetes Obes Metab. 2024 Mar 26. doi: 10.1111/dom.15557.
    >> Share

  1196. BELL DSH, Jerkins T
    The potential for improved outcomes in the prevention and therapy of diabetic kidney disease through 'stacking' of drugs from different classes.
    Diabetes Obes Metab. 2024 Mar 22. doi: 10.1111/dom.15559.
    >> Share

  1197. RODBARD HW, Barnard-Kelly K, Pfeiffer AFH, Mauersberger C, et al
    Practical strategies to manage obesity in type 2 diabetes.
    Diabetes Obes Metab. 2024 Mar 21. doi: 10.1111/dom.15556.
    >> Share

  1198. RIVERA FB, Lumbang GNO, Gaid DRM, Cruz LLA, et al
    Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regression.
    Diabetes Obes Metab. 2024 Mar 20. doi: 10.1111/dom.15529.
    >> Share

  1199. DEN BROK EJ, Svensson CH, Panagiotou M, van Greevenbroek MMJ, et al
    The effect of bolus advisors on glycaemic parameters in adults with diabetes on intensive insulin therapy: A systematic review with meta-analysis.
    Diabetes Obes Metab. 2024 Mar 19. doi: 10.1111/dom.15521.
    >> Share

  1200. BORNSTEIN SR, de Zeeuw D, Heerspink HJL, Schulze F, et al
    Aldosterone synthase inhibitor (BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: A multicentre, randomized, double-blind, placebo-controlled, Phase I trial.
    Diabetes Obes Metab. 2024 Mar 18. doi: 10.1111/dom.15518.
    >> Share

  1201. SHI C, Tan Y, Hu S, Qin Y, et al
    Effectiveness and safety of once-weekly subcutaneous semaglutide versus other glucose-lowering agents in real-world patients with type 2 diabetes: A retrospective, observational post-marketing study.
    Diabetes Obes Metab. 2024 Mar 18. doi: 10.1111/dom.15552.
    >> Share

  1202. PENG M, He S, Wang J, An Y, et al
    Efficacy of 1-hour postload plasma glucose as a suitable measurement in predicting type 2 diabetes and diabetes-related complications: A post hoc analysis of the 30-year follow-up of the Da Qing IGT and Diabetes Study.
    Diabetes Obes Metab. 2024 Mar 15. doi: 10.1111/dom.15547.
    >> Share

  1203. LAU D, Pearson GJ, Raggi P, Klarenbach S, et al
    Personalizing cardiovascular risk: Coronary artery calcium scans to improve statin use in adults with type 2 diabetes can be cost-effective in select individuals.
    Diabetes Obes Metab. 2024 Mar 15. doi: 10.1111/dom.15558.
    >> Share

  1204. FADINI GP, Bonora BM, Ghiani M, Anichini R, et al
    Oral or injectable semaglutide for the management of type 2 diabetes in routine care: A multicentre observational study comparing matched cohorts.
    Diabetes Obes Metab. 2024 Mar 13. doi: 10.1111/dom.15554.
    >> Share

  1205. JAIN AB, Reichert SM, Amadid H, Braae UC, et al
    Use of once-daily oral semaglutide and associated clinical outcomes among adults with type 2 diabetes in routine clinical practice in Canada: A multicentre, prospective real-world study (PIONEER REAL Canada).
    Diabetes Obes Metab. 2024 Mar 11. doi: 10.1111/dom.15493.
    >> Share

  1206. NYSTROM T, Andersson Franko M, Ludvigsson J, Lind M, et al
    Overweight or obesity, weight variability and the risk of retinopathy in type 1 diabetes.
    Diabetes Obes Metab. 2024 Mar 11. doi: 10.1111/dom.15545.
    >> Share

  1207. ZHAO H, Wu Y, Xie Y, Li Y, et al
    Hydrogel dressings for diabetic foot ulcer: A systematic review and meta-analysis.
    Diabetes Obes Metab. 2024 Mar 11. doi: 10.1111/dom.15544.
    >> Share

  1208. DOMAZET SL, Olesen TB, Stidsen JV, Svensson CK, et al
    Low-grade inflammation in persons with recently diagnosed type 2 diabetes: The role of abdominal adiposity and putative mediators.
    Diabetes Obes Metab. 2024 Mar 11. doi: 10.1111/dom.15514.
    >> Share

  1209. HELMINK MAG, Hageman SHJ, Eliasson B, Sattar N, et al
    Lifetime and 10-year cardiovascular risk prediction in individuals with type 1 diabetes: The LIFE-T1D model.
    Diabetes Obes Metab. 2024 Mar 8. doi: 10.1111/dom.15531.
    >> Share

  1210. SOHN TS, Han KA, Kim Y, Lee BW, et al
    A 52-week efficacy and safety study of enavogliflozin versus dapagliflozin as an add-on to metformin in patients with type 2 diabetes mellitus: ENHANCE-M extension study.
    Diabetes Obes Metab. 2024 Mar 8. doi: 10.1111/dom.15537.
    >> Share

  1211. POPOVIC DS, Patoulias D, Karakasis P, Koufakis T, et al
    Effect of tirzepatide on the risk of diabetic retinopathy in type 2 diabetes.
    Diabetes Obes Metab. 2024 Mar 8. doi: 10.1111/dom.15535.
    >> Share

  1212. YANG J, Shangguan Q, Xie G, Yang M, et al
    Sex-specific associations between haemoglobin glycation index and the risk of cardiovascular and all-cause mortality in individuals with pre-diabetes and diabetes: A large prospective cohort study.
    Diabetes Obes Metab. 2024 Mar 7. doi: 10.1111/dom.15541.
    >> Share

  1213. IVERSEN E, Christensen KM, Walls AB, Eickhoff MK, et al
    Performance of new and panel CKD-EPI equations in European adults with type 2 diabetes.
    Diabetes Obes Metab. 2024 Mar 6. doi: 10.1111/dom.15536.
    >> Share

  1214. HUANG Y, Wang S, Cai C, Huang X, et al
    Retinal vascular density as a potential biomarker of diabetic cerebral small vessel disease.
    Diabetes Obes Metab. 2024 Mar 4. doi: 10.1111/dom.15492.
    >> Share

  1215. TURNER LV, Riddell MC
    Pre-dinner walks may be superior to post-dinner walks for glucose time in range in adults with type 1 diabetes on hybrid closed-loop insulin delivery systems.
    Diabetes Obes Metab. 2024 Mar 4. doi: 10.1111/dom.15532.
    >> Share

  1216. HOYT JA, Cozzi E, D'Alessio DA, Thompson CC, et al
    A look at duodenal mucosal resurfacing: Rationale for targeting the duodenum in type 2 diabetes.
    Diabetes Obes Metab. 2024 Mar 4. doi: 10.1111/dom.15533.
    >> Share

  1217. BATDORF HM, Lawes LL, Cassagne GA, Fontenot MS, et al
    Accelerated onset of diabetes in non-obese diabetic mice fed a refined high-fat diet.
    Diabetes Obes Metab. 2024 Mar 4. doi: 10.1111/dom.15522.
    >> Share

  1218. REDDY M, Oliver N
    The role of real-time continuous glucose monitoring in diabetes management and how it should link to integrated personalized diabetes management.
    Diabetes Obes Metab. 2024;26 Suppl 1:46-56.
    >> Share

    February 2024
  1219. LIM S, Lee SH, Min KW, Lee CB, et al
    A multicentre, double-blind, placebo-controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add-on therapy in type 2 diabetic patients treated with metformin and dapagliflozin.
    Diabetes Obes Metab. 2024 Feb 29. doi: 10.1111/dom.15526.
    >> Share

  1220. VARGAS KG, Rutten T, Siemes B, Brockmeyer M, et al
    Assessing the potential for precision medicine in body weight reduction with regard to type 2 diabetes mellitus therapies: A meta-regression analysis of 120 randomized controlled trials.
    Diabetes Obes Metab. 2024 Feb 29. doi: 10.1111/dom.15519.
    >> Share

  1221. WILLIG MR, Stinson EJ, Looker HC, Piaggi P, et al
    Insulin resistance before type 2 diabetes onset is associated with increased risk of albuminuria after diabetes onset: A prospective cohort study.
    Diabetes Obes Metab. 2024 Feb 28. doi: 10.1111/dom.15505.
    >> Share

  1222. SWIFT C, Frazer M, Gronroos NN, Sargent A, et al
    Real-world glycated haemoglobin changes among type 2 diabetes mellitus patients treated with a maintenance dose of 7 mg or 14 mg of oral semaglutide.
    Diabetes Obes Metab. 2024 Feb 28. doi: 10.1111/dom.15516.
    >> Share

  1223. BONNET F, Balkau B, Lambert O, Diawara Y, et al
    The number of nephroprotection targets attained is associated with cardiorenal outcomes and mortality in patients with diabetic kidney disease. The CKD-REIN cohort study.
    Diabetes Obes Metab. 2024 Feb 28. doi: 10.1111/dom.15507.
    >> Share

  1224. ZHAO Y, Han M, Qie R, Zhang Y, et al
    Associations of body mass index trajectory, waist circumference trajectory, or both with type 2 diabetes mellitus risk in Chinese adults: The China-PAR project.
    Diabetes Obes Metab. 2024 Feb 28. doi: 10.1111/dom.15508.
    >> Share

  1225. IIJIMA H, Gouda M, Hida H, Mori-Anai K, et al
    Renal outcomes with sodium-glucose cotransporter 2 inhibitors in Japanese people with grade 3 chronic kidney disease and type 2 diabetes: Analysis of medical administrative databases.
    Diabetes Obes Metab. 2024 Feb 27. doi: 10.1111/dom.15461.
    >> Share

  1226. KUNUTSOR SK, Balasubramanian VG, Zaccardi F, Gillies CL, et al
    Glycaemic control and macrovascular and microvascular outcomes: A systematic review and meta-analysis of trials investigating intensive glucose-lowering strategies in people with type 2 diabetes.
    Diabetes Obes Metab. 2024 Feb 26. doi: 10.1111/dom.15511.
    >> Share

  1227. SHAO X, Lu J, Tao R, Wu L, et al
    Clinically relevant stratification of patients with type 2 diabetes by using continuous glucose monitoring data.
    Diabetes Obes Metab. 2024 Feb 26. doi: 10.1111/dom.15512.
    >> Share

  1228. SHEN W, Cai L, Wang B, Li J, et al
    Associations of a proinflammatory diet, habitual salt intake, and the onset of type 2 diabetes: A prospective cohort study from the UK Biobank.
    Diabetes Obes Metab. 2024 Feb 26. doi: 10.1111/dom.15517.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016